IGF-1R antibody and its use as a targeting carrier for treating cancer

By designing IGF-1R antibodies that can specifically bind and be internalized in cells as carriers of immunoconjugates, the failure of existing IGF-1R antibodies in the treatment of cancer is solved and the target of cancer cells is improved Direction and killing efficiency.

CN112851808BActive Publication Date: 2024-12-06PIERRE FABRE MEDICAMENT SAS
View PDF 25 Cites 0 Cited by

Patent Information

Application Number
CN202110050772.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2014-04-25
Filing Date
2015-04-27
Publication Date
2024-12-06
Estimated Expiration
2035-04-27

AI Technical Summary

Technical Problem

Existing IGF-1R antibodies have not been successful in the treatment of cancer, especially ineffective in patients with KRAS mutations, and IGF-1R is considered unsuitable as a target, resulting in the failure of IGF-1R antibodies in clinical trials.

Method used

An IGF-1R antibody or antigen-binding fragment thereof that specifically binds IGF-1R and is internalized in cells is developed as a vector for immunoconjugates to improve the targeting ability of cancer cells. Designed by specific amino acid sequences and domains, the antibody can efficiently bind IGF-1R and be internalized in the cell, thereby guiding cytotoxic agents into cancer cells.

Benefits of technology

Improve the internalization ability and targeting efficiency of IGF-1R antibodies, enhance the killing effect on cancer cells, and provide a potential new way to treat patients with KRAS mutations, solving the existing IGF-1R antibodies in clinical trials. failure problem.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002899050110000141
    Figure BDA0002899050110000141
  • Figure BDA0002899050110000181
    Figure BDA0002899050110000181
  • Figure BDA0002899050110000191
    Figure BDA0002899050110000191
Patent Text Reader

Abstract

The present invention relates to IGF-1R antibodies and their use as localization carriers for treating cancer. On the one hand, the present invention relates to antibodies or antigen-binding fragments thereof that can bind to IGF-1R and be internalized into cells by inducing internalization of IGF-1R. The present invention also includes the use of the antibodies as localization products or carriers conjugated to other anti-cancer compounds (such as toxins, radioactive elements or drugs), and their use for treating certain cancers.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 2015800307116, filed on April 27, 2015, entitled "IGF-1R antibody and its use as a positioning carrier for the treatment of cancer". Technical Field

[0002] This invention relates to novel antibodies, particularly monoclonal antibodies, capable of binding to IGF-1R, and the amino acid and nucleic acid sequences encoding said antibodies. In one aspect, this invention relates to novel antibodies or antigen-binding fragments thereof capable of binding to IGF-1R and being internalized into cells by inducing IGF-1R internalization. The invention also includes the use of said antibodies as targeting products or carriers conjugated with other anticancer compounds (such as toxins, radioactive elements, or drugs), and their use in the treatment of certain cancers. Background Technology

[0003] The insulin-like growth factor 1 receptor, known as IGF-1R (also called IGF1R or IGF-IR), is a receptor with tyrosine kinase activity and shares 70% homology with the insulin receptor IR. IGF-1R is a glycoprotein with a molecular weight of approximately 350,000. It is a heterotetrameric receptor, half of which is linked by disulfide bridges, and consists of an extracellular α-subunit and a transmembrane β-subunit. IGF-1R binds to both IGF1 and IGF2 (Kd#1nM) with high affinity, but can also bind to insulin with an affinity 100 to 1000 times lower. Conversely, IR binds to insulin with high affinity, although IGF binds to the insulin receptor with only an affinity 100 times lower. The tyrosine kinase domains of IGF-1R and IR share high sequence homology, although weaker homologous regions involve cysteine-rich regions located at the C-terminal portions of the α- and β-subunits, respectively. The sequence differences observed in the α-subunit are located in the ligand-binding region, thus resulting in the relative affinities of IGF-1R and IR for IGF and insulin, respectively. Differences in the C-terminal portion of the β-subunit lead to divergence in the signal transduction pathways of the two receptors; IGF-1R mediates mitotic, differentiation, and anti-apoptotic effects, while activation of IR primarily involves its role at the metabolic pathway level.

[0004] Cytoplasmic tyrosine kinase proteins are activated by the binding of ligands to the extracellular domains of their receptors. In turn, kinase activation involves stimulation of various intracellular substrates, including IRS-1, IRS-2, Shc, and Grb10. The two main substrates of IGF-1R are IRS and Shc, which mediate most of the growth and differentiation processes associated with IGF and its receptor attachment by activating numerous downstream effectors. Therefore, substrate effectiveness indicates the ultimate biological effects associated with IGF-1R activation. When IRS-1 is dominant, cells tend to proliferate and transform. When Shc is dominant, cells tend to differentiate. The pathway primarily involved in preventing apoptosis appears to be the phosphatidyl-inositol 3-kinase (PI3-kinase) pathway.

[0005] In the last decade, the role of the IGF system in oncogenesis has become a subject of in-depth research. This interest has led to the discovery that, in addition to its mitotic and anti-apoptotic properties, IGF-1R appears to be necessary for the establishment and maintenance of a transformative phenotype. Indeed, overexpression or constitutive activation of IGF-1R has been demonstrated to induce cell growth independent of fetal bovine serum-free mediators in many different cell types and to lead to tumor formation in nude mice. This is not a unique property in itself, as the products of many different overexpressed genes can transform cells, including receptors for many growth factors. However, key findings clearly demonstrating the major role of IGF-1R in transformation have shown that IGF-1R plays a crucial role in transformation. - The cells (in which the gene encoding IGF-1R is inactivated) are completely resistant to transformation by various agents that can typically transform the cells, such as bovine papillomavirus E5 protein, overexpression of EGFR or PDGFR, SV40 T antigen, activated ras, or a combination of the last two factors.

[0006] IGF-1R is expressed in many different tumors and tumor lines, and IGF promotes tumor growth through their attachment to IGF-1R. Other arguments supporting the role of IGF-1R in oncogenesis come from studies using murine monoclonal antibodies targeting the receptor or using negative-dominant IGF-1R. Indeed, murine monoclonal antibodies against IGF-1R inhibit the proliferation of many cell lines in culture, as well as the growth of tumor cells in vivo. Similarly, negative-dominant IGF-1R has been shown to inhibit tumor proliferation.

[0007] In this context, IGF-1R has long been considered a target of interest in oncology. Numerous projects targeting IGF-1R (humanized or human antibodies or small molecules) have begun developing IGF-1R antibodies for cancer treatment, and more than 70 clinical trials have been conducted across multiple indications. However, these projects have not yet been successful, and there are no IGF-1R antibodies on the market, despite frequent overexpression of this target described in many patients across a broad range of indications.

[0008] In addition, a series of clinical trials involving combinations of anti-IGF-1R antibodies and anti-EGFR antibodies targeting EGFR and IGF-1R failed because these antibodies were unable to treat patients with KRAS mutations.

[0009] Therefore, IGF-1R is not currently considered a primary target, and it no longer appears to be of particular interest in research on potential therapeutic antibodies.

[0010] However, it must be noted that efforts to generate IGF-1R antibodies focus on naked antibodies, i.e., antibodies useful through their inherent properties. In this sense, IGF-1R is considered an unsuitable target for generating immune conjugates such as antibody-drug conjugates (called "ADCs"), as IGF-1R is also widely expressed in normal cells, including blood vessels, as described. In this sense, it should be noted that most recent IGF-1R antibodies (i.e., AVE1642) have been developed as naked antibodies, without drug loading. This is the same as all other IGF-1R antibodies currently under development that have failed in clinical trials. Summary of the Invention

[0011] In one aspect, the present invention addresses these problems and describes an IGF-1R antibody capable of specifically binding to IGF-1R, such as one suitable for use in loading drugs. More specifically, the present invention relates to an IGF-1R antibody exhibiting specific properties, such as being an optimal candidate for loading in the case of immunoconjugates.

[0012] In a first embodiment, the present invention relates to an antibody, or an antigen-binding fragment thereof, i) which binds to human IGF-1R, and ii) which is internalized after binding to said human IGF-1R.

[0013] In the broadest sense, the terms "antibody," "antibodies," "ab," "Ab," or "immunoglobulin" are used interchangeably and include monoclonal antibodies, isolated, engineered, chemically synthesized, or recombinant antibodies (e.g., full-length or intact monoclonal antibodies), polyclonal antibodies, multivalent antibodies, or multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, provided they exhibit the desired biological activity. In one embodiment, the present invention relates to a recombinant antibody.

[0014] More specifically, such molecules are composed of glycoproteins containing at least two heavy chains (H) and two light chains (L) linked together by disulfide bonds. Each heavy chain contains a heavy chain variable region (or domain) (abbreviated here as HCVR or VH) and a heavy chain constant region. The heavy chain constant region contains three domains, CH1, CH2, and CH3. Each light chain contains a light chain variable region (abbreviated here as LCVR or VL) and a light chain constant region. The light chain constant region contains one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions called complementarity-determining regions (CDRs), which are scattered in more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including different cells of the immune system (e.g., effector cells) and the first complement (Clq) of the classical complement system.

[0015] The “IGF-1R binding fragment” or “antigen binding fragment” of the antibody according to the present invention is intended to represent any peptide, polypeptide or protein that retains the ability of the antibody to bind to a target (generally also referred to as an antigen).

[0016] In one embodiment, such an "antigen-binding fragment" is selected from Fv, scFv (sc represents single chain), Fab, F(ab')2, Fab', scFv-Fc fragments, or bispecific antibodies, or any fragment whose half-life is extended by chemical modification, such as the addition of poly(alkylene) glycols like polyethylene glycol ("polyglycolization") (polyglycolized fragments are referred to as Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG, or Fab'-PEG) ("PEG" represents polyethylene glycol), or by incorporation into liposomes, said fragment having at least one characteristic CDR of the antibody according to the invention. Preferably, the "antigen-binding fragment" will consist of or include a portion of the variable heavy or light chain of the antibody from which it is derived, said portion being sufficient to retain the same binding specificity and sufficient affinity as the antibody from which it originates, preferably said sufficient affinity being at least 1 / 100, more preferably at least 1 / 10, of the affinity of the antibody from which it originates for the target. More preferably, the “antigen-binding fragment” will consist of at least three CDRs CDR-H1, CDR-H2 and CDR-H3 of the heavy variable chain of the antibody from which it is derived, and three CDRs CDR-L1, CDR-L2 and CDR-L3 of the light variable chain.

[0017] The terms "binding" are intended to indicate that the antibody or any antigen-binding fragment thereof forms a relatively stable complex with the antigen under physiological conditions. Specific binding is characterized by a minimum of approximately 1 x 10-1 -6 M or a smaller equilibrium dissociation constant. Methods for determining whether two molecules bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, etc. For the avoidance of doubt, this does not mean that the antibody cannot bind to or interfere with another antigen at low levels. However, as one embodiment, the antibody binds only to the antigen.

[0018] As used in this specification, the term "IGF-1R antibody" should be interpreted similarly to "anti-IGF-1R antibody" and refers to an antibody capable of binding to IGF-1R.

[0019] In one embodiment of this application, the epitope of the antibody is located in the extracellular domain of human IGF-1R (also known as IGF-1R ECD).

[0020] In one specific implementation, the antibody, or any antigen-binding fragment thereof, can be 10x10 -10 Up to 1x10 -10 And more preferably 8x10 -10 Up to 2x10 -10 M's EC 50 Combine with IGF-1R.

[0021] In this sense, "EC" 50 "50%" refers to the effective concentration. More precisely, the term "half-maximum effective concentration" (EC50) is used. 50 The EC50 of a graded dose-response curve corresponds to the concentration of a drug, antibody, or toxin that induces half the response between baseline and maximum after a specific exposure period. It is commonly used as a measure of drug efficacy. Therefore, the EC50 of a graded dose-response curve... 50 The concentration of the compound at which 50% of its maximum effect was observed. EC50 of the quantum dose-response curve. 50 This indicates the concentration of the compound at which 50% of the population showed a response after exposure for a specific period. Concentration measurements typically follow an S-shaped curve, increasing rapidly with relatively small concentration changes. This can be mathematically determined through the derivation of the best-fit line.

[0022] As a preferred embodiment, the EC determined in this invention 50 The potency of the antibody in binding to IGF-1R ECD exposed on human tumor cells was characterized. EC was determined using FACS analysis. 50 Parameters. EC 50 The parameters reflect the antibody concentration required to achieve 50% maximum binding to human IGF-1R expressed on human tumor cells. A four-parameter regression curve fitting program (Prism software) was used for each EC... 50 The value is calculated as the midpoint of the dose-response curve. This parameter has been selected as representative of physiological / pathological conditions.

[0023] The term "epitope" refers to an antigenic region that is bound by an antigen-binding protein (including an antibody). Epitopes can be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes and contain residues that directly contribute to the affinity of the interaction. Epitopes can also be conformational, i.e., composed of non-linear amino acids; in other words, conformational epitopes consist of discontinuous amino acids. In some embodiments, epitopes may include determinants, which are chemically activated molecular surface groups such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and in some embodiments, may have specific three-dimensional structural features and / or specific charge features.

[0024] In one specific embodiment, the present invention relates to a method for selecting an internalizing antibody, or an internalized IGF-1R binding fragment thereof, said internalizing antibody, or internalized IGF-1R binding fragment thereof, which binds to and is internalized after binding to human insulin-like growth factor 1 receptor (IGF-1R), said method comprising the step of selecting the antibody:

[0025] i) The antibody binds to the IGF-1R shown in SEQ ID NO. 52, and

[0026] ii) The antibody does not bind to the IGF-1R shown in SEQ ID NO. 52 that contains an amino acid other than histidine at position 494 or an amino acid other than aspartic acid (ASP) at position 491. Preferably, the antibody does not bind to the IGF-1R shown in SEQ ID NO. 52 that contains an amino acid other than histidine at position 494 and an amino acid other than aspartic acid (ASP) at position 491.

[0027] In a more specific embodiment, the present invention relates to a method for selecting an internalizing antibody, or an internalizing IGF-1R binding fragment thereof, said internalizing antibody, or internalizing IGF-1R binding fragment thereof, which binds to human insulin-like growth factor 1 receptor (IGF-1R) and is internalized after binding to IGF-1R, said method comprising the steps of:

[0028] 1) Select antibody:

[0029] i) The antibody binds to the IGF-1R shown in SEQ ID NO. 52, and

[0030] ii) The antibody does not bind to the IGF-1R shown in SEQ ID NO. 52 that contains an amino acid other than histidine at position 494 or an amino acid other than aspartic acid (ASP) at position 491. Preferably, the antibody does not bind to the IGF-1R shown in SEQ ID NO. 52 that contains an amino acid other than histidine at position 494 and an amino acid other than aspartic acid (ASP) at position 491.

[0031] Then, from such antibodies

[0032] 2) Select an internalization antibody or its IGF-1R binding fragment, with an internalization percentage of at least 40% after binding to IGF-1R, preferably at least 50%, at least 60%, at least 70%, or at least 80%.

[0033] In another specific embodiment, the present invention relates to a method for selecting an internalizing antibody, or an internalized IGF-1R binding fragment thereof, said internalizing antibody, or internalized IGF-1R binding fragment thereof, which binds to human insulin-like growth factor 1 receptor (IGF-1R) and is internalized after binding to IGF-1R, said method comprising the steps of:

[0034] 1) Select an internalization antibody or its IGF-1R binding fragment, with an internalization percentage of at least 40% after binding to IGF-1R, preferably at least 50%, at least 60%, at least 70%, or at least 80%.

[0035] 2) Then, select antibodies from such antibodies:

[0036] i) The antibody binds to the IGF-1R shown in SEQ ID NO. 52, and

[0037] ii) The antibody does not bind to the IGF-1R shown in SEQ ID NO. 52 that contains an amino acid other than histidine at position 494 or an amino acid other than aspartic acid (ASP) at position 491. Preferably, the antibody does not bind to the IGF-1R shown in SEQ ID NO. 52 that contains an amino acid other than histidine at position 494 and an amino acid other than aspartic acid (ASP) at position 491.

[0038] In the method according to the invention, the steps of selecting antibodies based on their internalization and binding or non-binding characteristics of IGF-1R can be performed in any consecutive order.

[0039] According to one specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, said internalized antibody or internalized IGF-1R binding fragment thereof binding to human insulin-like growth factor 1 receptor (IGF-1R), for example by an internalized antibody or internalized IGF-1R binding fragment thereof obtained by one of the methods described above according to the present invention.

[0040] In another specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, said internalized antibody or internalized IGF-1R binding fragment thereof binding to the human insulin-like growth factor 1 receptor (IGF-1R) shown in SEQ ID NO. 52 and being internalized after binding to IGF-1R, and said internalized antibody or internalized IGF-1R binding fragment thereof not binding to the IGF-1R shown in SEQ ID NO. 82 or 92, preferably SEQ ID NO. 82 and 92.

[0041] For the antibody according to the invention, SEQ ID NO. 52 corresponds to the amino acid sequence of the human IGF-1R receptor, wherein histidine is at position 494, i.e., wild-type IGF-1R; however, SEQ ID NO. 82 corresponds to the mutant amino acid sequence of the human IGF-1R receptor, wherein arginine is at position 494; and SEQ ID NO. 92 corresponds to the mutant amino acid sequence of the human IGF-1R receptor, wherein alanine is at position 491.

[0042] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody is contained in the histidine amino acid at position 494 of SEQ ID NO. 52.

[0043] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises a histidine amino acid at position 494 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of at least 8 amino acids.

[0044] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises an aspartic amino acid at position 491 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of at least 8 amino acids.

[0045] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises a histidine amino acid at position 494 and an aspartic amino acid at position 491 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of at least 8 amino acids.

[0046] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises a histidine amino acid at position 494 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids.

[0047] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises a histidine amino acid at position 494 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of at least 8 amino acids, wherein the amino acid sequence comprising the epitope is selected from:

[0048] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 487 to position 494 of SEQ ID NO. 52.

[0049] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 488 to position 495 of SEQ ID NO. 52.

[0050] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 489 to position 496 of SEQ ID NO. 52.

[0051] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 490 to position 497 of SEQ ID NO. 52.

[0052] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 491 to position 498 of SEQ ID NO. 52.

[0053] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 492 to position 499 of SEQ ID NO. 52, and

[0054] - An amino acid sequence that is identical to or exhibits at least 80% identity with the amino acid sequence from position 493 to position 500 of SEQ ID NO. 52.

[0055] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises an aspartic amino acid at position 491 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids.

[0056] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises an aspartic amino acid at position 491 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of at least 8 amino acids, wherein the amino acid sequence comprising the epitope is selected from:

[0057] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 484 to position 491 of SEQ ID NO. 52.

[0058] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 485 to position 492 of SEQ ID NO. 52.

[0059] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 486 to position 493 of SEQ ID NO. 52.

[0060] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 487 to position 494 of SEQ ID NO. 52.

[0061] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 488 to position 495 of SEQ ID NO. 52.

[0062] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 489 to position 496 of SEQ ID NO. 52, and

[0063] - An amino acid sequence that is identical to or exhibits at least 80% identity with the amino acid sequence from position 490 to position 497 of SEQ ID NO. 52.

[0064] In a more specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises a histidine amino acid at position 494 and an aspartic acid at position 491 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids.

[0065] In a more specific embodiment, the present invention relates to an internalized antibody, or an internalized IGF-1R binding fragment thereof, wherein the epitope of the internalized antibody comprises a histidine amino acid at position 494 and an aspartic acid at position 491 of SEQ ID NO. 52, the epitope comprising an amino acid sequence of at least eight amino acids, wherein the amino acid sequence comprising the epitope is selected from:

[0066] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 487 to position 494 of SEQ ID NO. 52.

[0067] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 488 to position 495 of SEQ ID NO. 52.

[0068] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 489 to position 496 of SEQ ID NO. 52.

[0069] - An amino acid sequence that is identical to, or exhibits at least 80% identity with, the amino acid sequence from position 490 to position 497 of SEQ ID NO. 52, and

[0070] - An amino acid sequence that is identical to or exhibits at least 80% identity with the amino acid sequence from position 491 to position 498 of SEQ ID NO. 52.

[0071] In another specific embodiment, the present invention relates to an internalized antibody, or an internalized IGF-1R binding fragment thereof, said internalized antibody, or internalized IGF-1R binding fragment thereof, which binds to the human insulin-like growth factor 1 receptor (IGF-1R) shown in SEQ ID NO. 52 and is internalized after binding to IGF-1R, and said internalized antibody, or internalized IGF-1R binding fragment thereof, does not bind to the IGF-1R shown in SEQ ID NO. 82, or said epitope of said internalized antibody is contained in histidine amino acid at position 494 and / or aspartic amino acid at position 491 of SEQ ID NO. 52, wherein said internalization percentage after binding to IGF-1R is at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%. The internalization percentage of the antibody or its antigen-binding fragment thereof can be determined by any method known to those skilled in the art, such as, for example, the method described in this specification.

[0072] In one specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof according to the present invention, wherein the amino acid at position 494 of SEQ ID NO. 52, other than histidine, is arginine (SEQ ID NO. 82).

[0073] In one specific embodiment, the present invention relates to an internalized antibody or an internalized IGF-1R binding fragment thereof according to the present invention, wherein the amino acid at position 491 of SEQ ID NO. 52, other than aspartic acid, is alanine (SEQ ID NO. 92).

[0074] According to one embodiment, the present invention relates to an antibody, or an antigen-binding fragment thereof, which binds to and is internalized after binding to human insulin-like growth factor 1 receptor (IGF-1R), wherein said antibody is selected from:

[0075] i) An antibody comprising three heavy chain CDRs, CDR-H2 as shown in SEQ ID No. 2 and CDR-H3 as shown in SEQ ID No. 3, and three light chain CDRs, CDR-L2 as shown in SEQ ID No. 5;

[0076] ii) The antibody that competes with i) for binding to IGF-1R; and

[0077] iii) Antibodies that bind to the same IGF-1R epitope as the antibodies in i).

[0078] Competitive binding to IGF-1R can be determined by any method or technique known to those skilled in the art, such as, but not limited to, radioactive, Biacore, ELISA, flow cytometry, etc., or according to methods such as those described in this specification.

[0079] The binding of the same epitope can be determined by any method or technique known to those skilled in the art, such as, but not limited to, radioactive, Biacore, ELISA, flow cytometry, etc., or according to methods such as those described in this specification.

[0080] As described above, and contrary to common knowledge, this invention focuses on specific IGF-1R antibodies that exhibit a high degree of internalization ability upon binding to IGF-1R. As used herein, an "internalized" or "encapsulated" antibody (both expressions are similar) is an antibody that is taken up by the cell through binding to IGF-1R (meaning it "enters" the cell). Such antibodies are of interest as components of immuno-pharmaceutical conjugates, thus targeting or directing linked cytotoxic agents into target cells, preferably cancer cells. Once internalized, the cytotoxic agent induces cancer cell death.

[0081] Preferably, the antibodies according to the invention all exhibit the same CDR-H2, CDR-H3, and CDR-L2 sequences, while the other three CDRs are different. This observation appears to be consistent with common knowledge regarding antibody binding specificity, namely that CDR-H3 is described as the most important and relevant epitope recognition.

[0082] A key factor in the success of immunoconjugation therapy is considered to be the specificity of the target antigen and the internalization of the antigen-binding protein complex into cancer cells. Clearly, non-internalized antigens are less effective at delivering cytotoxic agents compared to internalized antigens. The internalization process is variable depending on the antigen and several parameters influenced by the antibody.

[0083] In immunoconjugates, the cytotoxic agent provides cytotoxic activity, the antibody provides its specificity for cancer cells, and the carrier is used to enter the cell and accurately locate the cytotoxic agent. Therefore, to improve immunoconjugates, antibodies can exhibit a high capacity for internalization into target cancer cells. The efficiency of antibody-mediated internalization varies significantly depending on the target epitope. Selecting effective IGF-1R internalizing antibodies requires not only studying IGF-1R downregulation but also investigating different experimental data after IGF-1R antibody internalization into cells.

[0084] In one embodiment, the internalization of the antibody according to the invention can be evaluated by immunofluorescence (as illustrated below in this application) or by any method or process specific to internalization mechanisms known to those skilled in the art.

[0085] The IGF-1R / antibody complex, after the antibody binds to the ECD of IGF-1R, is internalized, inducing a reduction in the amount of IGF-1R on the cell surface. This reduction can be quantified by any method known to those skilled in the art, such as Western blotting, FACS, immunofluorescence, etc., as non-limiting examples.

[0086] In one implementation, this reduction, which thus embodies internalization, is preferably measured by FACS and expressed as the difference or Δ between the average fluorescence intensity (MFI) measured at 4°C and the MFI measured after the antibody has been incubated at 37°C for 4 hours.

[0087] As a non-limiting example, based on MFI obtained with untreated cells and antibody-treated cells, this Δ was determined using i) breast cancer cells MCF7 after incubation with the antibody described herein for 4 hours, and ii) a second antibody labeled with Alexa488. This parameter is defined as calculated using the following formula: Δ(MFI) 4℃ -MFI 37℃ ).

[0088] Since MFI is proportional to the amount of IGF-1R expressed on the cell surface, this difference between MFI reflects the downregulation of IGF-1R.

[0089] In an advantageous aspect, the antibody or any antigen-binding fragment thereof consists of a monoclonal antibody that triggers at least 280, preferably at least 400, Δ(MFI) on MCF7. 4℃ –MFI 37℃ ).

[0090] More specifically, the above Δ can be measured according to the following procedure, which should be considered as an illustrative and non-limiting example:

[0091] a) Treat and incubate tumor cells of interest with the antibody of the present invention in a cold (4°C) or hot (37°C) complete culture medium;

[0092] b) Treat the cells treated in step a) and the untreated cells in parallel with the second antibody.

[0093] c) Using a second labeled antibody capable of binding to the antibody of the present invention, measure the MFI (representing the amount of IGF-1R present on the surface) of treated and untreated cells, and

[0094] d) Δ is calculated as the difference between the MFI obtained by untreated cells and the MFI obtained by treated cells.

[0095] From this ΔMFI, the internalization percentage can be determined: 100x(MFI) 4℃ -MFI 37℃ ) / MFI 4℃ .

[0096] According to the present invention, the percentage of internalization of the antibody or any antigen-binding fragment thereof appearing on MCF7 is included in the range of 70% to 90%, preferably 75% to 87%.

[0097] The specific advantages of the antibodies described here depend on their internalization rate.

[0098] As is well known, for immunoconjugates, it is desirable that the antibody used exhibits rapid internalization, preferably within 24 hours of administration of the antibody to the body, more preferably within 12 hours, and even more preferably within 6 hours.

[0099] In this invention, the internalization ratio is also referred to as cell surface antibody reduction or cell surface antibody decay, expressed as t1 / 2 (half-life) and corresponding to the time required to obtain a 50% reduction in ΔMFI (this aspect will be clearly understood from the following examples).

[0100] One specific advantage is that the antibody of the present invention has a t1 / 2 of 5 to 25 minutes, preferably 10 to 20 minutes.

[0101] One specific embodiment of the present invention relates to an antibody comprising three heavy chain CDRs shown in sequences SEQ ID No. 1, 2 and 3, and three light chain CDRs shown in sequences SEQ ID No. 4, 5 and 6.

[0102] One embodiment is an antibody or an antigen-binding fragment thereof comprising three heavy chain CDRs, said three heavy chain CDRs comprising, being composed of sequences SEQ ID NO.1, 2 and 3 or any sequence exhibiting at least 80%, preferably 85%, 90%, 95% or 98% identity with SEQ ID NO.1, 2 and 3; and three light chain CDRs, said three light chain CDRs comprising, or being composed of sequences SEQ ID NO.4, 5 and 6 or any sequence exhibiting at least 80%, preferably 85%, 90%, 95% or 98% identity with SEQ ID NO.4, 5 and 6.

[0103] In another embodiment, the antibody or any antigen-binding fragment thereof comprises three heavy chain CDRs, the three heavy chain CDRs comprising or consisting of sequences SEQ ID NO. 1, 2 and 3; and three light chain CDRs, the three light chain CDRs comprising or consisting of sequences SEQ ID NO. 4, 5 and 6.

[0104] The CDR region, or CDR, refers to the hypervariable region of the immunoglobulin heavy and light chains as defined by IMGT.

[0105] Regardless of antigen receptor, chain type, or species, the unique numbering of IMGT is used to compare variable domains (Lefranc M.-P., Immunology Today 18, 509 (1997) / Lefranc M.-P., The Immunologist, 7, 132-136 (1999) / Lefranc, M.-P., Pommié, C., Ruiz, M., Giudicelli, V., Foulquier, E., Truong, L., Thouvenin-Contet, V. and Lefranc, Dev. Comp. Immunol., 27, 55-77 (2003)). In the unique IMGT numbering, conserved amino acids always occupy the same position, such as cysteine ​​23 (first CYS), tryptophan 41 (conserved TRP), hydrophobic amino acid 89, cysteine ​​104 (second CYS), phenylalanine or tryptophan 118 (J-PHE or J-TRP). The unique IMGT numbering provides normalized delimitations for the frame regions (FR1-IMGT: positions 1 to 26, FR2-IMGT: 39 to 55, FR3-IMGT: 66 to 104 and FR4-IMGT: 118 to 128) and complementarity-determining regions CDR1-IMGT: 27 to 38, CDR2-IMGT: 56 to 65 and CDR3-IMGT: 105 to 117. Since vacancies represent unoccupied positions, the CDR-IMGT length (shown between parentheses and separated by dots, e.g., [8.8.13]) becomes crucial information. The IMGT unique numbering is used in the 2D diagram, named IMGT Colliers de Perles (Ruiz, M. and Lefranc, M.-P., Immunogenetics, 53, 857-883 (2002) / Kaas, Q. and Lefranc, M.-P., Current Bioinformatics, 2, 21-30 (2007)), and is used in the 3D structure in the IMGT / 3D structure DB (Kaas, Q., Ruiz, M. and Lefranc, M.-P., Tcell receptor and MHC structural data. Nucl. Acids. Res., 32, D208-D210 (2004)).

[0106] It must be understood that there is no contradictory statement in this specification, and the complementarity-determining region or CDR means the hypervariable region of the immunoglobulin heavy and light chains as defined by the IMGT numbering system.

[0107] However, CDRs may also be defined according to the Kabat numbering system (Kabat et al., Sequences of proteins of immune interest, 5th edition, USDA Department of Health and Human Services, NIH, 1991 and later). There are three heavy chain CDRs and three light chain CDRs. Here, depending on the context, the term "CDR" is used to refer to one or more, or even all, regions containing the majority of amino acid residues responsible for antibody-binding affinity to the antigen or epitope they recognize. For the sake of simplicity, CDRs according to Kabat are not defined. However, it will be apparent to those skilled in the art to use the definition of a CDR according to IMGT or the definition of a CDR according to Kabat.

[0108] In the context of this invention, "percentage identity" between two nucleic acid or amino acid sequences refers to the percentage of identical nucleotide or amino acid residues between the two sequences to be compared, obtained after optimal alignment. This percentage is purely statistical, and the differences between the two sequences are randomly distributed along their length. Comparison of two nucleic acid or amino acid sequences is conventionally performed by comparing the sequences after optimal alignment, which can be done by segment or by using an "alignment window". In addition to manual comparison, optimal alignment of sequences to be compared can be performed using Smith and Waterman’s local homology algorithm (1981) (Ad. App. Math. 2: 482), Neddleman and Wunsch’s local homology algorithm (1970) (J. Mol. Biol. 48: 443), Pearson and Lipman’s similarity search method (1988) (Proc. Natl. Acad. Sci. USA 85: 2444), or by using computer software based on these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics package, Genetics Computation Group, 575 Science Dr., Madison, WI, or by using comparison software BLAST NR or BLAST P).

[0109] The percentage identity between two nucleic acid or amino acid sequences is determined by comparing two optimally aligned sequences, wherein the nucleic acid or amino acid sequences to be compared may have additions or deletions compared to the reference sequence used for the optimal alignment between the two sequences. The percentage identity is calculated by determining the number of identical amino acid nucleotides or residues between the two sequences (preferably two complete sequences), dividing the number of identical sites by the total number of sites in the alignment window, and multiplying the result by 100 to obtain the percentage identity between the two sequences.

[0110] For example, the BLAST program "BLAST 2 Sequences" (Tatusova et al., "Blast 2sequences-a new tool for comparing protein and nucleotide sequences", FEMS Microbiol., 1999, Lett. 174: 247–250) available at http: / / www.ncbi.nlm.nih.gov / gorf / bl2.html can be used, using the default parameters (specifically the parameters "open vacancy penalty": 5, and "extended vacancy penalty": 2; the selected matrix is, for example, the "BLOSUM 62" matrix proposed by the program); the percentage identity between the two sequences to be compared can be calculated directly using the program.

[0111] For amino acid sequences exhibiting at least 80%, preferably 85%, 90%, 95%, or 98% identity with a reference amino acid sequence, preferred examples include those containing the reference sequence, with certain modifications (particularly deletion, insertion, or substitution of at least one amino acid, truncation, or extension). Where one or more continuous or discontinuous amino acids are substituted, it is preferred that the substituted amino acid is replaced by an "equivalent" amino acid. Here, the expression "equivalent amino acid" means any amino acid that can substitute for a structural amino acid without altering the corresponding antibody's biological activity, as well as any amino acid among the specific examples defined below.

[0112] Equivalent amino acids can be determined based on their structural homology with the amino acids they replace, or based on the results of comparative tests of the biological activities of various antigen-binding proteins that may be generated.

[0113] As a non-limiting example, Table 1 below summarizes possible substitutions that can be implemented without causing significant changes in the biological activity of the corresponding modified antigen-binding proteins; the opposite substitutions can naturally be made under the same conditions.

[0114] Table 1

[0115] Original residues replace Ala(A) Val, Gly, Pro Arg(R) Lys、His Asn(N) Gln Asp(D) Glu Cys(C) Ser Gln(Q) Asn Glu(E) Asp Gly(G) Ala His(H) Arg Ile(I) Leu Leu(L) Ile, Val, Met Lys(K) Arg Met(M) Leu Phe(F) Tyr Pro(P) Ala Ser(S) Thr、Cys Thr(T) Ser Trp(W) Tyr Tyr(Y) Phe, Trp Val(V) Leu, Ala

[0116] A specific aspect of this invention is an antibody or any antigen-binding fragment thereof that does not bind to the insulin receptor (IR). This aspect is of interest because the antibodies described herein will not have any negative impact on IR (meaning insulin metabolism).

[0117] In another embodiment, another advantageous aspect of the antibody of the present invention is its ability to bind not only to human IGF-1R but also to monkey IGF-1R, more specifically to rhesus monkey IGF-1R. This aspect is also of interest because it will facilitate toxicity and clinical trials.

[0118] In another embodiment, the antibody of the present invention consists of a monoclonal antibody.

[0119] As used herein, the term "monoclonal antibody" or "Mab" refers to an antibody obtained from a largely homogeneous group of antibodies, meaning that individual antibodies in the group are identical except for the possibility of naturally occurring mutations present in minimal quantities. Monoclonal antibodies are highly specific for a single epitope and can be produced by monoclonal B cells or hybridomas. Monoclonal antibodies can also be recombinant, i.e., produced through protein engineering. Monoclonal antibodies can also be isolated from a phage antibody library. Furthermore, unlike the preparation of polyclonal antibodies, which typically comprises different antibodies targeting different determinants or epitopes, each monoclonal antibody targets a single epitope of the antigen. This invention relates to an isolated antibody, or an antibody obtained from a natural source through purification, or an antibody obtained through genetic recombination or chemical synthesis.

[0120] In one implementation, the monoclonal antibodies herein include mouse, chimeric, and humanized antibodies, such as those described below.

[0121] The antibody can be derived from a murine hybridoma submitted to the National Center for Microbial Collection (CNCM) (Paris, France, 15 75724, 25 Rue Doctéur Roux, Pasteur Institute), obtained by cell fusion of immunized Balb / C mouse spleen / lymphocytes and myeloma Sp 2 / O-Ag 14 cell lines.

[0122] In another embodiment, the antibody of the present invention comprises a recombinant antibody. The term "recombinant antibody" refers to an antibody obtained by the expression of recombinant DNA in living cells. The recombinant antibody of the present invention is obtained by creating a DNA sequence that is not found in organisms using laboratory methods of gene recombination known to those skilled in the art.

[0123] In another embodiment, the antibody of the present invention is composed of a chemically synthesized antibody.

[0124] In one embodiment, the IGF-1R antibody of the present invention is composed of mouse antibodies, and is then referred to as m[the name of the antibody].

[0125] In one implementation, the IGF-1R antibody consists of a chimeric antibody, then referred to as c[the name of the antibody].

[0126] In one implementation, the IGF-1R antibody consists of a humanized antibody, then referred to as hz [the name of the antibody].

[0127] For the avoidance of doubt, in the following description, the terms "IGF-1R antibody" and "[antibody name]" are similar and include (unless otherwise stated) the mouse, chimeric, and humanized forms of the IGF-1R antibody and the "[antibody name]". When necessary, the prefixes m- (mouse), c- (chimeric), or hz- (humanized) are used.

[0128] In another embodiment, the antibody of the present invention is selected from:

[0129] a) An antibody comprising three heavy chain CDRs shown in sequences SEQ ID No. 7, 2 and 3 and three light chain CDRs shown in sequences SEQ ID No. 9, 5 and 11;

[0130] b) An antibody comprising three heavy chain CDRs shown in sequences SEQ ID No. 7, 2 and 3 and three light chain CDRs shown in sequences SEQ ID No. 10, 5 and 11;

[0131] c) An antibody comprising the three heavy chain CDRs shown in sequences SEQ ID No. 7, 2 and 3 and the three light chain CDRs shown in sequences SEQ ID No. 9, 5 and 12; and

[0132] d) An antibody comprising three heavy chain CDRs shown in sequences SEQ ID No. 8, 2 and 3 and three light chain CDRs shown in sequences SEQ ID No. 9, 5 and 11.

[0133] For clarity, Table 2 below shows the CDR sequences of preferred antibodies as defined by IMGT.

[0134] Table 2

[0135]

[0136] It will be obvious to those skilled in the art that any combination of the six CDRs as described above should be considered part of the present invention.

[0137] As can be observed from Table 2, all the antibodies described in the table have the same CDR-H2, CDR-H3, and CDR-L2 sequences, a characteristic that is of particular interest as mentioned above.

[0138] One specific aspect involves mouse (m) antibodies, or any antigen-binding fragments, characterized in that the antibody also comprises light and heavy chain constant regions derived from antibodies of a species heterologous to mice (especially humans).

[0139] Another specific aspect involves chimeric (c) antibodies, or any antigen-binding fragments, characterized in that the antibody also contains light and heavy chain constant regions derived from antibodies of a species heterologous to mice (especially humans).

[0140] In one embodiment of the present invention, the antibody is composed of a chimeric antibody.

[0141] A chimeric antibody is an antibody that comprises a combination of naturally occurring variable regions (light and heavy chains) of an antibody derived from a given species and constant regions of light and heavy chains of an antibody from a species heterologous to the given species.

[0142] Antibodies or chimeric fragments thereof can be prepared using recombinant gene technology. For example, chimeric antibodies can be produced by cloning recombinant DNA containing a promoter and a sequence encoding the variable region of a non-human (especially mouse) monoclonal antibody of the present invention, and a sequence encoding the constant region of a human antibody. According to the present invention, a chimeric antibody encoded by such a recombinant gene can be, for example, a mouse-human chimera, where the variable region derived from mouse DNA determines the specificity of the antibody, and the constant region derived from human DNA determines its isotype.

[0143] In a preferred, but not limiting, embodiment, the antibody of the present invention is selected from:

[0144] a) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 13 or exhibiting at least 80% identity with SEQ ID No. 13, and three light chain CDRs shown in sequences SEQ ID No. 9, 5 and 11;

[0145] b) An antibody comprising, or consisting of, a heavy chain variable domain of any sequence shown in SEQ ID No. 14 or exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 14, and three light chain CDRs shown in sequences SEQ ID No. 10, 5 and 11;

[0146] c) An antibody comprising, or consisting of, a heavy chain variable domain of any sequence shown in SEQ ID No. 15 or exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 15, and three light chain CDRs shown in sequences SEQ ID No. 9, 5 and 12;

[0147] d) An antibody comprising, or consisting of, a heavy chain variable domain of any sequence shown in SEQ ID No. 16 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 16, and three light chain CDRs shown in sequences SEQ ID Nos. 9, 5, and 11; and

[0148] e) An antibody comprising, or consisting of, a heavy chain variable domain of any sequence shown in SEQ ID No. 17 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 17, and three light chain CDRs shown in sequences SEQ ID No. 9, 5, and 12.

[0149] "Any sequence exhibiting at least 80%, preferably 85%, 90%, 95%, or 98% identity with SEQ ID NO. 13 to 17" refers to sequences representing the three heavy chain CDRs SEQ ID NO. 1, 2, and 3, as well as sequences other than those corresponding to the CDRs (i.e., SEQ ID NO. 1, 2, and 3) that exhibit at least 80%, preferably 85%, 90%, 95%, or 98% identity with the full-length sequences SEQ ID NO. 13 to 17, where "other than those corresponding to the CDRs" means "except for those corresponding to the CDRs".

[0150] In another preferred but non-limiting embodiment, the antibody of the present invention is selected from:

[0151] a) An antibody comprising a light chain variable domain of any sequence shown in SEQ ID No. 18 or exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 18, and three heavy chain CDRs shown in sequences SEQ ID No. 7, 2 and 3;

[0152] b) An antibody comprising a light chain variable domain of any sequence shown in SEQ ID No. 19 or exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 19, and three heavy chain CDRs shown in sequences SEQ ID No. 7, 2 and 3;

[0153] c) An antibody comprising a light chain variable domain of any sequence shown in SEQ ID No. 20 or exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 20, and three heavy chain CDRs shown in sequences SEQ ID No. 7, 2 and 3;

[0154] d) An antibody comprising a light chain variable domain of any sequence shown in SEQ ID No. 21 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 21, and three heavy chain CDRs shown in SEQ ID Nos. 8, 2, and 3; and

[0155] e) An antibody comprising a light chain variable domain of any sequence shown in SEQ ID No. 22 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 22, and three heavy chain CDRs shown in sequences SEQ ID No. 7, 2, and 3.

[0156] "Any sequence that exhibits at least 80%, preferably 85%, 90%, 95% or 98% identity with SEQ ID NO. 18 to 22" refers to sequences representing the three light chain CDRs SEQ ID NO. 4, 5 and 6, as well as sequences that exhibit at least 80%, preferably 85%, 90%, 95% or 98% identity with the full-length sequences SEQ ID NO. 18 to 22 other than the sequences corresponding to the CDRs (i.e. SEQ ID NO. 4, 5 and 6).

[0157] One embodiment of the present invention relates to an antibody selected from:

[0158] a) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 13 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 13, and a light chain variable domain of any sequence shown in SEQ ID No. 18 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 18;

[0159] (b) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 14 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 14, and a light chain variable domain of any sequence shown in SEQ ID No. 19 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 19;

[0160] c) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 15 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 15, and a light chain variable domain of any sequence shown in SEQ ID No. 20 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 20;

[0161] d) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 16 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 16, and a light chain variable domain of any sequence shown in SEQ ID No. 21 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 21; and

[0162] e) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 17 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 17, and a light chain variable domain of any sequence shown in SEQ ID No. 22 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 22.

[0163] The chimeric antibodies described herein can also be characterized by constant structural domains, and more specifically, the chimeric antibodies can be selected or designed, such as, but not limited to, IgG1, IgG2, IgG3, IgM, IgA, IgD, or IgE. More preferably, in the context of this invention, the chimeric antibody is IgG1 or IgG4.

[0164] One embodiment of the present invention relates to a chimeric antibody comprising the aforementioned variable domains VH and VL in the form of IgG1. More preferably, the chimeric antibody comprises a constant VH domain as shown in sequence SEQ ID No. 43 and a κ domain of VL as shown in sequence SEQ ID No. 45.

[0165] One embodiment of the present invention relates to a chimeric antibody comprising the aforementioned variable domains VH and VL in the form of IgG4. More preferably, the chimeric antibody comprises a constant VH domain as shown in sequence SEQ ID No. 44 and a κ domain of VL as shown in sequence SEQ ID No. 45.

[0166] In another preferred but non-limiting embodiment, the antibody of the present invention is selected from:

[0167] a) An antibody comprising or consisting of a heavy chain of any sequence shown in SEQ ID No. 23 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 23, and a light chain of any sequence shown in SEQ ID No. 28 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 28;

[0168] (b) An antibody comprising or consisting of a heavy chain of any sequence shown in SEQ ID No. 24 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 24, and a light chain of any sequence shown in SEQ ID No. 29 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 29;

[0169] c) An antibody comprising or consisting of a heavy chain of any sequence shown in SEQ ID No. 25 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 25, and a light chain of any sequence shown in SEQ ID No. 30 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 30;

[0170] d) An antibody comprising or consisting of a heavy chain of any sequence shown in SEQ ID No. 26 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 26, and a light chain of any sequence shown in SEQ ID No. 31 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 31; and

[0171] e) An antibody comprising or consisting of a heavy chain of any sequence shown in SEQ ID No. 27 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 27, and a light chain of any sequence shown in SEQ ID No. 32 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 32.

[0172] For clarity, Table 3 below shows the sequences of the preferred chimeric antibodies VH and VL, respectively.

[0173] Table 3

[0174]

[0175] Another specific aspect of the invention relates to a humanized antibody or an antigen-binding fragment thereof, characterized in that the constant regions of the light chain and heavy chain derived from the human antibody are λ or κ regions and γ-1, γ-2 or γ-4 regions, respectively.

[0176] In one embodiment of the present invention, the antibody is composed of a humanized antibody.

[0177] "Humanized antibody" means an antibody containing a CDR region derived from a non-human antibody, with other parts of the antibody molecule derived from one (or more) human antibodies. Furthermore, some backbone residues (called FRs) may be modified to maintain binding affinity.

[0178] Humanized antibodies or fragments thereof can be prepared using techniques known to those skilled in the art. Such humanized antibodies are preferably used in methods involving in vitro diagnostics or in vivo prophylactic and / or therapeutic treatments. Other humanization techniques also known to those skilled in the art include, for example, the “CDR grafting” technique described by PDL in patents EP 0 451 216, EP 0 682 040, EP 0 939 127, EP 0566 647 or US 5,530,101, US 6,180,370, US 5,585,089 and US 5,693,761. Also cited are US patents 5,639,641 or 6,054,297, 5,886,152 and 5,877,293.

[0179] As a specific embodiment of the invention, and as will be explained in more detail in the following examples, an antibody composed of hz208F2 is described herein. Such humanization can also be applied to other antibody portions of the invention.

[0180] In a preferred embodiment, the antibody according to the invention comprises a heavy chain variable domain (VH) having:

[0181] i) CDR-H1, CDR-H2, and CDR-H3, respectively, represented by sequences SEQ ID No. 7, 2, and 3.

[0182] ii) FR1, FR2, and FR3 (SEQ ID No. 46) derived from hominid IGHV1-46*01, and

[0183] iii) FR4 (SEQ ID No. 48) derived from hominid lineage IGHJ4*01.

[0184] In a preferred embodiment, the antibody according to the invention comprises a light chain variable domain (VL) having:

[0185] i) CDR-L1, CDR-L2, and CDR-L3, respectively, represented by sequences SEQ ID No. 9, 5, and 11,

[0186] ii) FR1, FR2, and FR3 (SEQ ID No. 47) derived from hominid IGKV1-39*01, and

[0187] iii) FR4 (SEQ ID No. 49) derived from hominid IGKJ4*01.

[0188] In a preferred, but non-limiting, embodiment of the invention, the antibody comprises:

[0189] a) A heavy chain having CDR-H1, CDR-H2, and CDR-H3 as shown in sequences SEQ ID No. 7, 2, and 3, respectively, and FR1, FR2, and FR3 (SEQ ID No. 46) derived from human lineage IGHV1-46*01, and FR4 (SEQ ID No. 48) derived from human lineage IGHJ4*01; and

[0190] b) A light chain having CDR-L1, CDR-L2 and CDR-L3 as shown in sequences SEQ ID No. 9, 5 and 11, respectively, and FR1, FR2 and FR3 (SEQ ID No. 47) derived from human lineage IGKV1-39*01, and FR4 (SEQ ID No. 49) derived from human lineage IGKJ4*01.

[0191] In one embodiment, the antibody according to the invention comprises a heavy chain variable domain (VH) as shown in sequence SEQ ID No. 33 and a light chain variable domain (VL) as shown in sequence SEQ ID No. 35. The humanized antibody will hereinafter be referred to as hz208F2 (“variant” or “Var.”1”).

[0192] In another embodiment, the antibody according to the invention comprises a heavy chain variable domain (VH) as shown in sequence SEQ ID No. 33, wherein the sequence SEQ ID No. 33 comprises at least one reversion mutation selected from residues 20, 34, 35, 38, 48, 50, 59, 61, 62, 70, 72, 74, 76, 77, 79, 82 and 95.

[0193] The term "reversion mutation" means that a human residue present in the germline is mutated or replaced by a corresponding residue initially present in the mouse sequence.

[0194] In another embodiment, the antibody according to the invention comprises a heavy chain variable domain (VH) as shown in sequence SEQ ID No. 33, wherein the sequence SEQ ID No. 33 comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 reversion mutations selected from residues 20, 34, 35, 38, 48, 50, 59, 61, 62, 70, 72, 74, 76, 77, 79, 82 and 95.

[0195] For clarity, Table 4 below shows the preferred reversion mutations.

[0196] Table 4

[0197]

[0198] In one embodiment, the antibody according to the invention comprises a light chain variable domain (VL) as shown in sequence SEQ ID No. 35, wherein the sequence SEQ ID No. 35 comprises at least one reversion mutation selected from residues 22, 53, 55, 65, 71, 72, 77 and 87.

[0199] In one embodiment, the antibody according to the invention comprises a light chain variable domain (VL) as shown in sequence SEQ ID No. 35, wherein the sequence SEQ ID No. 35 comprises 2, 3, 4, 5, 6, 7 or 8 reversion mutations selected from residues 22, 53, 55, 65, 71, 72, 77 and 87.

[0200] In another embodiment, the antibody according to the invention comprises:

[0201] a) The heavy chain variable domain (VH) shown in sequence SEQ ID No. 33, wherein sequence SEQ ID No. 33 contains at least one reversion mutation selected from residues 20, 34, 35, 38, 48, 50, 59, 61, 62, 70, 72, 74, 76, 77, 79, 82, and 95; and

[0202] b) The light chain variable domain (VL) shown in sequence SEQ ID No. 35, wherein the sequence SEQ ID No. 35 contains at least one reversion mutation selected from residues 22, 53, 55, 65, 71, 72, 77 and 87.

[0203] For clarity, Table 5 below shows the preferred reversion mutations.

[0204] Table 5

[0205] amino acid N° 22 53 55 65 71 72 77 87 mouse S R H R Y S N F people T S Q S F T S Y

[0206] In such an embodiment, the antibody according to the invention comprises all the above-described reversion mutations, corresponding to an antibody comprising the heavy chain variable domain (VH) shown in sequence SEQ ID No. 34 and the light chain variable domain (VL) shown in sequence SEQ ID No. 36. The humanized antibody will hereinafter be referred to as hz208F2 (“variant” or “Var.”3”).

[0207] In another embodiment, all humanized forms comprising variants 1 to 3 are also included in this invention. In other words, the antibody according to the invention corresponds to an antibody comprising the heavy chain variable domain (VH) shown in the “identical” sequence SEQ ID No. 41 and the light chain variable domain (VL) shown in the “identical” sequence SEQ ID No. 42. Generally, the humanized antibody will be referred to below as hz208F2 (“variant” or “Var.”2”).

[0208] In a preferred, but not limiting, embodiment of the invention, the antibody is selected from:

[0209] a) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 33 or exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 33, and three light chain CDRs shown in SEQ ID No. 9, 5 and 11;

[0210] b) An antibody comprising a heavy chain variable domain of any sequence shown in SEQ ID No. 34 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 34, and three light chain CDRs shown in sequences SEQ ID Nos. 9, 5, and 11; and

[0211] c) An antibody comprising a heavy chain variable domain selected from sequences shown in SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80 or having at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80; and three light chain CDRs shown in sequences SEQ ID No. 9, 5 and 11.

[0212] "Any sequence exhibiting at least 80%, preferably 85%, 90%, 95%, or 98% identity with SEQ ID No. 33, 34, 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, or 80" refers to sequences exhibiting three heavy chain CDRs SEQ ID NO. 1, 2, and 3, as well as sequences exhibiting at least 80%, preferably 85%, 90%, 95%, or 98% identity with the full-length sequences SEQ ID NO. 33, 34, 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, and 80 other than the sequences corresponding to the CDRs (i.e., SEQ ID NO. 1, 2, and 3).

[0213] In a preferred, but not limiting, embodiment of the invention, the antibody is selected from:

[0214] a) An antibody comprising a light chain variable domain of any sequence shown in SEQ ID No. 35 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 35, and three heavy chain CDRs shown in SEQ ID Nos. 7, 2, and 3; and

[0215] b) An antibody comprising a light chain variable domain of any sequence shown in SEQ ID No. 36 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 36, and three heavy chain CDRs shown in sequences SEQ ID No. 7, 2, and 3; and

[0216] c) An antibody comprising a light chain variable domain selected from sequences shown in SEQ ID No. 57 and 60 or having at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 57 or 60, and three heavy chain CDRs shown in sequences SEQ ID No. 7, 2, and 3.

[0217] "Any sequence exhibiting at least 80%, preferably 85%, 90%, 95%, or 98% identity with SEQ ID No. 35, 36, 57, or 60" refers to sequences exhibiting the three light chain CDRs SEQ ID NO. 4, 5, and 6, as well as sequences exhibiting at least 80%, preferably 85%, 90%, 95%, or 98% identity with the full-length sequences SEQ ID NO. 35, 36, 57, or 60 other than the sequences corresponding to the CDRs (i.e., SEQ ID NO. 4, 5, and 6).

[0218] The humanized antibodies described herein can also be characterized by constant structural domains, and more specifically, the humanized antibodies can be selected or designed, such as, but not limited to, IgG1, IgG2, IgG3, IgM, IgA, IgD, or IgE. More preferably, in the context of this invention, the humanized antibody is IgG1 or IgG4.

[0219] One embodiment of the present invention relates to a humanized antibody comprising the aforementioned variable domains VH and VL in the form of IgG1. More preferably, the humanized antibody comprises a constant VH domain as shown in sequence SEQ ID No. 43 and a κ domain of VL as shown in sequence SEQ ID No. 45.

[0220] One embodiment of the present invention relates to a humanized antibody comprising the aforementioned variable domains VH and VL in the form of IgG4. More preferably, the humanized antibody comprises a constant VH domain as shown in sequence SEQ ID No. 44 and a κ domain of VL as shown in sequence SEQ ID No. 45.

[0221] In another embodiment of the present invention, an antibody is selected from:

[0222] a) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 37 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 37, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 39 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 39;

[0223] b) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 38 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 38, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 40 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 40; and

[0224] c) An antibody comprising a heavy chain variable domain of any sequence selected from SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, and 80, or having at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, or 80, and a light chain variable domain of any sequence selected from SEQ ID No. 57 and 60, or having at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 57 or 60. For clarity, Table 6a below shows non-limiting examples of the VH and VL sequences of variant 1 (Var.1) and variant 3 (Var.3) of the humanized antibody hz208F2. A congruent sequence of variant 2 (Var.2) is also included.

[0225] Table 6a

[0226]

[0227] In another preferred but non-limiting embodiment, the antibody of the present invention is selected from:

[0228] a) An antibody comprising a heavy chain variable domain selected from the sequences shown in SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80 or having at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78 or 80; and three light chain CDRs shown in sequences SEQ ID No. 9, 5 and 11;

[0229] b) An antibody comprising a light chain variable domain selected from sequences shown in SEQ ID No. 57 and 60 or having at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 57 or 60; and three heavy chain CDRs shown in sequences SEQ ID No. 7, 2, and 3; and

[0230] (c) An antibody comprising a light chain variable domain comprising a sequence selected from SEQ ID No. 57 and 60 or having at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 57 or 60; and a heavy chain variable domain comprising a sequence selected from SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, and 80 or having at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, or 80.

[0231] Another embodiment of the present invention relates to an antibody selected from antibodies comprising or composed of the following:

[0232] a) A heavy chain selected from the sequences shown in SEQ ID Nos. 58, 63, 65, 67, 69, 71, 73, 75, 77, 79, and 81, or having at least 80%, preferably 85%, 90%, 95%, or 98% identity with any sequence of SEQ ID Nos. 58, 63, 65, 67, 69, 71, 73, 75, 77, 79, or 81; and

[0233] b) A light chain selected from sequences shown in SEQ ID No. 59 and 61, or having at least 80%, preferably 85%, 90%, 95%, or 98% identity with SEQ ID No. 59 or 61. Another embodiment of the invention relates to an antibody selected from: a) an antibody comprising a heavy chain variable domain of any sequence shown in or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 56, 62, 64, 66, 68, 70, 72, 74, 76, 78, and 80; and a light chain variable domain of any sequence shown in or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 57; and

[0234] (b) An antibody comprising a heavy chain variable domain of any sequence selected from SEQ ID No. 56, 64, 68 and 78, or exhibiting at least 80%, 85%, 90%, 95% or 98% identity with SEQ ID No. 56, 64, 68 or 78, and a light chain variable domain of any sequence selected from SEQ ID No. 60, or exhibiting at least 80% identity with SEQ ID No. 60.

[0235] Another embodiment of the present invention relates to an antibody selected from:

[0236] a) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 58 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 58, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0237] (b) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 58 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 58, and a light chain of any sequence shown in SEQ ID No. 61 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 61;

[0238] c) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 63 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 63, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0239] d) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 65 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 65, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0240] e) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 65 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 65, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 61 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 61;

[0241] f) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 67 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 67, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0242] g) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 69 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 69, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0243] h) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 69 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 69, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 61 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 61;

[0244] i) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 71 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 71, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0245] (j) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 73 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 73, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0246] k) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 75 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 75, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0247] (l) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 77 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 77, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0248] m) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 79 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 79, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59;

[0249] n) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 79 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 79, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 61 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 61; and

[0250] o) An antibody comprising, or consisting of, a heavy chain of any sequence shown in SEQ ID No. 81 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 81, and a light chain comprising, or consisting of any sequence shown in SEQ ID No. 59 or exhibiting at least 80%, 85%, 90%, 95%, or 98% identity with SEQ ID No. 59.

[0251] For clarity, Table 6b below shows non-limiting examples of the sequences (variable domains and full length) of VH and VL of different variants of the humanized antibody hz208F2.

[0252] Table 6b

[0253]

[0254]

[0255] Another aspect of the present invention is an antibody selected from:

[0256] i) Antibodies produced from hybridomas CNCM I-4757, CNCM I-4773, CNCM I-4775, CNCM I-4736, or CNCM I-4774 were deposited on May 30, 2013, June 26, 2013, June 26, 2013, April 24, 2013, and June 26, 2013, respectively, at the National Center for Microbial Culture Collection, Paris, France, 25 Rue Doctéur Roux, Pasteur Institute, 15 75724, France.

[0257] ii) The antibody that competes with i) for binding to IGF-1R; and

[0258] iii) Antibodies that bind to the same IGF-1R epitope as the antibodies in i).

[0259] According to another aspect, the present invention relates to a mouse hybridoma selected from hybridomas CNCM I-4757, CNCM I-4773, CNCM I-4775, CNCM I-4736 and CNCM I-4774 deposited at the National Center for Microbial Culture Collection on May 30, 2013, June 26, 2013, April 24, 2013 and June 26, 2013, respectively.

[0260] A new aspect of the present invention relates to an isolated nucleic acid that encodes an antibody or an antigen-binding fragment thereof according to the present invention.

[0261] The terms “nucleic acid,” “nucleic acid sequence,” “nucleic acid sequence,” “polynucleotide,” “oligonucleotide,” “polynucleotide sequence,” and “nucleotide sequence,” used interchangeably in this specification, refer to the precise nucleotide sequence of a defined fragment or region of a nucleic acid, whether modified or unmodified, containing or not containing non-natural nucleotides, and is a double-stranded DNA, single-stranded DNA, or a transcript of said DNA.

[0262] The sequences of this invention have been isolated and / or purified, i.e., through replication, by direct or indirect sampling, and by means of at least partial alteration of their environment. Reference is also made to obtaining isolated nucleic acids, for example, through genetic recombination in host cells, or through chemical synthesis.

[0263] The present invention also relates to a vector comprising a nucleic acid encoding an antibody or an antigen-binding fragment thereof according to the present invention.

[0264] This invention is particularly directed to cloning and / or expression vectors containing such nucleotide sequences.

[0265] The vector preferably contains elements that allow the expression and / or secretion of the nucleotide sequence in a given host cell. Therefore, the vector must contain a promoter, translation initiation and termination signals, and appropriate transcriptional regulatory regions. It must be able to be maintained stably in the host cell and optionally have specific signals that direct the secretion of the translated protein. Depending on the host cell used, those skilled in the art can select and optimize these different elements. For this purpose, the nucleotide sequence can be inserted into an autonomously replicating vector within the selected host, or an integrative vector within the selected host.

[0266] Such vectors are prepared using methods commonly used by those skilled in the art, and the resulting clones can be introduced into a suitable host using standard methods such as lipid transfection, electroporation, heat shock, or chemical methods.

[0267] Vectors are, for example, plasmids or viral vectors. They are used to transform host cells to clone or express the nucleotide sequences of the present invention.

[0268] The present invention also relates to the transformation of isolated host cells containing or including the above-described vectors.

[0269] The host cell can be selected from prokaryotic or eukaryotic systems, such as bacterial cells, yeast cells, or animal cells, especially mammalian cells (except human cells). Insect or plant cells can also be used.

[0270] The present invention also relates to animals (other than humans) with transformed cells.

[0271] On the other hand, a method for producing an antibody or antigen-binding fragment thereof according to the invention is provided, characterized in that the method comprises the following steps:

[0272] a) Culture the host cells according to the invention in a medium and under appropriate culture conditions; and

[0273] b) Recover the antibody or one of its antigen-binding fragments produced therefrom from the culture medium or from the cultured cells.

[0274] Transformed cells can be used in the method for preparing recombinant antibodies according to the invention. Methods for preparing recombinant antibodies are also included in this specification, which use the vector according to the invention and / or cells transformed with the vector according to the invention. Preferably, cells transformed with the aforementioned vector are cultured under conditions that allow for the expression of the aforementioned antibody and the recovery of the antibody.

[0275] As already mentioned, the host cell can be selected from prokaryotic or eukaryotic systems. In particular, nucleotide sequences favorable for secretion in this prokaryotic or eukaryotic system can be identified. The vector according to the invention carrying such sequences can therefore be advantageously used for the production of the recombinant protein to be secreted. In fact, the fact that the protein is present in the cell culture supernatant rather than in the host cell will facilitate the purification of these recombinant proteins of interest.

[0276] Antibodies can also be prepared by chemical synthesis. One such preparation method is also an object of this invention. Those skilled in the art know methods for chemical synthesis, such as solid-phase or partially solid-phase techniques used in conventional solution synthesis, through the concentration of fragments. The invention also includes polypeptides obtained by chemical synthesis that can contain the corresponding non-natural amino acids.

[0277] The present invention also includes antibodies or any antigen-binding fragments thereof that may be obtained by the methods described above.

[0278] According to one specific aspect, the present invention relates to the above-described antibody or antigen-binding fragment thereof, used as a localization vector for delivering a cytotoxic agent to a host target site, the host target site being composed of an epitope located in IGF-1R, preferably the IGF-1R extracellular domain, more preferably human IGF-1R (SEQ ID No. 50), and still more preferably the IGF-1R extracellular domain (SEQ ID No. 51), and still more preferably the N-terminus of the IGF-1R extracellular domain (SEQ ID No. 52), or any natural variant sequence thereof.

[0279] In a preferred embodiment, the host target site is a target site of mammalian cells, more preferably human cells, and more preferably cells that express IGF-1R naturally or through gene recombination.

[0280] Another aspect of the present invention is an antibody-drug conjugate comprising the aforementioned antibody or its antigen-binding fragment conjugated to a cytotoxic agent.

[0281] This invention relates to immunoconjugates comprising antibodies conjugated to cytotoxic agents as described in this specification.

[0282] The term "immunoconjugate" or "immuno-conjugate" generally refers to a compound that contains at least one targeting product, such as an antibody, which is physically linked to one or more therapeutic agents to create a highly targeted compound.

[0283] In a preferred embodiment, such a therapeutic agent consists of a cytotoxic agent.

[0284] "Cytotoxic agents" or "cytotoxins" refer to agents that, when administered to a subject, treat or prevent the development of abnormal cell proliferation by inhibiting or preventing cell function and / or causing cell death, preferably cancer development in the subject's body.

[0285] Many cytotoxic agents have been isolated or synthesized, enabling them to inhibit cell proliferation or (if not clearly defined) at least significantly destroy or reduce tumor cells. However, the toxic activity of these agents is not limited to tumor cells; non-tumor cells are also affected and can be destroyed. More specifically, side effects have been observed in rapidly regenerating cells, such as hematopoietic cells or epithelial cells, especially in mucous membranes. By way of example, gastrointestinal cells are significantly affected by the use of such cytotoxic agents.

[0286] One of the objectives of this invention is to provide a cytotoxic agent that allows for limiting side effects on normal cells while retaining high cytotoxicity against tumor cells.

[0287] More specifically, the cytotoxic agent may preferably consist of, but is not limited to, drugs (i.e., "antibody-drug conjugates"), toxins (i.e., "immunotoxins" or "antibody-toxin conjugates"), radioisotopes (i.e., "radioimmunoconjugates" or "antibody-radioisotope conjugates"), etc.

[0288] In a first preferred embodiment, the immunoconjugate consists of an antibody linked to at least one drug or pharmaceutical product. Such an immunoconjugate is referred to as an antibody-drug conjugate (or "ADC").

[0289] In the first embodiment, such a drug may be described according to its mode of action. As a non-limiting example, references may be made to alkylating agents (such as nitrogen mustard, alkyl sulfonates, nitrosoureas, oxazophorin, aziridine, or ethyleneimine), antimetabolites, antitumor antibiotics, mitotic inhibitors, chromatin function inhibitors, antiangiogenic agents, antiestrogens, antiandrogens, chelating agents, iron absorption stimulants, cyclooxygenase inhibitors, phosphodiesterase inhibitors, DNA inhibitors, DNA synthesis inhibitors, apoptosis stimulants, thymidine nucleotide inhibitors, T-cell inhibitors, interferon agonists, ribonucleoside triphosphate reductase inhibitors, aromatase inhibitors, estrogen receptor antagonists, tyrosine agonists, etc. Enzyme inhibitors, cell cycle inhibitors, taxanes, tubulin inhibitors, angiogenesis inhibitors, macrophage stimulants, neurokinin receptor antagonists, cannabinoid receptor agonists, dopamine receptor agonists, granulocyte-stimulating factor agonists, erythropoietin receptor agonists, somatostatin receptor agonists, LHRH agonists, calcium sensitizers, VEGF receptor antagonists, interleukin receptor antagonists, osteoclast inhibitors, free radical stimulants, endothelin receptor antagonists, vinca alkaloids, anti-hormonal or immunomodulatory agents, or any other new drugs that meet the criteria for cytotoxic or toxic activity.

[0290] For example, VIDAL 2010 cites this drug on the page about compounds attached to the "Cytoxins" section of the Oncology and Hematology column, and these cytotoxic compounds cited in this document are referred to here as preferred cytotoxic agents.

[0291] More specifically, but not limited to, the following drugs or pharmaceuticals are preferred according to the present invention: dichloromethyldiethylamine, chlorambucol, melphalan, chloride, pipebromen, prednimustin, disodic phosphate, estradiol, cyclophosphamide, altretamine, trelophosphamide, sulfofosfamide, ifosfamide, thiotepa, triethylamine, altetramine, carmustine, streptozotocin, fotiam, lomustine, busulfan, treosulfan, improsulfan, dacarbazine, cisplatin, oxaliplatin, lobaplatin, heptaplatin, miriplatin hydrate, carboplatin, methotrexate, pemetrexed, 5-fluorouracil. Pyridine, fluorouridine, 5-fluorodeoxyuridine, capecitabine, cytarabine, fludarabine, cytosine arabinoside, 6-mercaptopurine (6-MP), nerabine, 6-mercapguanine (6-TG), chlorodeoxyadenosine, 5-azacytidine, gemcitabine, cladribine, deoxycofromycin, tegafur, pentostatin, doxorubicin, idarubicin, idarubicin, mitoxantrone, styromycin, bleomycin, procainazole Mitomycin C, Bleomycin, Procarbazine, Paclitaxel, Docetaxel, Vincristine, Vincristine, Vinorelbine, Topotecan, Irinotecan, Etoposide, Pentorubicin, Amrubicin Hydrochloride, Pirarubicin, Iridazole, Zolaxobin, Epirubicin, Idarubicin and Teniposide, Razosen, Marimasta, Palmasta, Prolinesta, Tannostat, Ilomasta, CGS-27023A, Halofurone, COL-3, Neovastat, Thalidomide, CDC501, DMXAA, L-651582, Squalamine, Endostatin, SU5416, SU6668, Interferon-α, EMD121974, Interleukin-12, IM862, Angiogenesis Inhibitor, Tamoxifen, Toremifene, Raloxifene, Droloxifen, Iodoxyfene, Anastrozole, Letrozole, Exemestane, Flutamide, Nilumethicone, Spironolactone, Cyproterone Acetate, Finasteride, Cimetidine, Bortezomib, Velcade, Bicalutamide, Cyproterone Acetate, Flutamide, Fulvestran, Exemestane, Dasati Nitrogen, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Sorafenib, Sunitinib, Retinol, Rexinoid, Methoxalene, Methyl Aminolevulinate, Aldesleukine, OCT-43, Denileukin Diflitox, Interleukin-2, Tasonermine, Lentinan, Cizonan, Roquimec, Pidotimod, Pergamase, Thymopentin, Poly(I:C), Procodazol, Tic BCG, CorynebacteriumParvum), NOV-002, ukrain, levamisole, 1311-chTNT, H-101, simvastatin, interferon α2a, interferon α2b, interferon γ1a, interleukin-2, mobelin, Rexin-G, texileukin, aclarubicin, actinomycin, arglabin, asparaginase, carzinophilin, chromomycin, donomycin, folinic acid, masorofol, new preparation Oncogenes, Pepromycin, Sarcomacin, Solanine, Trabectedin, Strezocin, Testosterone, Cummingerin, Sinecatechins, Alivitan, Belotecone Hydrochloride, Capprotestone, Drotandrone, Elimex, Ethinylestradiol, Etoposide, Fluorometestosterone, Formestane, Fosfetrol, Goserelin Acetate, Hexylaminolevulinic Acid, Histamine Relin, Hydroxyprogesterone, Ixaspiron, Leuprorelin, Medroxyprogesterone Acetate, Megestrol Acetate Acetate, Methylprednisolone, Methyltestosterone, Mitefosine, Dibromomannitol, Nandrolone phenylpropionate, Norethindrone acetate, Prednisolone, Prednisone, Teseirolimus, Testrolide, Fluorohydroprednisolone, Triptorelin, Vaportide acetate, Netsistatin ester, Acridine, Arsenic trioxide, Bismuth subsalicylate, Chlortrianisene, Cisdiamine dichloroplatinum, Cyclophosphamide, Diethylstilbestrol, Hexamethylmelamine, Hydroxyurea, Lenadiol Amine, chlordamine, mechlorethanamine, mitotane, nedaplatin, nimustine hydrochloride, pamidronate, piperbbromide, porphyrin sodium, ramustine, razorizine, semustine, sobuzozine, mesylate, triethylene melamine, zoledronic acid, carmustine mesylate, fazodazole HCl, nafoxidine, amylglutathione, carmoflu, clofarabine, cytosine arabinoside, decitabine, deoxyfluorouridine, enoxabin, fludarabine phosphate, fluorouracil, tegafur, uracil nitrogen mustard, abalex, bexarotine, raltiterxed, tamibarbitine, temozolomide, vorinostat, megestrol acetate, disodium clodronate, levamisole, nano iron oxide, iron isomaltose.isomaltoside), celecoxib, isobutylasteride, bendamustine, hexamethylmelamine, dibromoceramide, sirolimus, pralatrexate, TS-1, decitabine, bicalutamide, flutamide, letrozole, disodium clodronate, degarelix, toremifene citrate, histamine dihydrochloride, DW-166HC, diamine nitroacin, decitabine, irinoteacn hydrochloride, acridine, romididesin, retinoic acid, cabazitaxel, vandetanil, lenalidomide, ibandronic acid, mitefocin, vitespen, mivamolide, nadroparin, granisetron, ondansetron, tropisetron, alipril, ramosetron Dolastron mesylate, fosapiramate meglumine, cannabinol, aprepitant, dronabinol, TY-10721, ergoestradiol maleate, epiceramide, defibrinolytic acid, dabigatran ester, filgrastim, pefexine, reditux, erythropoietin, morastine, olprene interleukin, sipuleucel-T, M-Vax, acetyl-L-carnitine, donepezil hydrochloride, 5-aminolevulinic acid, methyl aminolevulinic acid, cetrorexone acetate, icodextrin, leuprolide, metbylphenidate, octreotide, aminozanol, prasafone, tetraene-menaquinone, anethole dithiolethione, dulcitol, cinacalcet hydrochloride, afaxetine, omeprazole, thyroglobulin, thymosin, ubenimex, imiquimod, everolimus, sirolimus, H-101, lasoxifene, tralostane, incardronate, gangliosides, piperatanide sodium, vertoporfin, minodronate, zoledronic acid, gallium nitrate, alendronate sodium, etidronate disodium, pamidronate disodium, dutasteride, antimony gluconate sodium, armodafinib, dexazosin, amifostine, WF-10, temoporphyrin, dabepoetine alpha, ansistatin, saxagstatin, parivamine, R-744, napidemin, olprene interleukin, denileukin diftitox, cristaspase, buserelin, deserelin, lanreotide, octreotide, pilocarpine, bosentan, cacimycin, maytansine, nicotinic acid esters, and pyrrolobenzodiazepines, especially those disclosed in PCT application No. WO2011 / 130598.

[0292] In another embodiment, the immunoconjugate consists of an antibody linked to at least one radioisotope. Such an immunoconjugate is called an antibody-radioisotope conjugate (or "ARC").

[0293] To selectively destroy tumors, antibodies can include highly radioactive atoms. Various radioactive isotopes can be used to produce ARC, such as, but not limited to, At... 211 C13 N 15 O 17 、Fl 19 I 123 I 131 I 125 In 111 Y 90 Re 186 Re 188 、Sm 153 , tc 99 m、Bi 212 P 32 Pb 212 Radioactive isotopes of Lu, gadolinium, manganese or iron.

[0294] Any method or process known to those skilled in the art can be used to incorporate such a radioactive isotope into ARC. As a non-limiting example, tc 99 m or I 123 Re 186 Re 188 and In 111 It can attach via cysteine ​​residues. 90 It can attach via lysine residues. 123 Attachment can be performed using the IODOGEN method.

[0295] Several examples can be cited to illustrate the common sense of ARC professionals, such as ARC... It is a compound composed of an anti-CD20 monoclonal antibody and an In chelator bound via a thiourea linker. 111 Or Y 90 ARC composed of radioactive isotopes; or It consists of an anti-CD33 antibody linked to calichimycin (US 4,970,198; 5,079,233; 5,585,089; 5,606,040; 5,693,762; 5,739,116; 5,767,285; 5,773,001). More recently, an ADC called Adcetris (corresponding to Brentuximab vedotin) has also been mentioned, which has recently been approved by the FDA for the treatment of Hodgkin's lymphoma.

[0296] In another embodiment, the immunoconjugate consists of an antibody linked to at least one toxin. Such an immunoconjugate is called an antibody-toxin conjugate (or "ATC").

[0297] Toxins are potent and specific poisons produced by living organisms. They are typically composed of amino acid chains, which can vary in molecular weight, ranging from hundreds (peptides) to hundreds of thousands (proteins). They can also be low-molecular-weight organic compounds. Toxins are produced by many organisms, such as bacteria, fungi, algae, and plants. Many of them are highly toxic, exhibiting toxicity several orders of magnitude stronger than nerve agents.

[0298] The toxins used for ATC can include, but are not limited to, all types of toxins, which can exert their cytotoxic effects through mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition.

[0299] Available enzymatically active toxins and their fragments include diphtheria toxin A chain, non-bound active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, absinthecin A chain, sarcin, tung oil protein, carnation protein, Phytolaca americana protein (PAPI, PAPII, and PAP-S), bitter gourd inhibitor, jatropha toxin, croton toxin, sapaonaria officinalis inhibitor, white tree toxin, mitogellin, localized trachomatis, phenolmycin, enoxacin, and trichothecene.

[0300] Small molecule toxins, such as dorlastatin, auristatin, especially monomethyl auristatin E (MMAE), trichothecene, and CC1065, and derivatives of these toxins with toxic activity, may also be considered here. Dorlastatin and auristatin have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cell division, and possess anticancer and antifungal activities.

[0301] "Connector", "connector unit" or "link" refers to a chemical part containing a covalent bond or atomic chain that covalently attaches an antibody to at least one cytotoxic agent.

[0302] Connectors can be prepared using a variety of bifunctional protein coupling agents, such as N-succinimide-3-(2-pyridyl dithio)propionate (SPDP), succinimide-4-(N-maleimidemethyl)cyclohexane-1-carboxylate (SMCC), iminothiones (IT), bifunctional derivatives of imine esters (such as hexamethylenediimide HCl), active esters (such as disuccinimide octanoate), aldehydes (such as glutaraldehyde), diazid compounds (such as bis(p-azidobenzoyl)hexamethylenediamine), diazo derivatives (such as bis(p-diazobenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and biactive fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Carbon-14 labeled benzyl-3-methylethyltriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating cytotoxic agents to a targeting system. Other crosslinking linker agents may be BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfonyl-EMCS, sulfonyl-GMBS, sulfonyl-KMUS, sulfonyl-MBS, sulfonyl-SIAB, sulfonyl-SMCC, sulfonyl-SMPB, and SVSB (succinimide-(4-vinyl sulfone)benzoate), which are commercially available (e.g., Pierce Biotechnology, Inc., Rockford, I11, USA).

[0303] The connector can be either "uncuttable" or "cuttable".

[0304] In a preferred embodiment, it includes a "cleavable adapter" to facilitate the intracellular release of the cytotoxic agent. For example, acid-labile adapters, peptidase-sensitive adapters, light-labile adapters, dimethyl adapters, or disulfide-containing adapters may be used. In a preferred embodiment, the adapter is cleavable under intracellular conditions, thereby cleaving the adapter in the intracellular environment to release the cytotoxic agent from the antibody.

[0305] For example, in some embodiments, the linker is cleavable by a cleaving agent present in the intracellular environment (e.g., within lysosomes, endosomes, or cell membrane caveoles). The linker can be, for example, a peptide linker that is cleaved by intracellular peptidases or proteases (including, but not limited to, lysosomal or endosomal proteases). Typically, the peptide linker is at least 2 amino acids long or at least 3 amino acids long. Cleavage agents can include cathepsins B and D, as well as plasmin, all of which are known to hydrolyze dipeptide drug derivatives, resulting in the release of the active drug within the target cell. For example, a peptide linker (such as a Phe-Leu or Gly-Phe-Leu-Gly linker) that can be cleaved by the thiol-dependent protease cathepsin B, which is highly expressed in cancerous tissue, can be used. In specific embodiments, the peptide linker that can be cleaved by intracellular proteases is a Val-Cit linker or a Phe-Lys linker. One advantage of using intracellular proteases to hydrolyze and release cytotoxic agents is that the agent is often attenuated when conjugated, and the serum stability of the conjugate is generally high.

[0306] In other embodiments, the cleavable connector is pH-sensitive, meaning it is sensitive to hydrolysis at a specific pH value. Typically, pH-sensitive connectors are hydrolyzable under acidic conditions. For example, acid-labile connectors that are hydrolyzable in lysosomes (such as hydrazones, ureas, thioureas, cis-aconitamides, orthoesters, acetals, ketals, etc.) can be used. Such connectors are relatively stable under neutral pH conditions, such as those in blood, but unstable below pH 5.5 or 5.0 (approximate to the pH of lysosomes). In some embodiments, the hydrolyzable connector is a thioether connector (e.g., a thioether attached to a therapeutic agent via an acylhydrazone bond).

[0307] In some other embodiments, the connector can be cut under reducing conditions (e.g., disulfide connectors). Various disulfide connectors are known in the art, including those formed, for example, using SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate), and SMPT (N-succinimidyl-oxycarbonyl-α-methyl-α-(2-pyridyl-dithio)toluene), SPDB, and SMPT.

[0308] As a non-limiting example of an uncuttable or "irreducible" connector, reference may be made to the immunoconjugate trastuzumab-DM1 (TDM1), which combines trastuzumab with the linked chemotherapeutic agent maytansine.

[0309] In a preferred embodiment, the immunoconjugates of the present invention can be prepared by any method known to those skilled in the art, such as, but not limited to, i) reacting the nucleophilic group of an antibody with a divalent linker reagent and then reacting it with a cytotoxic agent, or ii) reacting the nucleophilic group of a cytotoxic agent with a divalent linker reagent and then reacting it with the nucleophilic group of an antibody.

[0310] When antigen-binding proteins are glycosylated, the nucleophilic groups on the antibody include, but are not limited to, N-terminal amino groups, side-chain amino groups such as lysine, side-chain thiols, and hydroxyl or amino groups of sugars. Amines, thiols, and hydroxyl groups are nucleophilic and can react with electrophilic groups on the linker moiety to form covalent bonds. Linker reagents include, but are not limited to, reactive esters such as NHS esters, HOBt esters, halocarboxylate esters, and acid halides; alkyl and benzyl halides such as haloacetamides; aldehydes, ketones, carboxyl groups, and maleimide groups. Antibodies may have reducible interchain disulfide bonds, i.e., cysteine ​​bridges. Treatment with a reducing agent such as DTT (dithiothreitol) can make the antibody reactive and conjugated to the linker reagent. Thus, each cysteine ​​bridge will theoretically form two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into the antibody through any reaction known to those skilled in the art. As a non-limiting example, reactive thiol groups can be introduced into the antibody by introducing one or more cysteine ​​residues.

[0311] Immunohistotropic conjugates can also be generated by introducing an electrophilic moiety into the antibody, which can react with nucleophilic substituents of a linker reagent or cytotoxic agent. The sugar in the glycosylated antibody can be oxidized to form an aldehyde or ketone group, which can react with the amino group of the linker reagent or cytotoxic agent. The resulting imine Schiff base group can form a stable bond or can be reduced to form a stable amine bond. In one embodiment, the carbohydrate moiety of the glycosylated antibody reacts with galactose oxidase or sodium periodate to generate a carbonyl group (aldehyde and ketone) in the antibody, wherein the carbonyl group can react with a suitable group on the drug. In another embodiment, an antibody containing an N-terminal serine or threonine residue can react with sodium periodate, resulting in the production of an aldehyde that substitutes for the first amino acid.

[0312] In some preferred embodiments, the connector unit may have the following general formula:

[0313] --Ta--Ww--Yy--

[0314] in:

[0315] -T- stands for stretcher unit;

[0316] a is 0 or 1;

[0317] -W- represents an amino acid unit;

[0318] w is an independent integer from 1 to 12;

[0319] -Y- represents the spacing unit;

[0320] y is 0, 1 or 2.

[0321] When the extension unit (-T-) is present, the antibody is linked to an amino acid unit (-W-). Useful functional groups that may be present in the antibody, whether natural or chemically modified, include thiol, amino, hydroxyl, anomeric hydroxyl groups of carbohydrates, and carboxyl groups. Suitable functional groups are thiol and amino. If present, a thiol group can be generated by reducing the intramolecular disulfide bond of the antibody. Alternatively, a thiol group can be generated by reacting the amino group of the lysine moiety of the antibody with 2-iminothione or other thiol-generating agents. In a specific embodiment, the antibody is a recombinant antibody and is engineered to carry one or more lysine residues. More preferably, the antibody may be engineered to carry one or more cysteine ​​residues (see ThioMabs).

[0322] In some specific embodiments, the extension unit forms a bond with the sulfur atom of the antibody. The sulfur atom may be derived from the thiol (-SH) group of the reduced antibody.

[0323] In some other specific embodiments, the extension unit is linked to the antibody via a disulfide bond between the sulfur atom of the antibody and the sulfur atom of the extension unit.

[0324] In other specific embodiments, the reactive group of the extension contains a reactive site that can react with the amino group of the antibody. The amino group can be the amino group of arginine or lysine. Suitable amine reactive sites include, but are not limited to, active esters such as succinimidyl ester, 4-nitrophenyl ester, pentafluorophenyl ester, anhydride, acyl chloride, sulfonyl chloride, isocyanate, and isothiocyanate.

[0325] In another aspect, the reactive functional groups of the extension contain reaction sites that can react with modified carbohydrate groups present on the antibody. In one specific embodiment, the antibody is enzymatically glycosylated to provide the carbohydrate moiety. The carbohydrate can be mildly oxidized with a reagent such as sodium periodate, and the carbonyl unit of the resulting oxidized carbohydrate can be condensed with an extension containing a functional group (such as hydrazine, oxime, reactive amine, hydrazine, aminothiourea, hydrazide ester, or arylhydrazine).

[0326] If a spacer unit is present, the amino acid unit (-W-) connects the extension unit (-T-) to the spacer unit (-Y-); if a spacer unit is absent, the amino acid unit (-W-) connects the extension unit to the cytotoxic agent.

[0327] As mentioned above, -Ww- can be a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide, or dodecapeptide unit.

[0328] In some embodiments, the amino acid unit may comprise amino acid residues, such as, but not limited to, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, lysine, arginine, arginine protected by toluenesulfonyl or nitro groups, histidine, ornithine, ornithine protected by acetyl or formyl groups, and citrulline. Exemplary amino acid linker components preferably include dipeptides, tripeptides, tetrapeptides, or pentapeptides.

[0329] Exemplary dipeptides include: Val-Cit, Ala-Val, Ala-Ala, Val-Ala, Lys-Lys, Cit-Cit, Val-Lys, Ala-Phe, Phe-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp-Cit, Phe-Ala, and Phe-N. 9 -Toluenesulfonyl-Arg, Phe-N 9 -nitro-Arg.

[0330] Exemplary tripeptides include: Val-Ala-Val, Ala-Asn-Val, Val-Leu-Lys, Ala-Ala-Asn, Phe-Phe-Lys, Gly-Gly-Gly, D-Phe-Phe-Lys, and Gly-Phe-Lys.

[0331] Exemplary tetrapeptides include: Gly-Phe-Leu-Gly (SEQ ID NO.53) and Ala-Leu-Ala-Leu (SEQ ID NO.54).

[0332] Exemplary pentapeptides include: Pro-Val-Gly-Val-Val (SEQ ID NO.55).

[0333] Amino acid residues containing amino acid linker components include naturally occurring amino acids, as well as minor amino acids and non-natural amino acid analogs, such as citrulline. The amino acid linker components can be designed and optimized for enzymatic cleavage selectivity against specific enzymes, such as tumor-associated proteases, cathepsins B, C, and D, or plasminogen activators.

[0334] The amino acid units of the linker can be enzymatically cleaved by enzymes (including but not limited to tumor-associated proteases) to release cytotoxic agents.

[0335] It is possible to design and optimize the enzymatic cleavage selectivity of amino acid units for specific tumor-associated proteases. Suitable units are those whose cleavage is catalyzed by proteases, cathepsins B, C and D, and plasmin.

[0336] When a spacer unit (-Y-) is present, it links an amino acid unit to a cytotoxic agent. Spacer units generally come in two types: self-immolative and non-self-immolative. A non-self-immolative spacer unit is one in which, after enzymatic cleavage of the amino acid unit from the immunoconjugate, some or all of the spacer unit retains its binding to the cytotoxic agent. Examples of non-self-immolative spacer units include, but are not limited to, (glycine-glycine) spacer units and glycine spacer units. For the release of the cytotoxic agent, an independent hydrolysis reaction must occur within the target cell to cleave the glycine-drug unit bond.

[0337] In another implementation, the non-self-removing spacer unit (-Y-) is -Gly-.

[0338] In one embodiment, the immunoconjugate lacks a spacer unit (y = 0). Alternatively, immunoconjugates containing a self-removing spacer unit can release the cytotoxic agent without requiring a separate hydrolysis step. In these embodiments, -Y- is linked to the p-aminobenzyl alcohol (PAB) unit of -Ww- via the nitrogen atom of the PAB group, and is directly linked to -D via a carbonate, carbamate, or ether group.

[0339] Other examples of self-removing spacers include, but are not limited to, aromatic compounds that are electronically equivalent to a PAB group, such as 2-aminoimidazolium-5-methanol derivatives and ortho- or para-aminobenzylacetals. Upon hydrolysis of the amide bond, spacers that readily undergo cyclization can be used, such as substituted and unsubstituted 4-aminobutyric acid amides, appropriately substituted bicyclic [2.2.1] and bicyclic [2.2.2] ring systems, and 2-aminophenylpropionic acid amides.

[0340] In an alternative embodiment, the spacer unit is a branched bis(hydroxymethyl)styrene (BHMS) unit, which can be used to incorporate additional cytotoxic agents.

[0341] Drug load, also known as drug-antibody ratio (DAR), is the average amount of PBD drug bound to the reagent per cell.

[0342] In the case of antibody IgG1 isotype, after partial antibody reduction, the drug binds to cysteine. The drug loading ranges from 1 to 8 parts of drug (D) per part of antibody, that is, 1, 2, 3, 4, 5, 6, 7 and 8 parts of drug are covalently attached to the antibody.

[0343] In the case of antibody IgG2 isotype, where the drug is bound to cysteine ​​after partial antibody reduction, the drug loading ranges from 1 to 12 parts of drug (D) per antibody, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 parts of drug are covalently attached to the antibody.

[0344] An ADC consists of a collection of cell-binding agents (e.g., antibodies) conjugated to a drug in the range of 1 to 8 or 1 to 12 parts.

[0345] When a drug is bound to lysine, the drug loading may range from 1 to 80 parts of drug (D) per part of antibody, even though upper limits of 40, 20, 10, or 8 parts are preferred. The composition of an ADC comprises a collection of cell-binding agents (e.g., antibodies) conjugated to a drug ranging from 1 to 80, 1 to 40, 1 to 20, 1 to 10, or 1 to 8 parts.

[0346] In ADC formulations derived from conjugation reactions, the average amount of drug per antibody can be characterized using conventional methods. The quantitative distribution of ADCs in terms of drug ratio can also be determined. For some antibody-drug conjugates, the drug ratio is also limited by the number of attachment sites on the antibody. For example, an antibody may have only one or a few cysteine ​​thiol groups, or only one or a few fully reacted thiol groups to which a linker can attach. Higher drug loadings, such as drug ratios greater than 5, can lead to aggregation, insolubility, toxicity, or loss of cellular permeability in some antibody-drug conjugates.

[0347] Some antibodies possess reducible interchain disulfide bonds, or cysteine ​​bridges. Treatment with a reducing agent such as DTT (dithiothreitol) can make the antibody reactive and conjugate it with a linker reagent. Therefore, each cysteine ​​bridge theoretically forms two reactive thiol nucleophiles. Additional nucleophilic groups are introduced into the antibody by the reaction of lysine with 2-iminothiane (Traut's reagent), which leads to the conversion of the amine to a thiol. Reactive thiol groups can be introduced into the antibody (or fragments thereof) by engineering one, two, three, four, or more cysteine ​​residues (e.g., to prepare mutant antibodies containing one or more non-natural cysteine ​​amino acid residues). US 7521541 teaches the engineering of antibodies by introducing reactive cysteine ​​amino acids.

[0348] Cysteine ​​amino acids can be engineered at the reaction site in antibodies without forming intrachain or intermolecular disulfide bonds (Junutula et al., 2008b Nature Biotech., 26(8):925-932; Dornan et al. (2009) Blood 114(13):2721-2729; US 7521541; US ​​7723485; WO2009 / 052249). Engineered cysteine ​​thiols can react with the linker reagents or pharmaceutical linker reagents of the present invention, which have thiol-reactive, electrophilic groups such as maleimide or α-haloamide, to form an ADC having a cysteine-engineered antibody and a PBD drug moiety. Thus, the position of the drug moiety can be designed, controlled, and is known. Drug loading can be controlled because the engineered cysteine ​​thiol group typically reacts with thiol-reactive linker reagents or pharmaceutical linker reagents in high yield. IgG antibodies are engineered to introduce cysteine ​​amino acids by substitution at a single site on the heavy or light chain, resulting in two new cysteine ​​residues on the symmetrical antibody. The near-homogeneity of the conjugated product ADC can be used to achieve drug loading close to 2.

[0349] Furthermore, the present invention also relates to the use of the above-mentioned immunoconjugates or antibody-drug conjugates as drugs.

[0350] Similarly, the present invention also relates to the above-mentioned immune conjugates or antibody-drug conjugates for the treatment of cancer.

[0351] This invention relates to the use of the above-described antibody-drug conjugate as a medicine. In a specific embodiment, this invention relates to the use of the above-described antibody-drug conjugate for treating cancer. In a more specific embodiment, this invention relates to the use of the above-described antibody-drug conjugate for treating cancers expressing IGF-1R or IGF-1R-related cancers.

[0352] IGF-1R-related cancers include tumor cells that express or overexpress all or part of IGF-1R on their surface.

[0353] More specifically, the cancers mentioned are breast cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, stomach cancer, glioma, lung cancer, melanoma, osteosarcoma, ovarian cancer, prostate cancer, rhabdomyosarcoma, kidney cancer, thyroid cancer, endometrial cancer, and any drug resistance.

[0354] In another aspect, the present invention relates to the use of antibody-drug conjugates according to the present invention in the treatment of cancers expressing IGF-1R.

[0355] Another subject of the invention is a pharmaceutical composition comprising an antibody or antibody-drug conjugate, or immunoconjugate, as described in the specification according to the invention.

[0356] More specifically, the present invention relates to a pharmaceutical composition comprising the antibody, or antibody-pharmaceutical conjugate, or immunoconjugate according to the present invention, and at least one excipient and / or a pharmaceutically acceptable carrier.

[0357] This invention relates to a pharmaceutical composition comprising the above-described antibody or antibody-drug conjugate, and at least one excipient and / or a pharmaceutically acceptable carrier.

[0358] In this specification, the terms "pharmaceuticalally acceptable carrier" or "excipient" are intended to indicate that the compound or combination of compounds enters the pharmaceutical composition without causing secondary reactions and allows, for example, the administration of the active compound, its lifespan and / or efficacy in vivo, its solubility in solution, or its preservation. These pharmaceutically acceptable carriers and excipients are well known and have been adapted by those skilled in the art as a function of the properties of the selected active compound and the mode of administration.

[0359] Preferably, these immunoconjugates are administered via a systemic route, particularly via intravenous, intramuscular, intradermal, intraperitoneal, or subcutaneous route, or via oral administration. In a more preferred manner, the composition containing the immunoconjugate is administered sequentially several times.

[0360] The administration method, dosage, and optimal form of the drug can be determined based on the criteria that are generally considered when establishing a treatment appropriate for the patient (e.g., the patient's age or weight, the severity of his / her general condition, treatment tolerance, and any side effects noted).

[0361] In another aspect, the present invention relates to a pharmaceutical composition comprising the antibody or antibody-drug conjugate or immunoconjugate according to the present invention described above, and at least one excipient and / or a pharmaceutically acceptable carrier, for treating cancer. More specifically, the present invention relates to a pharmaceutical composition comprising the antibody, or antibody-drug conjugate or immunoconjugate according to the present invention described above, and at least one excipient and / or a pharmaceutically acceptable carrier, for treating cancer expressing IGF-1R.

[0362] This invention relates to a method for treating cancer in a subject, and particularly for treating cancer expressing IGF-1R, comprising administering to the subject an effective amount of at least the antibody-drug conjugate according to the invention. The invention also relates to a method for treating cancer in a subject, and particularly for treating cancer expressing IGF-1R, comprising administering to the subject an effective amount of the pharmaceutical composition according to the invention.

[0363] In another embodiment, the present invention relates to a method of delivering a drug or pharmaceutical product to cancer cells expressing IGF-1R in a subject, comprising administering to the subject an effective amount of at least an antibody-drug conjugate or a pharmaceutical composition according to the present invention.

[0364] Other features and advantages of the invention are further presented in the following description with reference to examples and figures, as shown in the figure captions below. Attached Figure Description

[0365] Figure 1 An example of Biacore binding profiles obtained by capturing hIGF-1R ECD with an anti-His-tagged antibody.

[0366] Figure 2 Epitope mapping scheme defined by a set of 15 anti-hIGF-1R monoclonal antibodies, which define 5 epitope groups. The group numbering is not related to the sequence position or the 3D structure of the antigen.

[0367] Figures 3A to 3C Antibodies binding to human natural IGF-1R were analyzed by FACS. Figure 3A The titration curves represent the titrations of a chimeric anti-IGF-1R Ab for each epitope cluster on the MCF-7 cell line. MFI represents the average fluorescence intensity. Figure 3B Representing mouse and chimeric anti-IGF-1R antibody against MCF-7 cell line EC 50 . Figure 3C Represents the chimeric anti-IGF-1R antibody against the B cells of the MCF-7 cell line. max .

[0368] Figure 4A and Figure 4B hIGF-1R recognition was assessed using transfected cells as a comparison with untransfected cells. Figure 4A Representative in IGF-1R + On cell lines, titration curves represent a chimeric anti-IGF-1R Ab for each epitope cluster. MFI represents the average fluorescence intensity. Figure 4B Represents human IGF-1R – In cell lines, binding represents one chimeric anti-IGF-1R Ab for each epitope cluster. MFI represents the average fluorescence intensity.

[0369] Figure 5A and Figure 5B The specificity of Ab against hIGF-1R versus hIR was assessed using transfected cells. Figure 5A Represents mouse anti-IGF-1R Ab against hIR +The binding of transfected cell lines. Figure 5B Represents chimeric anti-IGF-1R Ab against IR + Cell line binding. MFI represents the average fluorescence intensity. In columns A and B, a commercially available anti-hIR antibody described as GRO5 (Calbiochem) has been introduced as a positive control.

[0370] Figure 6 Binding of mouse anti-IGF-1R Ab to the IM-9 cell line. MFI represents the mean fluorescence intensity. GRO5 anti-hIR Mab was introduced as a positive control.

[0371] Figure 7A , Figure 7B and Figure 7C Evaluation of monkey IGF-1R identification. Figure 7A The titration curves represent a chimeric anti-IGF-1R Ab for each epitope cluster on the COS-7 cell line. MFI represents the average fluorescence intensity. Figure 7B Representing mouse and chimeric anti-IGF-1R antibodies against COS-7 cell line EC 50 . Figure 7C Represents chimeric anti-IGF-1R antibody against hIGF-1R + EC of transfected cells and COS-7 cells 50 GR11L (Calbiochem) was introduced as a positive control.

[0372] Figure 8 The binding of c208F2 to hIGF-1R ECD or cynomolgus monkey IGF-1R ECD was compared using Biacore assays. Sensing maps were obtained on a Biacore X100 based on SPR technology using a CM5 sensor chip activated with more than 11,000 RU of mouse anti-His-tagged antibody chemically grafted onto a carboxymethyl dextran matrix. Experiments were run at 25°C at a flow rate of 30 μl / min using HBS-EP+ as run and sample dilution buffer. The figure shows the superposition of four independent sensing maps aligned on the x-axis at the start of the first analyte injection, and a baseline defined just before the first injection on the y-axis. Sensing maps obtained by capturing recombinant soluble IGF-1R based on human sequences are marked with diamonds. Sensing maps obtained by capturing recombinant soluble IGF-1R based on cynomolgus monkey sequences are marked with triangles. White symbols correspond to blank cycles (5 injections of run buffer), and black symbols correspond to injections of c208F2 at concentrations ranging from 5 to 80 nM.

[0373] Figure 9Evaluation of the intrinsic role of anti-hIGF-1R antibodies in receptor phosphorylation compared to IGF1.

[0374] Figure 10 Mouse anti-hIGF-1R inhibits IGF-1R phosphorylation in response to IGF-1.

[0375] Figure 11 At 37°C, cell surface binding to the anti-IGF-1R antibody was downregulated. MCF-7 cells were incubated at 4°C or 37°C with 10 μg / ml of each antibody for 4 hours. This figure represents ΔMFI.

[0376] Figure 12A and Figure 12B Antibody surface attenuation. Antibodies bound to the cell surface were assessed at 37°C after 10, 20, 30, 60, and 120 min. Figure 12A This represents the percentage of remaining IGF-1R compared to the signal strength measured at 4°C. Figure 12B This represents the half-life calculation using Prims software and an exponential decay fit.

[0377] Figures 13A to 13O Antibody internalization kinetics were assessed by FACS analysis. Cells were incubated with 10 μg / ml mouse Ab at 37°C for 0, 30, or 60 min. Cells were then permeabilized or depermeabilized and incubated with a secondary antibody, mouse IgG-Alexa 488. The membrane corresponds to the signal intensity of the non-permeabilized cell. The total corresponds to the signal intensity after cell permeabilization, and the cytoplasm corresponds to the internalized Ab. The name of each antibody evaluated is described at the top of each figure.

[0378] Figure 14A and Figure 14B Imaging Ab internalization. Figure 14A MCF-7 cells were incubated with m208F2 at 4°C for 20 min, and washed at 37°C for [a)], 15[b)], 30[c)], and 60[d)] min prior to incubation. Cells were fixed and permeabilized. m208F2 Ab was visualized using anti-mouse IgG Alexa488, and Lamp-1 was visualized using rabbit anti-Lamp-1 antibody and secondary rabbit IgG Alexa 555. Figure 14B MCF-7 cells were incubated at 37°C with each of the other anti-hIGF-1R mouse antibodies to be tested for 30 minutes, followed by staining as described above. Colocalization was identified using the highliter colocalization plugin in ImageJ software.

[0379] Figure 15 : Lysosomal pathways involved in antibody degradation.

[0380] Figures 16A to 16NEvaluation of binding of anti-hIG-1R mouse antibodies at different pH values. EC50 of different antibody binding was evaluated on MCF-7 buffers using buffers with different pH values ​​ranging from 5 to 8.

[0381] Figure 17A and Figure 17B The ability of the selected anti-IGF-1R antibody to induce cytotoxicity was assessed using the Fab-ZAP assay. A) MCF-7 cells were incubated with increasing concentrations of chimeric anti-IGF-1R antibody in combination with a human Fab-ZAP kit. Cell viability was measured using a luminescent cell viability assay. A c9G4 chimeric antibody was used as an irrelevant antibody. B) IC50 from the results described in A). 50 .

[0382] Figure 18 i) Cytotoxic efficacy, ii) Effect of pH on Ab / IGF-1R binding, iii) Effect of Ab on IGF-1-induced phosphorylation of IGF-1R, and iv) Correlation between antibody clusters.

[0383] Figures 19A to 19D Characterization of binding to the first humanized form of c208F2 Mab. For human cell line MCF-7 ( Figure 19A ), monkey cell line COS-7 ( Figure 19B ) and mouse cell lines transfected with human insulin receptor ( Figure 19C The binding characteristics of hz208F2 VH3 / VL3 mAb were evaluated on [a specific cell line / organism]. Binding to mouse and chimeric 208F2 mAb was evaluated in parallel. The expression of hIR in transfected cell lines was validated using the anti-hIR antibody clone GRO5. Figure 19D ).

[0384] Figures 20A to 20D ELISA validation of the AF305-NA polyclonal antibody, which has been used for IHC assay. Figure 20A : Binding with hIGF-1R, Figure 20B : Binding to human recombinant IR. Compared with control Ab GRO5 on these hIR-transfected cells ( Figure 20C ), without hIR EDC and transfected cells ( Figure 20D Recognition of cellular IR expressed by )

[0385] Figure 21 Validation of hIGF-1R staining on FFPE sections of xenografts expressing different levels of hIGF-1R. Hs746T was introduced as a negative control.

[0386] Figure 22A and Figure 22BhIGF-1R expression was assessed on normal FFPE tissue sections. Placental sections were used as a positive control of normal tissue, while positive tumor xenograft tissue was introduced in each run to correct for hIGF-1R expression.

[0387] Figure 23 hIGF-1R expression was evaluated on NSCL FFPE tissue sections. Four cases are represented where strong staining was observed in most groups of the tissues analyzed.

[0388] Figure 24 Evaluation of hIGF-1R expression on FFPE tissue sections of breast cancer. Three cases representing strong staining observed in the test group of the analyzed tissues are shown.

[0389] Figure 25 Evaluation of hIGF-1R expression on FFPE tissue sections from different tumors.

[0390] Figure 26 The results are a superposition of sensor maps obtained using an SPR-based Biacore X100 device at 25°C. The SPR-based Biacore X100 device features a CM5 sensor chip activated with approximately 12,000 RU of mouse anti-His-tagged monoclonal antibody in two flow cells. The mouse anti-His-tagged monoclonal antibody was chemically grafted onto a carboxymethyl dextran matrix. HBS-EP+ was used as the run buffer at a flow rate of 30 μl / min. Each sensor map (the first marked with a triangle, the second with a diamond) corresponds to one complete cycle.

[0391] 1- During a period of one minute, a solution of recombinant h-IGF-1R (10 μg / ml) was injected into the second flow cell.

[0392] 2. For the first sensor map: inject the running buffer 5 times during each 90s interval.

[0393] For the second sensor map: five injections of anti-IGF-1R c208F2 antibody solution at an increasing concentration were performed each time for 90 seconds.

[0394] 3- Determine the 300s delay for the dissociation kinetic rate.

[0395] 4- Surface regeneration was achieved by injection of 10 mM glycine, HCl, pH 1.5 buffer over a period of 45 s.

[0396] Figure 27The sensor map corresponding to the sensor map obtained with the concentration of anti-IGF-1R c208F2 solution within the growth range minus the blank sensor map (5 injections of HBS-EP+) is shown in gray. The theoretical sensor map corresponding to the 1:1 model has the following parameters: k on = (1.206 ± 0.036) x 10 6 M -1 .s -1 k off = (7.81 ± 0.18) x 10 -5 s -1 Rmax = 307.6 ± 0.3 RU is represented by a thin black line. The calculated concentrations of c208F2 are reported on the graph: only the highest concentration (24 nM) is considered a constant.

[0397] Figure 28 The dissociation constant corresponds to the average of four experiments run for each antibody and to the expression ratio in pM: k off / k on x 10 12 The error bars correspond to the standard deviation (n=4).

[0398] Figure 29 The half-life corresponds to the average of four experiments run for each antibody and to the expression ratio in h: Ln(2) / k off / 3600. The error bars correspond to the standard deviation (n=4).

[0399] Figure 30 : The superposition of two sensor images corresponding to two cycles of an experiment conducted on a Biacore X100 device at a flow rate of 30 μl / min and at 25 °C.

[0400] The first step of the cycle corresponds to the injection of a 10 μg / ml c208F2 antibody solution into the second flow cell of a CM5 sensor chip activated by grafting more than 10,500 RU of mouse anti-human IgG Fc monoclonal antibody, which is chemically linked to a carboxymethyl dextran matrix via its amine functional groups, during a 60-second period. The second step corresponds to the injection of an extracellular domain solution of h-IGF-1R (solid rhombus) or m-IGF-1R (hollow rhombus) from crude cell culture supernatant with a 120-second delay during a 120-second period. The bidirectional arrows indicate the locations where antibody capture and IGF-1R binding levels were measured in this study.

[0401] Figure 31: A histogram representing the ratio between the IGF-1R binding level obtained for each chimeric h / m IGF-1R construct and the c208F2 level captured on the sensor chip in the second flow cell during the corresponding period.

[0402] Figure 32A and Figure 32B : Histogram representing the EC50 of hz208F2 H076 / L024 at pH 5 to pH 8. Acidic pH reduces the binding ability of humanized IGF-1R antibodies hz208F2 H076 / L024(A) and hz208F2(H077 / L018(B)).

[0403] Figure 33 The binding of Hz208F2 (10 μg / ml) to 170 RU of the wild-type soluble form of h-IGF1R (black rhombus) or 120 RU of the mutant C29 (Asp491>Ala) of this receptor was demonstrated. Each receptor was captured by its C-terminal 66His tag on the CM5 sensor chip. Experiments were run using a Biacore X100 device at 25 °C with classic HBS-EP+ as the run buffer at a flow rate of 30 μl / min. Detailed Implementation

[0404] Example

[0405] All hybridomas mentioned in this invention have been deposited at the National Center for Microbial Culture Collection and identified in Table 7 below.

[0406] Table 7

[0407] Hybridoma name CNCM Reference Submission Date 101H8 CNCM I-4733 April 24, 2013 201F1 CNCM I-4769 June 26, 2013 208F2 CNCM I-4757 May 30, 2013 212A11 CNCM I-4773 June 26, 2013 214F8 CNCM I-4775 June 26, 2013 219D6 CNCM I-4736 April 24, 2013 213B10 CNCM I-4774 June 26, 2013 102H8 CNCM I-4767 June 26, 2013 110G9 CNCM I-4768 June 26, 2013 415A8 CNCM I-4778 June 26, 2013 410G4 CNCM I-4777 June 26, 2013 414E1 CNCM I-4738 April 24, 2013 433H9 CNCM I-4780 June 26, 2013 105G2 CNCM I-4735 April 24, 2013 832E5 CNCM I-4765 May 30, 2013

[0408] Example 1: Generation of IGF-1R antibody

[0409] To generate a mouse monoclonal antibody (MAb) targeting the human extracellular domain (ECD) of the human IGF-1 receptor (hIGF-1R), five BALB / c mice were immunized three times subcutaneously (sc) with 10 μg of rhIGF-1R protein (R&D Systems, catalog number 391-GR). Optionally, some animals were immunized three additional times with 10 μg of the mouse extracellular domain (ECD) of IGF-1R (R&D Systems, catalog number 6630-GR / Fc). The first immunization was performed in the presence of complete Freund's adjuvant (Sigma, St. Louis, MD, USA). Subsequent immunizations included incomplete Freund's adjuvant (Sigma). Three days prior to fusion, mice were boosted with 10 μg of rhIGF-1R protein. Then, splenocytes and lymphocytes were harvested from one of five immunized mice (selected after serum titration of all mice), and prepared by spleen perfusion and dissection of proximal lymph nodes, respectively, and fused into SP2 / 0-Ag14 myeloma cells (ATCC, Rockwell, MD, USA). The fusion protocol was described by Kohler and Milstein (Nature, 256:495-497, 1975). The fused cells were then selected by HAT. Generally, for the preparation of monoclonal antibodies or their functional fragments, especially murine ones, it is possible to involve those techniques specifically described in the manual "Antibodies" (Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY, pp. 726, 1988). Approximately 10 days after fusion, clones of the hybrid cells were screened. For primary screening, the secretion of mab targeting the rhIGF-1R ECD protein in the supernatant of hybridomas was assessed by FACS analysis using human breast MCF7 tumor cells (ATCC) and / or monkey COS7 cells (transformed from African green monkey kidney-SV40), wherein the monkey COS7 cells express monkey IGF-1R on their cell surface. More precisely, for selection by flow cytometry, 10 5One cell line (MCF7 or COS7) was seeded in each well of a 96-well plate containing PBS with 1% BSA and 0.01% sodium azide (FACS buffer). After centrifugation at 2000 rpm for 2 minutes, the buffer was removed, and the hybridoma supernatant to be tested was added. After incubation at 4°C for 20 minutes, the cells were washed twice, and Alexa 488-conjugated goat anti-mouse antibody diluted 1 / 500° in FACS buffer (#A11017, Molecular Probes Inc., Eugene, USA) was added, followed by incubation at 4°C for 20 minutes. After a final wash with FACS buffer, the cells were analyzed by FACS (Facscalibur, Becton-Dickinson) after adding propidium iodide to each tube to a final concentration of 40 μg / ml. Wells containing only cells and cells incubated with a second Alexa 488-conjugated antibody were included as negative controls. An isotype control (Sigma, ref M90351MG) was used in each experiment. Evaluate at least 5000 cells to calculate the mean fluorescence intensity (MFI).

[0410] In addition, an internalization assay was performed to select only the internalization antibody. For this assay, MCF7 tumor cell lines were cultured for 3 days in RMPI 1640 containing 1% L-glutamine and 10% FACS without phenol red before the experiment. Cells were then isolated using trypsin, and 100 μl of 4.10... 5 Cell suspensions of 100 cells / ml were seeded in 96-well multi-well plates in RPMI 1640 free of phenol red, containing 1% L-glutamine and 5% FBS. After centrifugation at 2000 rpm for 2 min, the cells were resuspended in 50 μl of hybridoma supernatant or control antibody solution (1 μg / ml of positive and isotype controls). After incubation at 4°C for 20 min, the cells were centrifuged at 2000 rpm for 2 min and resuspended in cold (4°C) or hot (37°C) complete culture medium. The cells were then incubated at 37°C or 4°C for 2 h. The cells were then washed three times with FACS buffer. Cells were incubated with Alexa 488-labeled goat anti-mouse IgG antibody for 20 min and washed three times before FACS analysis of the propidium iodide-negative cell population.

[0411] Following FACS analysis, two parameters were determined: (i) the difference between the fluorescence signal detected on the cell surface incubated at 4°C and the fluorescence signal obtained from cells incubated at 37°C with a hybridoma supernatant, and (ii) the percentage of IGF-1R remaining on the cell surface.

[0412] The percentage of remaining hIGF-1R is calculated as follows:

[0413] Remaining IGF-1R percentage = (MFI) Ab37℃ / MFI Ab4℃ )x 100

[0414] In addition, three ELISAs (before or after cloning) were performed to investigate antibody binding to recombinant human (hIGF-1R) and mouse (mIGF-1R) proteins and recombinant human insulin receptor (hIR) proteins. Hybridoma secretion antibodies that showed binding on rh- and / or rm-IGF-1R but not on rhIR were retained. Briefly, 96-well ELISA plates (Costar 3690, Corning, NY, USA) were coated overnight at 4°C with 100 μl / well of 0.6 μg / ml rhIGF-1R protein (R&D Systems, catalog 391-GR), 1 μg / ml rmIGF-1R protein (R&D Systems, catalog 6630-GR / Fc), or 1 μg / ml rhIR protein (R&D Systems, catalog 1544-IR / CF) in PBS. The plates were then blocked for 2 hours at 37°C with PBS containing 0.5% gelatin (#22151, Serva Electrophoresis GmbH, Heidelberg, Germany). Once the saturated buffer was discarded by flicking the plate, 100 μl of each supernatant dilution was added to the wells (undiluted hybridoma supernatant or serially diluted supernatant) and incubated at 37°C for 1 hour. After three washes, 100 μl of horseradish peroxidase-conjugated polyclonal goat anti-mouse IgG (#115-035-164, Jackson Immuno-Research Laboratories, Inc., Sigrove, PA, USA) was added at a 1 / 5000 dilution to PBS containing 0.1% gelatin and 0.05% Tween 20 (w:w) and incubated at 37°C for 1 hour. The ELISA plates were then washed three times and TMB (#UP664782, Uptima, Interchim, France) substrate was added. After incubating at room temperature for 10 minutes, the reaction was terminated with 1M sulfuric acid, and the optical density at 450 nm was measured.

[0415] Antibodies of interest are amplified and cloned using limiting dilution. Once isotyped, one clone of each code is amplified and frozen. Each antibody of interest is then produced for further characterization using an in vitro production system called CellLine (Integra Biosciences).

[0416] In contrast to untransfected cells, additional assays to address binding specificity were performed using FACS analysis on IM9 cells (B lymphoblasts expressing human IR) and hIGF-1R transfected cells.

[0417] All data corresponding to the selected antibodies are summarized in Table 8. Interestingly, it is noted that among the selected antibodies, i) based on their selectivity for hIGF-1R versus hIR and ii) their ability to induce IGF-1R internalization, some were able to recognize their targets in ELISA and FACS settings, while others were very good binders when studied by cytometry, and very poor binders when evaluated by ELISA. m280F2, m212A11, m213B10, m214F8, and m219D6 belong to the latter group that did not recognize the coated protein well.

[0418]

[0419] Example 2: Using Biacore's SPR technique for plotting experimental characterization of anti-IGF-1R antibody epitopes Clustering

[0420] To investigate the diversity of responses to IGF-1R, the selected antibodies were plotted using Biacore and clustered based on their competitive characteristics.

[0421] Briefly, epitope mapping experiments were performed on a Biacore X device using a CM5 sensor chip activated by an anti-His-tagged antibody (His Capture Kit, GE Healthcare, catalog number 28-9950-56). Over 11,000 RU of antibody was chemically grafted onto a carboxymethyl dextran matrix using an amine kit chemistry. Experiments were performed at 25°C and a flow rate of 1 μl / min using HBS-EP buffer (GE Healthcare) as the run and sample dilution buffer.

[0422] The epitope plotting experiments followed the same protocol:

[0423] A solution of 1-soluble hIGF-1R heterotetramer (2α chain and extracellular domain of 2β chain expressing an additional C-terminal 10-His tag (R&D Systems catalog number 305-GR)) was injected into two flow cells at a concentration of 5 μg / ml over a 1-minute period.

[0424] 2-Then the solution of the anti-hIGF-1R antibody to be tested (classically 50 μg / ml) is injected only into flow cell 1 over a period of 60 to 90 seconds to achieve (or at least approach) saturation of the hIGF-1R binding sites.

[0425] 3- Under the same conditions, inject a solution of a second antibody, which serves as a potential competitor, into both flow cells or only into the second flow cell.

[0426] 4. Finally, the solution of the third antibody can be injected into both flow cells under the same conditions.

[0427] 5-Then, the surface is regenerated by injecting 10 mM glycine and HCl pH 1.5 buffer over 30 s.

[0428] This experiment clearly demonstrates that if two antibodies can simultaneously bind to the same molecule of hIGF-1R, it proves that the binding region (epitope) of each antibody is far enough to allow this. Conversely, if the binding of one antibody to hIGF-1R prevents the binding of the second antibody, it indicates that the two antibodies recognize the same epitope. Finally, in cases of partial competition, overlap of epitopes recognized by the two test antibodies can be suspected. Thus, epitope region sets are defined. The complexity of the results generally increases with the size of the antibody set used in the experiment.

[0429] Figure 1 An example of a typical cycle for an epitope mapping experiment using an SPR-based Biacore X device is described. The sensor plot shows that the reaction (RU) is a function of time (seconds) in flow cells 1 (black rhombus) and 2 (white rhombus). In stage 1, a solution of the antigen: soluble recombinant hIGF-1R with two C-terminal 10-His tags was injected into a CM5 sensor chip on both flow cells, wherein the concentration of anti-His-tagged mouse antibody chemically linked to a carboxymethyl dextran matrix was 5 μg / ml at a flow rate of 10 μl / min.

[0430] In stage 2, a solution of the first antibody (219D6) to be tested at a concentration of 50 μg / ml was injected into flow cell 1. Then, in stage 3, a solution of the second antibody (101H8) at a concentration of 50 μg / ml was injected into flow cell 2. Subsequently, in stage 4, a solution of the third antibody (201F1) at a concentration of 50 μg / ml was injected into both flow cells. The reaction after these injections clearly showed that the binding of 201F1 to IGF-1R was blocked by 101H8 but not by 219D6. Antibodies 201F1 and 219D6 clearly belong to different epitope groups. Figure 2 The clustering resulting from a holistic analysis of 15 selected candidates is described, and it is demonstrated that immunization of mice with hIGF-1R produced a range of antibodies exhibiting good diversity. Specifically, five distinct groups of Mabs recognizing different epitopes were generated.

[0431] Example 3: Analysis of antibody binding to human natural IGF-1R by FACS

[0432] The binding properties of a series of anti-IGF-1R antibodies to the human MCF-7 breast cancer cell line (ATCC#HTB-22) were evaluated by FACS analysis using increasing antibody concentrations. For this purpose, cells (1 × 10⁻⁶) were incubated in FACS buffer (PBS, 0.1% BSA, 0.01% NaN₃) at 4 °C. 6 Cells / ml were incubated with anti-IGF-1R antibody for 20 minutes. They were then washed three times and incubated for an additional 20 minutes at 4°C in the dark with a suitable second antibody conjugated to Alexa 488, followed by three washes in FACS buffer. Live cells were immediately bound to anti-IGF-1R antibody, which was identified using propidium iodide (which stains dead cells). The maximum signal intensity obtained with each antibody was set as B. max The fluorescence intensity was expressed as the mean fluorescence intensity (MFI). The binding EC, expressed as molar concentration (M), was calculated using nonlinear regression analysis (GraphPad Prims 4.0). 50 .

[0433] The titration curves for each mouse or chimeric Ab demonstrated that all generated antibodies were able to recognize the native IGF-1R form with typical saturation spectra. Figure 3A To rank the antibodies and compare the binding properties of mouse and chimeric antibodies, nonlinear regression analysis was used to determine the binding EC50 of each compound. 50 Each mouse Ab and its corresponding chimeric form EC 50 The comparison shows that the two forms exhibit the same binding characteristics, proving that Ab chimerism does not affect IGF-1R recognition. Figure 3B EC 50 The range is 1.2 × 10 -8 Up to 4.4×10 -10 Antibodies belonging to group 2 and c102H8 belonging to group 3a showed better EC. 50 Regarding B max analyze( Figure 3C Compared to the other, the three Abs (414E1(G3b), 105G2(G4), and 832E5(G5)) have lower B values. max EC50 and B max The values ​​are summarized in Table 9.

[0434] Table 9

[0435] Group Ac <![CDATA[B max ]]> <![CDATA[EC 50 (M)]]> G1 c101H8 905 2.8E-09 G3a c102H8 951 8.5E-10 G4 c105G2 805 4.9E-09 G3a c110G9 992 1.4E-09 G1 c201F1 936 1.5E-08 G2 c208F2 981 6.7E-10 G2 c212A11 991 6.7E-10 G2 c214F8 1069 5.0E-10 G2 c219D6 993 4.7E-10 G2 c213B10 1103 4.4E-10 G3b c410G4 1020 2.6E-09 G3b c414E1 795 6.0E-09 G3a c415A8 1142 1.6E-09 G3b c433H9 1032 1.7E-09 G5 c832E5 691 1.2E-08

[0436] Example 4: Using IGF-1R or IR-transfected cells or IM9 cells that naturally express significant levels of IR to confirm Recognize antibody specificity

[0437] To confirm the specificity of the generated antibody against hIGF-1R versus hIR, stable transfectants expressing either hIGF-1R or hIR were evaluated by FACS analysis. Briefly, cells were incubated with incremental concentrations of the chimeric mAb for 20 min at 4°C in FACS buffer (PBS, 0.1% BSA, 0.01% NaN3). Cells were then washed three times and incubated in the dark at 4°C with a suitable second antibody conjugated with Alexa 488, followed by an additional 20 min incubation, and then washed three times in FACS buffer. Immediate binding of live cells to the anti-IGF-1R antibody was performed, and these live cells were identified using propidium iodide (which stains dead cells). The binding EC50, expressed as molar concentration (M), was calculated using nonlinear regression analysis (GraphPad Prims 4.0). 50 .

[0438] Compared to untransfected cells ( Figure 4B In cell lines transfected with hIGF-1R ( Figure 4A The titration curves obtained confirmed the binding specificity of the chimeric Ab to human IGF-1R. EC 50 and B max The values ​​are summarized in Table 10. In this assay, antibodies from groups G2 and G3a showed the best EC values. 50 .

[0439] Table 10

[0440] Group Ac <![CDATA[B max ]]> <![CDATA[EC 50 (M)]]> G1 c101H8 2107 1.2E-09 G1 c201F1 2500 1.1E-08 G2 c208F2 2008 3.2E-10 G2 c212A11 2513 4.4E-10 G2 c214F8 2094 2.7E-10 G2 c219D6 2521 5.5E-10 G2 c213B10 2029 3.3E-10 G3a c102H8 2594 5.4E-10 G3a c110G9 2189 5.2E-10 G3a c415A8 2728 7.0E-10 G3b c410G4 1667 7.1E-10 G3b c414E1 2265 1.9E-09 G3b c433H9 2165 6.5E-10 G4 c105G2 2396 1.7E-09 G5 c832E5 1998 7.3E-09

[0441] To verify that mouse and chimeric antibodies do not bind to hIR, a stable cell line expressing human IR was used. The recognition of human cell surface hIR by mouse and chimeric antibodies was performed using FACS analysis. Increasing concentrations of mouse or chimeric mAbs were applied to hIR... + Transfected cell lines were incubated in FACS buffer (PBS, 0.1% BSA, 0.01% NaN3) at 4°C for 20 min. Cells were then washed three times and incubated in the dark at 4°C with a suitable secondary antibody conjugated with Alexa 488, followed by an additional 20 min incubation, and then washed three times in FACS buffer. Immediate binding of live cells to anti-IGF-1R antibody was performed, and the live cells were identified using propidium iodide (which stains dead cells). The binding EC50, expressed as molar concentration (M), was calculated using nonlinear regression analysis (GraphPad Prims 4.0). 50 Commercially available specific anti-IGF-1R antibody, clone GR11L, and anti-hIR antibody clone GRO5 were used as positive controls. c9G4 was introduced as an irrelevant antibody (isotype control).

[0442] High levels of hIR expression on the cell surface of transfected cells were confirmed using the commercially available anti-hIR antibody GRO5. Even when using high concentrations of mouse ( Figure 5A ) or chimera ( Figure 5B Anti-hIGF-1R Ab, no hIR was observed. + The binding of transfected cells to the cell surface. These results demonstrate that neither mouse nor chimeric anti-hIGF-1R Abs recognize hIR.

[0443] The specific recognition of hIGF-1R by IM9 cells (a B-lymphoma cell line expressing hIR) was also demonstrated compared to IR. Figure 6 For this FACS analysis, the procedure was the same as previously described, and mouse anti-IGF-1R antibody was used to prevent cross-reactivity with the secondary anti-human Ab (IM9 cells express human Ig on their cell surface). Figure 6 The results shown in the figure further confirm that the expected signal was observed using the GRO5 anti-hIR antibody, while none of the mouse antibodies evaluated showed any significant binding signal on this cell line.

[0444] Example 5: Analysis of antibodies binding to monkey natural IGF-1R by FACS and Biacore

[0445] One of the first prerequisites for regulating toxicological studies is identifying the relevant animal species to evaluate the selected compounds. Since the range of antibodies described herein does not recognize mouse IGF-1R, the most likely species for toxicological evaluation is a non-human primate (NHP).

[0446] To evaluate the binding of anti-IGF-1R antibody to monkey IGF-1R, the binding of mouse and chimeric anti-IGF-1R antibodies to the COS-7 cell line was assessed by FACS analysis using incremental antibody concentrations. Cells (1 × 10⁻⁶ cells / year) were incubated in FACS buffer (PBS, 0.1% BSA, 0.01% NaN₃) at 4°C. 6 Cells (cells / ml) were incubated with anti-IGF-1R antibody for 20 min. Cells were then washed three times and incubated at 4°C in the dark with a suitable secondary antibody conjugated to Alexa 488, followed by an additional 20 min incubation, and finally washed three times in FACS buffer. Immediately, binding to the anti-IGF-1R antibody was assessed on live cells identified using propidium iodide (which stains dead cells). The binding EC50, expressed as molar concentration (M), was calculated using nonlinear regression analysis (GraphPad Prims 4.0). 50 .

[0447] Titration curves obtained on the COS-7 monkey cell line showed that, except for 832E5 mAb, all anti-hIGF-1R Abs specifically recognized IGF-1R expressed on the surface of the monkey cell line. Figure 7AEC for each mouse and chimeric Ab. 50 The determination shows that there are two comparable forms regarding their binding characteristics to monkey IGF-1R. Figure 7B These results show that all generated anti-hIGF-1R antibodies, except for mAb 832E5, recognized monkey IGF-1R.

[0448] Binding EC to COS-7 cells compared to IGF-1R cells transfected with COS-7 cells 50 The comparison was conducted to confirm the magnitude of recognition of the chimeric antibody in humans compared to that in monkeys with IGF-1R. Figure 7B The results shown demonstrate that all antibodies, except 832E5mAb, exhibit similar recognition of human and monkey IGF-1R.

[0449] To confirm the identification of another type of monkey, cells were transfected with IGF-1R from cynomolgus monkeys to produce soluble monkey IGF-1R ECDs, and Biacore assays were performed with one of the chimeric antibodies (c208F2) to compare the binding properties of hIGF-1R or cynomolgus monkey IGF-1R.

[0450] Recognition experiments were run on a Biacore X100 device using a CM5 sensor chip activated by an anti-His-tagged antibody (His Capture Kit, GE Healthcare, catalog number 28-9950-56). Over 11,000 RU of antibody was chemically grafted onto a carboxymethyl dextran matrix using amine kit chemistry. Experiments were performed at 25°C and a flow rate of 30 μl / min using HBS-EP buffer (GE Healthcare) as the run and sample dilution buffer. A single-cycle kinetic protocol was used to define the kinetic parameters of binding to hIGF-1R by the chimeric form of the 208F2 anti-IGF-1R antibody (c208F2) compared to macaque IGF-1R.

[0451] A solution of a soluble recombinant form of IGF-1R heterotetramer (consisting of an extracellular domain of a 2β chain and a 2α chain expressing an additional C-terminal 10-His tag) based on either a human sequence (R&D system, catalog number 305-GR-50) or a cynomolgus monkey sequence (produced in-house) was injected for 1 minute in a second flow cell at a dilution defined for capturing approximately 160 RU of antigen. A solution of the second antibody was either injected in both flow cells under the same conditions or only in the second flow cell. Following the capture phase, either five injections of run buffer (90 seconds each) or five concentrations of c208F2 of the growth range (90 seconds each) were injected in both flow cells. At the end of the fifth injection, the dissociation rate was defined by running buffer. Surface regeneration was then achieved by injecting 10 mM glycine, HCl pH 1.5 buffer over 30 seconds.

[0452] The calculated signal corresponds to the difference between the reaction in flow cell 2 (with trapped IGF-1R) and the reaction in flow cell 1 (without any IGF-1R molecules). Figure 8 ).

[0453] For each IGF-1R molecule (human or cynomolgus monkey), the signal caused by injection of c208F2 at concentrations within the growth range was corrected by subtracting the signal obtained from five injections of buffer (dual reference). The generated sensor maps were analyzed using Biaevaluation software with a 1:1 model. Kinetic rates were evaluated independently (two kinetic rates of c208F2 binding to each IGF-1R) or generally (the same kinetic rate of c208F2 binding to human and cynomolgus monkey IGF-1R). The quality of the fit was assessed by a Chi2 / Rmax ratio below 0.05 RU.

[0454] The binding kinetic rates defined for each IGF-1R (see Table 11) are close, and fitting of two sensor plots using the same kinetic rates yields good quality. The c208F2 antibody also recognizes recombinant human and cynomolgus monkey IGF-1R with a dissociation constant (KD) of approximately 0.2 nM. The affinity defined in this study corresponds to the functional affinity (or avidities) of the antibody for approximately 160 RU of captured human and cynomolgus monkey IGF-1R.

[0455] Table 11

[0456] IGF1R kon[1 / Ms] koff[1 / s] Kd[nM] Chi2 / Rmax people 1.52E+06 3.40E-04 0.23 0.045 Crab-eating macaques 1.85E+06 3.10E-04 0.17 0.032 Humans and crab-eating macaques 1.52E+06 3.33E-04 0.22 0.039

[0457] Example 6: The inherent role of the generated antibody in IGF-1R phosphorylation

[0458] It is well known that antibodies can induce agonistic effects when they bind to tyrosine kinase receptors. Since we did not want to select such agonist antibodies, we investigated the assessment of hIGF-1R phosphorylation using chimeric antibodies.

[0459] For this purpose, MCF-7 cells were incubated overnight in serum-free medium. Then, the test IGF-1 (100 nM) or Ab (10 μg / ml) was added at 37°C for 10 minutes. The medium was discarded, and cells were scraped off at 4°C for 90 minutes in lysis buffer (pH 7.5) containing 10 mM Tris-HCl buffer (pH 7.5), 15% NaCl (1 M), 10% detergent mixture (10 mM Tris-HCl, 10% Igepal lysis buffer) (Sigma Chemical), 5% sodium deoxycholate (Sigma Chemical), 1% protease inhibitor mixture complete™ tablets (Roche), and 1% phosphatase inhibitor mixture kit II (Calbiochem). Lysates were clarified by centrifugation at 4°C, heated at 100°C for 5 minutes and held at -20°C, or directly loaded onto 4–12% SDS-PAGE gels. Incubation with the primary antibody for 2 hours at room temperature was followed by incubation with the secondary antibody linked to HRP for 1 hour at room temperature. The membrane was washed in TBST before protein visualization using ECL. Quantitative blotting was performed using ImageJ software. Phosphorylated protein values ​​were normalized using GAPDH. Phosphorylation of hIGF-1R in response to IGF-1 was considered a 100% stimulus. The effect of anti-hIGF-1R Abs on hIGF-1R phosphorylation was determined by the percentage of IGF-1-induced phosphorylation.

[0460] Figure 9 The results described represent the average percentage of pIGF-1R responding to chimeric anti-IGF-1RAb in three independent + / -SD experiments compared to IGF-1. As shown, no significant or minimal (<20%) phosphorylation of hIGF-1R was detected when MCF-7 cells were incubated with 10 μg of anti-IGF-1R Ab.

[0461] Example 7: Inhibition of IGF-1R phosphorylation in response to IGF-1 by mouse anti-hIGF-1R antibody

[0462] To characterize the selected antibodies, their ability to inhibit IGF1-induced phosphorylation was investigated. For this purpose, MCF-7 cells were incubated overnight in serum-free medium. Then, at 37°C, the cells were incubated with mouse anti-hIGF-1Ab for 5 min, followed by the addition of IGF-1 for 2 min. The medium was discarded, and cells were scraped off at 4°C for 90 min in lysis buffer (pH 7.5) containing 10 mM Tris-HCl buffer (pH 7.5), 15% NaCl (1 M), 10% detergent mixture (10 mM Tris-HCl, 10% Igepal lysis buffer) (Sigma Chemical), 5% sodium deoxycholate (Sigma Chemical), 1% protease inhibitor mixture complete™ tablets (Roche), and 1% phosphatase inhibitor mixture kit II (Calbiochem). Lysates were clarified by centrifugation at 4°C, heating at 100°C for 5 min and holding at -20°C, or directly loaded onto 4–12% SDS-PAGE gels. Incubation with the first antibody for 2 hours at room temperature, followed by incubation with the second antibody linked to HRP for 1 hour at room temperature. The membrane was washed in TBST before protein visualization using ECL. Quantitative blotting was performed using ImageJ software. Phosphorylated protein values ​​were normalized using GAPDH. Phosphorylation of hIGF-1R in response to IGF-1 was considered a 100% stimulus. The effect of anti-hIGF-1R Abs on hIGF-1R phosphorylation was determined by the percentage of IGF-1-induced phosphorylation.

[0463] The addition of m105G2, m101H8, or m9G4 (an unrelated mouse antibody) does not inhibit the phosphorylation of hIGF-1R in response to IGF-1. Figure 10 The addition of m201F1 moderately reduces hIGF-1R phosphorylation in response to IGF-1 (approximately 40% reduction). All other anti-IGF-1R Abs strongly inhibit hIGF-1R phosphorylation in response to IGF-1 (reduction greater than 80%). The best inhibitors of IGF1-induced hIGF-1R phosphorylation are m208F2, m212A11, and m214F8 Mab.

[0464] Example 8: Study on IGF-1R internalization by FACS analysis of the generated anti-IGF-1R antibody.

[0465] MCF-7 cells were incubated with 10 μg / ml of chimeric antibody at 4°C for 20 min. Cells were then washed and incubated at 4°C or 37°C for 4 h. The amount of antibody bound to the cell surface was determined using a secondary antibody on a FacsCalibur flow cytometer (Becton Dickinson). ΔMFI, defined as the difference between the MFI measured at 4°C and the MFI measured at 37°C after a 4-hour incubation period, corresponds to the amount of internalized Ab. Figure 11 And ΔMFI is shown in Table 12. The internalization percentage of 10 μg / ml Ab is calculated as follows: 100 * (MFI at 4°C – MFI at 37°C) / MFI at 4°C, and is shown in Table 11. The maximum value of ΔMFI calculated for each chimeric antibody ( Figure 11 There is no correlation between the displayed group and the internalized maximum value.

[0466] Table 12

[0467] Group Ab Internalization percentage ΔMFI <![CDATA[EC 50 ]]> G1 c101H8 75 254 4.2E-09 G1 c201F1 75 222 8.4E-08 G2 c208F2 83 288 1.8E-10 G2 c212A11 80 322 2.7E-10 G2 c214F8 87 403 2.2E-10 G2 c219D6 80 353 4.4E-10 G2 c213B10 85 369 2.3E-10 G3a c102H8 71 262 7.9E-10 G3a c110G9 79 309 1.2E-09 G3a c415A8 78 327 1.2E-09 G3b c410G4 82 321 3.7E-09 G3b c414E1 68 229 3.1E-09 G3b c433H9 79 323 1.1E-09 G4 c105G2 81 260 7.2E-09 G5 c832E5 40 92 2.0E-08

[0468] To determine whether antibodies that also recognize monkey IGF-1R could internalize the receptor, the same internalization experiments were performed. The results summarized in Table 13 demonstrate that all the antibodies tested were able to mediate monkey IGF-1R internalization.

[0469] Table 13

[0470]

[0471] To further evaluate the kinetics of the reduction in antibody binding on the cell surface, MCF-7 cells were seeded in 96-well plates and incubated at 4°C with 10 μg / ml mouse antibody for 20 min. Cells were then washed to remove unbound antibodies and incubated at 37°C in medium for 10, 20, 30, 60, or 120 min. At each time point, cells were centrifuged and surface-labeled with a secondary anti-mouse IgG-Alexa488 on ice to determine the amount of antibody remaining on the cell surface. At 4°C, the fluorescence intensity of each mouse antibody and at each time point was normalized by signal (percentage of remaining IGF-1R) and fitted to exponential decay to determine the half-life (t1 / 2). t1 / 2 was considered the time required for a 50% reduction in signal, as measured at 4°C. Figure 12A and Figure 12B As shown, the surface levels of all mice Ab decreased rapidly within the first 30 minutes, and this reduction was almost maximum after 60 minutes of incubation. Figure 12A Regarding mouse Ab, the calculated half-life is within 10 to 18 minutes. Figure 12B There was no correlation between antibody surface attenuation and the Ab group.

[0472] To verify that the reduction in cell surface signaling was due to Ab internalization rather than receptor shedding, cells were incubated with mouse Ab at 37°C for 0, 30, and 60 minutes. Figures 13A to 13O Cells were then fixed and permeabilized or not permeabilized to determine the antibodies bound to the cell surface (without permeabilization) and the total antibody signal corresponding to cell surface-bound + internalized Abs (with permeabilization). The amount of internalized Abs (cytoplasm) was determined as follows: MFI after permeabilization – MFI without permeabilization. This experiment showed that the decrease in cell surface-bound Abs was due to the increase in cytoplasmic Abs, demonstrating that the Abs were internalized. Figures 13A to 13O Furthermore, as indicated by the reduction in signal after permeation (overall), Ab degradation begins after 1 hour of incubation.

[0473] Example 9: Study on IGF-1R internalization after confocal analysis of the generated anti-IGF-1R antibody

[0474] To further confirm antibody internalization, confocal microscopy was performed to assess the subcellular distribution of the antibody after cell transport. Cells were incubated, fixed, and permeabilized with anti-hIGF-1R Ab at 37°C. Cells were then stained with a secondary antibody, Alexa-488, and a rabbit anti-lLamp-1 antibody, visualized using a secondary anti-rabbit IgG, Alexa 555. Prior to incubation at 37°C, mouse 208F2 Ab localized to the membrane of MCF-7 cells. Figure 14A Furthermore, no co-localization with lysosomal markers was observed, and lamp-1 was noted using the highliter co-localization plugin in ImageJ software. After 15 minutes of incubation, cell surface-bound antibodies decreased sharply. Accompanying this decrease in cell surface-bound antibodies, intracellular antibody infiltration into vesicles was detected. Rare co-localization with lamp-1 was observed. After 30 minutes of incubation, cell surface-bound antibodies were almost undetectable. However, co-localization of Abs into lysosomes increased. After 1 hour of incubation, intracellular Ab staining decreased, as did the number of Abs co-localized with lamp-1. The kinetics of these cell surface-bound antibodies and their intracellular accumulation correlated with the kinetics of antibody surface decay as measured by FACS. Additionally, as described in previous FACS studies, degradation of mouse Abs began after 1 hour of incubation using confocal microscopy.

[0475] The internalization of all other anti-IGF-1R mouse antibodies and their co-localization with Lamp-1 were also evaluated. Figure 14B ).

[0476] Example 10: Inhibition of Ab degradation using the lysosomal inhibitor bafilomycin A1

[0477] To confirm that antibodies reaching lysosomes are degraded, cells were treated with or without bafloxacin A1 (a potent inhibitor of lysosomal function). Cells were then incubated with 10 μg / ml of the test Ab at 4°C, washed, and incubated at 37°C for 2 hours. Internalized Abs were detected using a secondary anti-mouse IgG-Alexa 488Ab after cell permeabilization. The addition of bafloxacin A1 prevented the degradation of intracellular Abs. Figure 15 This indicates that Ab was effectively internalized and entered the lysosome for degradation.

[0478] Example 11: The effect of pH on antibody IGF-1R binding and its correlation with cytotoxic efficacy.

[0479] Antibodies are selected based on their internalization potential and, as shown above, co-localize with early endosomes before entering the lysosomal compartment. Therefore, an approach of interest is to select antibodies where the stability of Ab-hIGF-1R binding is regulated by pH, and preferably antibodies that preferentially dissociate from IGF-1R when the pH becomes acidic. Indeed, the main difference between early endosomes and lysosomes is their intraluminal pH: approximately 6 in the endosome compartment and approximately 4.5 in the lysosomal compartment. It is well known that once internalized after ligand binding (IGF1), hIGF-1R returns to the cell surface via the recycling pathway.

[0480] Not in line with theory, the hypothesis described here is that antibodies that tend to release earlier from their targets at acidic pH levels may favor target recirculation into the membrane and thus could be considered better candidates for immunoconjugation methods. To investigate whether some of our antibodies exhibit such a property and to correlate this property with cytotoxic activity, binding of mouse anti-hIGF-1R Mab to the MCF-7 cell line was performed in buffers at different pH values. Increasing concentrations of mouse mAb were incubated on the MCF-7 cell line for 20 minutes at different pH values ​​ranging from 5 to 8 at 4°C. Cells were then washed three times and incubated in FACS buffer with a suitable secondary antibody conjugated to Alexa 488. Cells were incubated for an additional 20 minutes at 4°C in the dark, followed by three washes in FACS buffer. Immediate binding of live cells to the anti-hIGF-1R antibody was performed, identified using propidium iodide staining of dead cells. The binding EC50, expressed as molar concentration (M), was calculated using nonlinear regression analysis (GraphPad Prims 4.0). 50 .

[0481] ECs belonging to epitope group 3B that resist hIGF-1R 50 Not significantly affected by pH ( Figures 16A to 16NThe binding capacity of anti-hIGF-1R Abs belonging to epitope group 3a is generally enhanced at acidic pH. Conversely, the binding capacity of anti-hIGF-1R Abs belonging to epitope groups 1, 2, and 4 is decreased at acidic pH.

[0482] To determine whether acidic pH had a positive effect on immunoconjugate-induced cytotoxicity, the commercially available Fab-ZAP human assay (ATS BIO) was used. Briefly, MCF7 cells were seeded at 2000 cells / well in 96-well plates and left overnight for adhesion. On the second day, cells were treated with 0.45 μg / mL Fab-ZAP and increments of chimeric anti-IGF-1R Ab. A c9G4 monoclonal antibody that does not bind to the cell surface was used as a negative control. On day 6, cell viability was measured using the CellTiter Glo Luminesence cell viability assay from Promega (Madison, Wisconsin). Figure 17A As shown, anti-IGF-1R Abs in groups 4 and 5 did not induce any cytotoxicity against MCF-7, while moderate to high cytotoxicity (groups 1, 3a, and 3b) was measured in the other groups. Figure 17B In China, IC 50 The determination confirmed that group 2 had the highest cytotoxic potency, indicating that these antibodies would be best suited for ADC (antibody-drug conjugate) or ATC methods.

[0483] exist Figure 17A and Figure 17B The results summarized in the study showed that among the 15 chimeric MABs evaluated, c208F2, c219D5, c212A11, c213B10, and c214F8 achieved the best cytotoxic activity, all of which belonged to group 2. However, other antibodies from groups 1 and 4 also showed sensitivity to the acidic pH of IGF-1R binding and were not clustered as the best candidates for cytotoxicity, suggesting that this property may be desired but insufficient to explain the specific characteristics of antibodies from group 2. To better understand the specific characteristics of this group of antibodies, a correlation study was conducted on the available data of all generated antibodies. The results of this analysis indicate that phosphorylation inhibition and reduced binding ability to hIGF-1R are needed in an acidic pH environment to obtain optimal cytotoxic activity. Figure 18In fact, the binding of 101H8(G1), 201F1(G1), and 105G2(G4) is reduced in acidic pH environments, but they are poor phosphorylation inhibitors, showing low cytotoxic activity. On the other hand, 102H8(G3a), 110G9(G3a), 415A8(G3a), 410G4(G3b), 414E1(G3b), and 433H9(G3b) are effective inhibitors of IGF1-induced phosphorylation, but they are insensitive to pH changes or their binding is enhanced at acidic pH, demonstrating only moderate cytotoxic activity in Fab-ZAP human assays.

[0484] Binding of the humanized anti-IGF-1R Mab to the MCF-7 cell line was performed in buffers at different pH values. Incremental concentrations of the humanized mAb were incubated on the MCF-7 cell line for 20 minutes at different pH values ​​ranging from 5 to 8 at 4°C. Cells were then washed three times and incubated in FACS buffer with a suitable Alexa 488-conjugated secondary antibody. Cells were incubated in the dark at 4°C for an additional 20 minutes, followed by three washes in FACS buffer. Immediate binding of live cells to the anti-IGF-1R antibody was performed, identified using propidium iodide staining of dead cells. The binding EC50, expressed as molar concentration (M), was calculated using nonlinear regression analysis (GraphPad Prims 4.0). 50 Humanized anti-IGF-1R antibodies exhibit lower binding capacity at acidic pH conditions, such as... Figure 32A and Figure 32B As shown.

[0485] Example 12: 208F2 Evaluation of Mab's humanization

[0486] 12.1 Evaluation of the combination and internalization of the first humanized form hz208F2 VH3 / VL3 (also known as hz208F2 H026 / L024)

[0487] In MCF-7, COS-7 and NIH 3T3 IR + Binding of the first humanized form of c208F2 mAb was evaluated on cell lines. Incremental concentrations of m208F2, c208F2, or hz208F2VH3VL3 were added to each cell line at 4°C and maintained for 20 minutes. Cells were then washed, and the binding of the tested mAb was visualized using the corresponding secondary antibody. To validate the expression of human IR in transfected cell lines, the commercially available anti-hIR antibody clone GRO5 was used, and its recognition map is shown in (…). Figure 19D (Example above)

[0488] In MCF-7 ( Figure 19A ) or Monkey COS-7 ( Figure 19BCellular comparisons of the humanized form with mouse or chimeric forms showed a close spectrum among the three tested forms. The humanization process does not alter the specificity of antibody recognition, and it is fully comparable to the mouse and chimeric forms, which do not cross-react with the human insulin receptor. Figure 19C ).

[0489] The calculated EC50 values ​​of the first humanized form of c208F2 for human cell line MCF-7 and monkey cell line COS-7 were calculated. 50 EC determined by the mouse or chimeric form of 208F2 50 resemblance.

[0490] The ability of mAb hz208F2 VH3 / VL3 to internalize was assessed by flow cytometry. MCF-7 cells were incubated with 10 μg / ml of antibody at 4°C for 20 min. Cells were then washed and incubated at 4°C or 37°C for 4 h. The amount of antibody bound to the cell surface was determined using a secondary antibody. ΔMFI, defined as the difference between the MFI measured at 4°C and 37°C after a 4-hour incubation period, corresponds to the amount of internalized Ab. ΔMFI is presented in Table 14a. The percentage of internalization of the 10 μg / ml Ab was calculated as follows: 100 * (MFI at 4°C – MFI at 37°C) / MFI at 4°C, and is shown in Table 14a. Therefore, the humanized hz208F2 VH3 / VL3 exhibited similar binding and internalization properties compared to those measured with the corresponding mouse and chimeric 208F2 antibodies.

[0491] Table 14a

[0492]

[0493] 12.2 Evaluation of the subsequent humanization of hz208F2

[0494] mAb 208F2 is humanized, and its binding properties were evaluated for 16 humanized variants (including the first form described in 12.1). The binding properties of the humanized variants were evaluated using FACS analysis of the human MCF-7 breast cancer cell line and the monkey cell line Cos-7 with increasing antibody concentrations. For this purpose, cells (1 × 10⁻⁶ cells / year) were in FACS buffer (PBS, 0.1% BSA, 0.01% NaN₃) at 4°C. 6Cells / ml were incubated with anti-IGF-1R humanized antibody for 20 min. They were then washed three times and incubated for an additional 20 min at 4°C in the dark with a suitable second antibody conjugated to Alexa488, followed by three washes in FACS buffer. Immediate binding of live cells to the anti-IGF-1R antibody was performed, and these live cells were identified using propidium iodide (which stains dead cells). The binding EC50, expressed as molar concentration (M), was calculated using nonlinear regression analysis (GraphPad Prims 4.0). 50 .

[0495] EC of humanized variants 50 All humanized variants showed equivalent binding properties in both human and monkey cell lines. EC50 of the humanized antibody. 50 The summary is in Table 14b.

[0496] Table 14b

[0497]

[0498] 12.3 Evaluation of the internalization of another form of humanization of hz208F2

[0499] MCF-7 cells were incubated with 10 μg / ml humanized antibody at 4°C for 20 min. Cells were then washed and incubated at 4°C or 37°C for 4 h. The amount of antibody bound to the cell surface was determined using a secondary antibody on a FacsCalibur flow cytometer (Becton Dickinson). ΔMFI, defined as the difference between the MFI measured at 4°C and the MFI measured at 37°C after a 4-hour incubation period, corresponds to the amount of internalized Ab. ΔMFI is presented in Table 14c. The percentage of 10 μg / ml Ab internalization was calculated as follows: 100 * (MFI at 4°C – MFI at 37°C) / MFI at 4°C. The humanized antibody hz208F2 H077 / L018 induced significant internalization of IGF-1R.

[0500] Table 14c

[0501]

[0502] Example 13: IGF-1R as a target for the immunoconjugation method.

[0503] An IHC study was established to validate hIGF-1R as a target for the immunoconjugation approach. In practice, a useful target for this approach would require significant overexpression on tumor cells compared to normal cells. Another characteristic of a suitable target for the immunoconjugation approach is its prevalence of overexpression in a substantial percentage of patient populations across many indications.

[0504] To assess whether hIGF-IR could be considered a suitable target for an immunoconjugation approach, a commercially available polyclonal antibody (AF305-NA from R&D Systems) described as specific to the extracellular domain (EDC) of hIGF-1R was selected for comparison with hIR. The first step of our procedure was to verify the specificity of AF305-NA for the hIGF-1R ECD and its lack of recognition of hIR. For this purpose, a series of ELISA assays were performed on human IGF-1R and hIR ECD proteins using the protocol detailed above.

[0505] Figure 20A The results described demonstrate that the polyclonal anti-hIGF-1R antibody effectively recognizes hIGF-1R ECD. The GR11L antibody (Calbiochem), used as a positive control, yielded the expected profile. As described by the supplier, Figure 20B Unlike the anti-hIR GRO5 Mab (Calbiochem) used as a positive control in ELISA, AF305-NA does not recognize hIR. Similarly, FACS analysis of the polyclonal AF305-NA against hIR... + Binding assessment of transfected cells confirmed that it does not recognize cellular forms of hIR ( Figure 20D ), while the anti-hIR GRO5 antibody exhibited the desired spectrum on transfected cells ( Figure 20C This demonstrates that they express high levels of hIR. As expected, GR11L, which recognizes hIGF-1R and was introduced as a negative control in the experiment, showed high levels of hIR. + No signal was observed on the transfected cells. Figure 20C ).

[0506] For hIGF-1R distribution studies, the AF305-NA antibody was thoroughly validated, and an IHC protocol was established on a Discovery Ultraautostainer Ventana. Briefly, after dewaxing, antigen retrivial was performed at 96°C for 32 min using CC1 in EDTA pH 8 buffer. The primary antibody (AF305-NA) was incubated at 37°C for 1 h. After washing, polymeric HRP-OMap anti-goat IgG (Ventana) was incubated at 37°C for 16 min, followed by visualization using DAB chromogenetics. Finally, the tissues were counterstained with hematoxylin. Slides were then placed in Eukitt medium. To validate IHC staining, a group of tumor tissues from xenografts were selected based on their in vitro hIGF-1R expression. Figure 21As shown, strong membrane staining was observed on three positive tissues (MCF-7, NCI-H23, and NCI-H82). No membrane staining was observed on Hs746t, which was selected as a negative tumor. For staining analysis, slides were scanned using an HT scanner from Roche Ventana, and quantitative IGF-1R staining was performed using Virtuoso software (Roche Ventana). For tissue analysis, if possible, scoring was performed for four fields of view (FOV) for each tumor with more than 50 cells to improve the statistical accuracy of the algorithm. According to the HER2 membrane algorithm, tissue scores were +++ (also described as 3+), ++ to +++ (also described as 2+ to 3+ or ++ / +++), ++ (also described as 2+), and + (also described as 1+). A score of (+) was defined according to the CAP / ASCO testing guidelines for weak or incomplete membrane staining, or weak, complete membrane staining of less than 10% of the cells in the sample. A score described as complete membrane staining (++) indicates heterogeneous or weak staining, but with a distinct circumferential distribution in at least 10% of cells, or strong complete membrane staining in 30% or fewer tumor cells. A score of (+++) corresponds to uniform strong membrane staining in more than 30% of invasive tumor cells. When the tumor score is (++) to (+++), it traduces heterogeneity in the tumor analysis tissue. (-) means no hIGF-1R expression was detected, and (c) means staining is purely cytoplasmic. Cytoplasmic staining is characterized by the absence of membrane staining, resulting in cell separation.

[0507] Then, the above procedures were used to conduct extended studies on normal and tumor tissues. Figure 22A and Figure 22B ).

[0508] For these studies, normal and tumor TMA from Superbiochips were used for distribution and epidemiological studies. Two different controls were introduced in each automated staining cycle. One control consisted of placental sections, a known positive control for IGF-1R expression, and tissue provided with normal TMA. The second series of controls were on slides of three tumor xenograft tissues showing scores of 2+ or 3+ (MCF-7 and NCI-H23, NCI-H82, respectively). The latter control was added in each staining run sequence to correct for expression.

[0509] As expected, placental tissue from xenografts was positive for hIGF-1R. Strong membrane staining was observed in all four controls. In the first group of normal human tissues ( Figure 22AIn the gastrointestinal tract (esophagus, small intestine, colon, and rectum), a slight membrane detection of IGF-1R never exceeded 1+. For all other analyzed tissues, membrane expression of IGF-1R was not observed. In the second group of normal human tissues ( Figure 22B Mild membrane staining (never exceeding 1+) of IGF-1R was observed in the kidney structures. Strong membrane staining (++) was observed on the epithelium of the prostate and urethra. No strong membrane staining was observed in other tissues. This expression pattern strongly suggests that hIGF-1R may be a good target for ADC or ATC methods.

[0510] To determine the potential indications for immune conjugates targeting IGF-1R, the above-described procedure was used to analyze the expression of IGF-1R in tumor samples from the lung, breast, head and neck, bladder, and kidney of patients.

[0511] Of the 69 lung samples studied, 67 were explainable. IGF-1R expression was quantified as described above. Figure 23 As shown, strong membrane expression was detected in many cancers compared to normal adjacent tissues, which were negative, consistent with our description above in normal tissues. All analyzed cases are summarized in Table 15. 55% of ++ or +++ cases were observed, encompassing all subtypes of lung cancer. Squamous cell lung cancer was the most frequently expressing tumor of hIGF-1R, with 70% of ++, ++ / +++, or +++ cases, and only 43% of tumors retained +++ and ++ / +++. These results are consistent with publicly available data describing the high polysomy or hIGF-1R amplification commonly seen in patients with squamous cell lung cancer.

[0512] Table 15

[0513] IGF-1R expression normal tissue Lung adenocarcinoma, well-differentiated, 18 / 30, T2bN2M0, IIIA, 103, 6. (-) (-) Lung adenocarcinoma, well-differentiated, 0 / 15, T2aN0M0, IB, 104 6 (-) (-) Lung adenocarcinoma, well-differentiated, 0 / 39, T2aN0M0, IB, 108 6 (+) (-) Lung adenocarcinoma, well-differentiated, 22 / 22 T3N2M0 IIIA, 157 6 (-) (-) Lung adenocarcinoma, moderately differentiated, 0 / 6, T2aN0M0, IB, 156 6 (+) (-) Lung adenocarcinoma, moderately differentiated, 0 / 30, T2aN0M0, IB, 102 6 (+) (-) Lung adenocarcinoma, moderately differentiated, 0 / 12, T2aN0M0, IB, 158 6 (+) (-) Lung adenocarcinoma, moderately differentiated, 2 / 15, T3N2M0, IIIA, 159, 6. (-) (-) IGF-1R expression normal tissue Lung squamous cell carcinoma, well-differentiated, 5 / 43, T2aN1M0, IIA, 101, 6 (+) to (++) (-) Lung squamous cell carcinoma, well-differentiated, 0 / 15, T2aN0M0, IB 109 6 (+) to (++) (-) Lung squamous cell carcinoma, well-differentiated, 2 / 20, T3N2M0, IIIA, 113, 6. (+++) (-) Lung squamous cell carcinoma, well-differentiated, 4 / 61, T2aN1M0, IIA, 115, 6. (++) to (+++) (-) Lung squamous cell carcinoma, well-differentiated, 0 / 17, T2aN0M0, IB 120 6 (++) to (+++) (-) Lung squamous cell carcinoma, well-differentiated, 1 / 46, T2bN1M0, IIB1, 121, 6. (++) to (+++) (-) Lung squamous cell carcinoma, well-differentiated, 1 / 43 T2aN1M0 IIA 123 6 (++) to (+++) (-) Lung squamous cell carcinoma, well-differentiated, 8 / 28, T2aN2M0, IIIA, 136 6 (++) (-) Lung squamous cell carcinoma, well-differentiated, 0 / 17, T2aN0M0, IB 137 6 (++) (-) Lung squamous cell carcinoma, well-differentiated, 0 / 19, T2aN0M0, IB 139 6 (++) (-) Lung squamous cell carcinoma, well-differentiated, 4 / 32, T2aN2M0, IIIA, 144, 6. (++) (-) Lung squamous cell carcinoma, well-differentiated, 0 / 24, T2bN0M0, IIA, 148 6 (+++) (-) Lung squamous cell carcinoma, well-differentiated, 5 / 40, T2bN1M0, IIB1, 150, 6. (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 20, T2aN0M0, IB, 155 6 (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 1 / 15, T2bN1M0, IIB 105 6 (+) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 8, T2aN0M0, IB, 106 6 (+) to (++) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 16, T3N0M0, IIB 110 6 (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 16, T2aN0M0, IB 118 6 (-) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 34, T2bN0M0, IIA, 119 6 (++) (-) Lung squamous cell carcinoma, moderately differentiated, 5 / 18, T2aN2M0, IIIA, 126 6 (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 1 / 25, T2aN1M0, IIA, 129, 6 (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 22, T2bN0M0, IIA, 130 6 (++) to (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 3 / 21, T2aN1M0, IIA, 131, 6 (-) (-) Lung squamous cell carcinoma, moderately differentiated, 2 / 18, T1bN1M0, IIA, 134, 6 (+) to (++) (-) Lung squamous cell carcinoma, moderately differentiated, 1 / 33, T2aN1M0, IIA, 138, 6 (++) (-) Lung squamous cell carcinoma, moderately differentiated, 1 / 25, T2aN1M0, IIA, 145 6 (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 21, T2aN0M0, IB, 146 6 (++) to (+++) (-) Lung squamous cell carcinoma, moderately differentiated, 0 / 28, T3N0M0, IIB 151 6 (++) (-) Lung squamous cell carcinoma, poorly differentiated 0 / 50, T4N0M0, IIIA, 132 6 (+++) (-) Lung squamous cell carcinoma, poorly differentiated 1 / 3, T2aN2M0 IIIA, 135 6 (-) (-) Lung squamous cell carcinoma, poorly differentiated, 0 / 22, T3N0M0, IIB 140 6 (+) to (++) (-) Lung squamous cell carcinoma, poorly differentiated 0 / 22 T2aN0M0 IB 141 6 (+++) (-) Lung squamous cell carcinoma, poorly differentiated, 0 / 18, T2bN0M0, IIA, 128 6 (++) (-) Lung squamous cell carcinoma, poorly differentiated 0 / 11 T2aN0M0 IB 147 6 (+) to (++) (-) Lung squamous cell carcinoma, poorly differentiated 0 / 12 T2aN0M0 IB 152 6 (++) (-) Lung squamous cell carcinoma, poorly differentiated, 0 / 14, T3N0M0, IIB 153 6 (-) (-) Lung squamous cell carcinoma, spindle cells 0 / 10 T1bN0M0 IA 122 6 (++) (-) IGF-1R expression normal tissue Lung squamous cell carcinoma 0 / 6 T3N0M0 IIB 111 6 (-) (-) Lung squamous cell carcinoma 0 / 14 T2aN0M0 IB 154 6 (+++) (-) IGF-1R expression normal tissue Large cell neuroendocrine carcinoma of the lung (0 / 7, T2aN0M0, IB 112 6) (+++) (-) Large cell neuroendocrine carcinoma of the lung (0 / 38) T3N0M0 IIB 133 6 (+) (-) IGF-1R expression normal tissue Large cell lung cancer 0 / 9 T2aN0M0 IB 114 6 (++) to (+++) (-) Large cell lung cancer 0 / 14 T1bN0M0 IA 125 6 (+) (-) Large cell lung cancer 0 / 33 T2aN0M0 IB 142 6 (++) (-) IGF-1R expression normal tissue Lung bronchioloalveolar carcinoma, non-mucinous, 7 / 17, T3N2M0, IIIA, 107 mmol / L. (-) (-) Bronchioloalveolar carcinoma of the lung, non-mucinous, 0 / 8, T2bN0M0, IIA, 116 6 (-) (-) Bronchioloalveolar carcinoma of the lung, non-mucinous, 2 / 24 years old, T1aN1M0, IIA, 149 6 (+) (-) Bronchioloalveolar carcinoma of the lung, mucinous 0 / 8, T2aN0M0, IB 117 6 (-) (-) Bronchioloalveolar carcinoma of the lung, mucinous 0 / 24, T2aN0M0, IB 124 6 (++) (-) Bronchioloalveolar carcinoma of the lung, mucinous 0 / 9, T3N0M0, IIB 127 6 n / a (-) Lung bronchioloalveolar carcinoma, mucinous 1 / 11, T1b, N1, M0, IIA, 143, 6 (+) (-)

[0514] Another study investigated IGF-1R expression in a series of 10 breast cancer samples. Figure 24 The results shown demonstrate that IGF-1R is highly expressed in cancerous tissue compared to adjacent normal tissue. The staining data summarized in Table 16 show that 66% of the analyzed cases were ++, ++ / +++, or +++, and 22% were +++ or ++ / +++.

[0515] Table 16

[0516]

[0517] * Case shown

[0518] Finally, IGF-1R overexpression was observed in a range of tumors, including those of the head and neck, urinary tract, bladder, and kidneys. Figure 25Furthermore, in comparison with normal adjacent tissues, high overexpression of IGF-1R was observed in the tumor sample.

[0519] In summary, these results are consistent with the immunoconjugation approach for treating a wide range of IGF-1R-positive tumors, including those of the lung, breast, head and neck, urinary tract, bladder, and kidney.

[0520] Example 14: Definition of five chimeric anti-IGF-1R antibodies (c208F2, c213B10, c212A11, c214F8, and The dissociation constant (Kc219D6) of soluble recombinant human IGF-1R bound to c219D6 and humanized (VH3 / VL3) 208F2 antibodies. D )

[0521] via dissociation rate (k) off ) and binding rate (k on The ratio between these two values ​​defines the dissociation constant (K) of the antibody binding to recombinant soluble human IGF-1R. D Kinetic experiments were performed on a Biacore X100 device using a CM5 sensor chip activated by a mouse anti-His-tagged monoclonal antibody. Approximately 12,000 RU of antibody was chemically grafted onto a carboxymethyl dextran matrix using an amine kit chemistry.

[0522] HBS-EP+ buffer (GE Healthcare) was used as the run and sample dilution buffer, and experiments were performed at 25°C at a flow rate of 30 μl / min.

[0523] A single-cycle kinetic protocol was used to define the kinetic parameters for the binding of the anti-IGF-1R antibody to soluble recombinant human IGF-1R, which is captured by its two C-terminal 10-histidine tags.

[0524] A solution of soluble recombinant human IGF-1R heterotetramer: the extracellular domain of the 2α chain and the 2β chain expressing an additional C-terminal 10-His tag (R&D Systems, catalog number 305-GR-50) was injected into a second flow cell at a concentration of 10 μg / ml over a 1-minute period. In each of the 24 cycles achieved in this study, a mean of 587 RU (with a standard deviation of 24 RU) of soluble receptor was captured.

[0525] 2. Following the capture phase, inject run buffer five times (90 seconds per injection) or inject one of six antibodies at five different concentrations within the growth range (90 μl per injection) into two flow cells. At the end of the fifth injection, run buffer is passed through over a 5-minute period to define the dissociation rate.

[0526] 3-Then inject 10mM glycine and HCl pH 1.5 buffer during 45s to generate the surface.

[0527] The calculated signal corresponds to the difference between the reaction in flow cell 2 (with captured IGF-1R) and the reaction in flow cell 1 (without any IGF-1R molecules).

[0528] For each IGF-1R, the signal generated due to the increased concentration range of one antibody was corrected by subtracting the signal obtained from 5 injections of buffer (dual reference). See [link to relevant documentation]. Figure 26 .

[0529] The sensor image was analyzed using Biaevaluation software at a 1:1 scale.

[0530] For each antibody, four trials were run using two different concentration ranges: the first two trials for each antibody were 40, 20, 10, 5, and 2.5 nM, and the last two trials were run at 24, 12, 6, 3, and 1.5 nM.

[0531] For the six antibodies tested in this experiment, when the higher concentration was defined as a constant and the other four concentrations were calculated, the experimental data showed significant differences compared to those with k-values. off The 1:1 model fits well for the values ​​(see [reference]). Figure 27 ).

[0532] With ratio k off / k on Calculated dissociation constant (K) D ) and with the ratio Ln(2) / k off The calculated half-life of the complex is in Figure 28 and Figure 29 The values ​​are represented by bars. They correspond to the average of four independent experiments run on each antibody. Error bars correspond to the standard deviation of the values ​​(n=4).

[0533] The dissociation constant is in the range of 10 to 100 pM. The c208F2 antibody indicates a weaker affinity for h-IGF-1R (a higher dissociation constant value) (with a K+ of approximately 75 pM). D ), and its humanized form is at least similar to the chimeric form (with approximately 60 pM K D The other four anti-IGF-1R chimeric antibodies showed very similar affinity (K0) for hIGF1-R. D (Approximately 30 pM). Differences in affinity are primarily related to the dissociation rate of the complex or the resulting half-life. In chimeric and humanized (VH3 / VL3) forms, the half-life of the complex with 208F2 is 2 to 3 hours. For the four other chimeric antibodies, the mean half-life is 7.0 to 9.4 hours.

[0534] These very slow dissociation kinetics are clearly related to the bivalent structure of the antibody, which is capable of simultaneously binding two neighboring h-IGF-1R molecules through its two Fab arms. In this case, the level of captured IGF-1R molecules may have an impact on the dissociation rate. The affinity defined in this study corresponds to the functional affinity (or affinity) of approximately 600 RU of antibody-captured h-IGF-1R. A 3-fold difference in KD was observed between the data shown above (Table 10) and the values ​​represented in Example 13, which is related to the change in the level of hIGF-1R capture (600 RU vs. 160 RU in Example 5).

[0535] Example 15: Defining mouse IGF-1R specific residues using soluble chimeric forms h / m IGF-1R recombinant protein White prevents c208F2 from binding.

[0536] Binding assays of c208F2 antibody against a soluble form of chimeric h / m IGF-1R recombinant protein were performed on a Biacore X100 device using a CM5 sensor chip activated by a mouse anti-human IgG Fc monoclonal antibody. Over 10,500 RU of anti-Fc antibody was chemically grafted onto carboxymethyl dextran matrices in both flow cells using an amine kit.

[0537] HBS-EP+ buffer was used as the run and sample dilution solution, and experiments were performed at 25°C at a flow rate of 30 μl / min.

[0538] The experimental setup is as follows:

[0539] 1- Inject a C208F2 solution with a concentration of 10 μg / ml into the second flow cell over a period of 60 seconds.

[0540] 2- The IGF-1R constructs tested corresponded to concentrated supernatants of culture medium diluted 10-fold in run buffer. One construct was injected with a 120-second delay during each cycle.

[0541] 3- Regenerate the two flow cells by injecting 10 mM glycine and HCl pH 1.7 buffer over a 30 s period.

[0542] Figure 30 The superposition of two cycles is shown. h-IGF-1R and m-IGF-1R supernatants were injected during the first and second cycles, respectively. This experiment clearly shows that m-IGF-1R cannot bind to the c208F2 antibody; the locations used to determine the c208F2 capture level and IGF-1R binding level are indicated by double-headed arrows.

[0543] The extracellular domains of IGFR (excluding the signal peptide) consist of 805 and 806 amino acids, respectively, from human and mouse sequences.

[0544] 869 residues (96%) are identical in both structures. 37 residues in the mouse sequence differ from the corresponding human sequence. One difference corresponds to a nick.

[0545] like Figure 31 As shown, of the seven chimeric constructs tested, four (C1 (SEQ ID No. 83), C4 (SEQ ID No. 86), C7 (SEQ ID No. 88), and C8 (SEQ ID No. 89) bind well to c208F2, just like h-IGF-1R, while three constructs (C2 (SEQ ID No. 84), C3 (SEQ ID No. 85), and C6 (SEQ ID No. 87)) do not bind to c208F2, just like mIGF-1R (SEQ ID No. 91).

[0546] The absence of binding at both C1 and C2 indicates that the mouse-specific residues blocking c208F2 binding are located in the N-terminal half of the protein. Therefore, the last 11 specific mouse amino acids in the C-terminal half have no effect on c208F2 binding.

[0547] The lack of binding at C3 demonstrates the major contribution from Arg, a mouse-specific residue at position 494, rather than His. This result is confirmed by the lack of binding at C6, which contains two mouse-specific residues, His494>Arg and Ser501>Trp.

[0548] The binding of C4 indicates the absence of the single mouse-specific residue Trp at position 501 of the chimeric IGF-1R, which is not responsible for the binding of C2 and C6.

[0549] The binding of C7 indicates that none of the 17 mouse-specific residues present in this construct play any role (weight) in blocking the binding of c208F2.

[0550] Similarly, the binding of C8 excludes four other mouse-specific residues.

[0551] The C12 mutant of human IGF1R represents three mouse residues in the L1 domain: Phe instead of Tyr at position 28, Ile instead of Val at position 125, and Leu instead of Met at position 156, binding c208F2 with a sub-nanomolar dissociation constant. This experiment confirms that the L1 domain is not involved in antibody binding, or at least that the three positions that distinguish the mouse and human sequences are not responsible for the lack of antibody binding to the mouse form of IGF1R.

[0552] like Figure 33As shown, hz208F2 cannot bind the C29 mutant (Asp491>Ala) of h-IGF1R (white diamond) captured on the CM5 sensor chip in a soluble form via its 6His C-terminal tag at 120 RU, while the same antibody solution clearly binds the wild-type form of the soluble receptor at 170 RU (black diamond). This is because His 494 and Asp 491 are crucial for the affinity of hz208F2 for IGF1R. Crystallographic data show that these two residues are exposed on the receptor surface within the FnR3 domain.

[0553] In summary, these results demonstrate that hz208F2 binds to the FnR3 domain of IGF-1R, and that the epitopes recognized by this antibody contain His 494 and Asp 491, which are crucial for antibody binding. Sequence Listing <110> Pierre Fabre Pharmaceuticals <120> IGF-1R antibodies and their use as targeting vectors in cancer treatment <130> 601625CG-661323 <150> US61984160 <151> 2014-04-25 <160> 92 <170> PatentIn version 3.5 <210> 1 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Consistency CDR-H1 <220> <221> MISC_FEATURE <222> (3)..(3) <223> Thr can be replaced by Ser. <220> <221> MISC_FEATURE <222> (8)..(8) <223> Tyr can be replaced by Phe <400> 1 Gly Tyr Thr Phe Thr Ser Tyr Tyr 1 5 <210> 2 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Consistency CDR-H2 <400> 2 Ile Trp Pro Gly Asp Gly Ser Thr 1 5 <210> 3 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Consistency CDR-H3 <400> 3 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr 1 5 10 <210> 4 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Consistency CDR-L1 <220> <221> MISC_FEATURE <222> (4)..(4) <223> Ser can be replaced by Asn <400> 4 Gln Asp Ile Ser Lys Tyr 1 5 <210> 5 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Consistent CDR-L2 <400> 5 Tyr Thr Ser 1 <210> 6 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Consistency CDR-L3 <220> <221> MISC_FEATURE <222> (5)..(5) <223> Thr can be replaced by Ala <400> 6 Gln Gln Gly Ser Thr Leu Pro Tyr Thr 1 5 <210> 7 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR-H1 <400> 7 Gly Tyr Thr Phe Thr Ser Tyr Tyr 1 5 <210> 8 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR-H1 <400> 8 Gly Tyr Ser Phe Thr Ser Tyr Phe 1 5 <210> 9 <211> 6 <212> PRT <213> Artificial sequence <220> <223> CDR-L1 <400> 9 Gln Asp Ile Ser Lys Tyr 1 5 <210> 10 <211> 6 <212> PRT <213> Artificial sequence <220> <223> CDR-L1 <400> 10 Gln Asp Ile Asn Lys Tyr 1 5 <210> 11 <211> 9 <212> PRT <213> Artificial sequence <220> <223> CDR-L3 <400> 11 Gln Gln Gly Ser Thr Leu Pro Tyr Thr 1 5 <210> 12 <211> 9 <212> PRT <213> Artificial sequence <220> <223> CDR-L3 <400> 12 Gln Gln Gly Ser Ala Leu Pro Tyr Thr 1 5 <210> 13 <211> 120 <212> PRT <213> Artificial sequence <220> <223> c208F2, heavy chain, VH <400> 13 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Leu 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Asp Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser 115 120 <210> 14 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> c212A11, heavy chain, VH <400> 14 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser 115 120 <210> 15 <211> 120 <212> PRT <213> Synthetic Sequence <220> <223> c214F8, heavy chain, VH <400> 15 Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Arg Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser 115 120 <210> 16 <211> 120 <212> PRT <213> Artificial sequence <220> <223> c219D6, heavy chain, VH <400> 16 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Phe Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser 115 120 <210> 17 <211> 120 <212> PRT <213> Synthetic Sequence <220> <223> c213B10, heavy chain, VH <400> 17 Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Arg Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser 115 120 <210> 18 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> c208F2, light chain, VL <400> 18 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Ile Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60​​​​​​​​​​​​​​​​​​​​ <220> <223> c212A11, light chain, VL <400> 19 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 20 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> c214F8, light chain, VL <400> 20 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Phe Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Ile Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Thr Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Ala Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 21 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> c219D6, light chain, VL <400> 21 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 22 <211> 107 <212> PRT[[ID=2�]]<0002'274><213> Synthetic sequence <220> <223> c213B10, light chain, VL<00'02277><400> 22 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Ile Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 5'0 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Thr Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Ala Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 23 <211> 449 <212> PRT <213> Synthetic Sequence <220> <223> c208F2, heavy chain, full length <400> 23 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr[[ID=3A]] 20 25 30 Tyr Ile Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Leu 35 40 45[[ID=3B]] Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Asp Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 24 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> c212A11, heavy chain, full length <400> 24 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 25 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> c214F8, heavy chain, full length <400> 25 Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Arg Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 26 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> c219D6, heavy chain, full length <400> 26 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Phe Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 27 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> c213B10, heavy chain, full length <400> 27 Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Arg Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Ala Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 28 <211> 214 <212> PRT <213> Artificial Sequence <220>[[ID=********]] <223> c208F2, light chain, full length <400> 28 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Ile Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Val Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 [[ID=1,6]]Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 [[ID=,20]]Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr S180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 29 <211> 214 <212> PRT <213> Artificial Sequence <,220> <223> c212A11, light chain, full length <400> 29 It should be noted that there seems to be an unclear or incorrect format in the original text with some parts like "<210> 29", "<211> 214", etc. The translation is done as accurately as possible based on the existing text, but these parts might need further clarification for a more precise understanding. Also, there was a minor error in the original text where "S180" was likely a typo and should be "180", which has been corrected in the translation for better continuity. Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 30 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> c214F8, light chain, full length <400> 30 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Phe Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Ile Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 [[ID=,46]]Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Thr Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Ala Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 2​​​​​​​​​​​​​​​​​​ Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 32 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> c213B10, light chain, full length <400> 32 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Gln Pro Asp Gly Thr Ile Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Thr Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Ser Ala Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 33 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 (var.1) Heavy Chain, VH <400> 33 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Trp Pro Gly Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser<​​​​​​​​​​​​​​​​​ 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 35 <211> 107 <212> PRT <213> artificial sequence <220> <223> hz208F2 (var. 1), VL <400> 35 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 36 <211> 107 <212> PRT <213> artificial sequence <220> <223> hz208F2 (var.3), VL <400> 36 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 37 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 (var. 1), heavy chain, full length <400> 37 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Trp Pro Gly Asp Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 38 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 (var.3), heavy chain, full length <400> 38 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 39 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 (var. 1), light chain, full length <400> 39 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 40 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 (var.3), light chain, full length <400> 40 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 41 <211> 120 <212> PRT <213> Artificial sequence <220> <223> hz208F2 (var.2) heavy chain, VH <220> <221> MISC_FEATURE <222> (20)..(20) <223> Met can be replaced by Val. <220> <221> MISC_FEATURE <222> (34)..(34) <223> Ile can be replaced by Met. <220> <221> MISC_FEATURE <222> (35)..(35) <223> Tyr can be replaced by His. <220> <221> MISC_FEATURE <222> (38)..(38) <223> Lys can be replaced by Arg <220> <221> MISC_FEATURE <222> (48)..(48) <223> Leu can be replaced by Met. <220> <221> MISC_FEATURE <222> (50)..(50) <223> Trp can be replaced by Ile <220> <221> MISC_FEATURE <222> (59)..(59) <223> Lys can be replaced by Ser <220> <221> MISC_FEATURE <222> (61)..(61) <223> Asn can be replaced by Ala <220> <221> MISC_FEATURE <222> (62)..(62) <223> Glu can be replaced by Gln <220> <221> MISC_FEATURE <222> (70)..(70) <223> Leu can be replaced by Met. <220> <221> MISC_FEATURE <222> (72)..(72) <223> Ala can be replaced by Arg. <220> <221> MISC_FEATURE <222> (74)..(74) <223> Lys can be replaced by Thr. <220> <221> MISC_FEATURE <222> (76)..(76) <223> Ser can be replaced by Thr. <220> <221> MISC_FEATURE <222> (77)..(77) <223> Asn can be replaced by Ser. <220> <221> MISC_FEATURE <222> (79)..(79) <223> Ala can be replaced by Val. <220> <221> MISC_FEATURE <222> (82)..(82) <223> Phe can be replaced by Glu. <220> <221> MISC_FEATURE <222> (95)..(95) <223> Phe can be replaced by Tyr <400> 41 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 50 55 60 Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Phe Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 42 <211> 107 <212> PRT <213> Artificial sequence <220> <223> hz208F2 (var. 2), light chain, VL <220> <221> MISC_FEATURE <222> (22)..(22) <223> Ser can be replaced by Thr. <220> <221> MISC_FEATURE <222> (53)..(53) <223> Arg can be replaced by Ser. <220> <221> MISC_FEATURE <222> (55)..(55) <223> His can be replaced by Gln. <220> <221> MISC_FEATURE <222> (65)..(65) <223> Arg can be replaced by Ser. <220> <221> MISC_FEATURE <222> (71)..(71) <223> Tyr can be replaced by Phe <220> <221> MISC_FEATURE <222> (72)..(72) <223> Ser can be replaced by Thr. <220> <221> MISC_FEATURE <222> (77)..(77) <223> Asn can be replaced by Ser. <220> <221> MISC_FEATURE <222> (87)..(87) <223> Phe can be replaced by Tyr <400> 42 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 43 <211> 329 <212> PRT <213> Artificial Sequence <220> <223> Constant domain (VH) IgG1 <400> 43 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly 325 <210> 44 <211> 326 <212> PRT <213> Artificial Sequence <220> <223> Constant Domain (VH) IgG4 (S228P) <400> 44 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly 325 <210> 45 <211> 107 <212> PRT <213> artificial sequence <220> <223> structure <400> 45 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 [[ID=1~3]]<210> 46 <211> 98 <212> PRT <213> Artificial Sequence <220> <223> Human germline IGHV1-46*01[[ID=~]] <400> 46 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg <210> 47 <211> 95 <212> PRT <213> Artificial sequence <220> <223> Human lineage IGKV1-39*01 <400> 47 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro 85 90 95 <210> 48 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Human lineage IGHJ4*01 <400> 48 Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10 15 <210> 49 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Human lineage IGKJ4*01 <400> 49 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 1 5 10 <210> 50 <211> 1367 <212> PRT <213> Artificial sequence <220> <223> IGF-1R (human) <400> 50 Met Lys Ser Gly Ser Gly Gly Gly Ser Pro Thr Ser Leu Trp Gly Leu 1 5 10 15 Leu Phe Leu Ser Ala Ala Leu Ser Leu Trp Pro Thr Ser Gly Glu Ile 20 25 30 Cys Gly Pro Gly Ile Asp Ile Arg Asn Asp Tyr Gln Gln Leu Lys Arg 35 40 45 Leu Glu Asn Cys Thr Val Ile Glu Gly Tyr Leu His Ile Leu Leu Ile 50 55 60 Ser Lys Ala Glu Asp Tyr Arg Ser Tyr Arg Phe Pro Lys Leu Thr Val 65 70 75 80 Ile Thr Glu Tyr Leu Leu Leu Phe Arg Val Ala Gly Leu Glu Ser Leu 85 90 95 Gly Asp Leu Phe Pro Asn Leu Thr Val Ile Arg Gly Trp Lys Leu Phe 100 105 110 Tyr Asn Tyr Ala Leu Val Ile Phe Glu Met Thr Asn Leu Lys Asp Ile 115 120 125 Gly Leu Tyr Asn Leu Arg Asn Ile Thr Arg Gly Ala Ile Arg Ile Glu 130 135 140 Lys Asn Ala Asp Leu Cys Tyr Leu Ser Thr Val Asp Trp Ser Leu Ile 145 150 155 160 Leu Asp Ala Val Ser Asn Asn Tyr Ile Val Gly Asn Lys Pro Pro Lys 165 170 175 Glu Cys Gly Asp Leu Cys Pro Gly Thr Met Glu Glu Lys Pro Met Cys 180 185 190 Glu Lys Thr Thr Ile Asn Asn Glu Tyr Asn Tyr Arg Cys Trp Thr Thr 195 200 205 Asn Arg Cys Gln Lys Met Cys Pro Ser Thr Cys Gly Lys Arg Ala Cys 210 215 220 Thr Glu Asn Asn Glu Cys Cys His Pro Glu Cys Leu Gly Ser Cys Ser 225 230 235 240 Ala Pro Asp Asn Asp Thr Ala Cys Val Ala Cys Arg His Tyr Tyr Tyr 245 250 255 Ala Gly Val Cys Val Pro Ala Cys Pro Pro Asn Thr Tyr Arg Phe Glu 260 265 270 Gly Trp Arg Cys Val Asp Arg Asp Phe Cys Ala Asn Ile Leu Ser Ala 275 280 285 Glu Ser Ser Asp Ser Glu Gly Phe Val Ile His Asp Gly Glu Cys Met 290 295 300 Gln Glu Cys Pro Ser Gly Phe Ile Arg Asn Gly Ser Gln Ser Met Tyr 305 310 315 320 Cys Ile Pro Cys Glu Gly Pro Cys Pro Lys Val Cys Glu Glu Glu Lys 325 330 335 Lys Thr Lys Thr Ile Asp Ser Val Thr Ser Ala Gln Met Leu Gln Gly 340 345 350 Cys Thr Ile Phe Lys Gly Asn Leu Leu Ile Asn Ile Arg Arg Gly Asn 355 360 365 Asn Ile Ala Ser Glu Leu Glu Asn Phe Met Gly Leu Ile Glu Val Val 370 375 380 Thr Gly Tyr Val Lys Ile Arg His Ser His Ala Leu Val Ser Leu Ser 385 390 395 400 Phe Leu Lys Asn Leu Arg Leu Ile Leu Gly Glu Glu Gln Leu Glu Gly 405 410 415 Asn Tyr Ser Phe Tyr Val Leu Asp Asn Gln Asn Leu Gln Gln Leu Trp 420 425 430 Asp Trp Asp His Arg Asn Leu Thr Ile Lys Ala Gly Lys Met Tyr Phe 435 440 445 Ala Phe Asn Pro Lys Leu Cys Val Ser Glu Ile Tyr Arg Met Glu Glu 450 455 460 Val Thr Gly Thr Lys Gly Arg Gln Ser Lys Gly Asp Ile Asn Thr Arg 465 470 475 480 Asn Asn Gly Glu Arg Ala Ser Cys Glu Ser Asp Val Leu His Phe Thr 485 490 495 Ser Thr Thr Thr Ser Lys Asn Arg Ile Ile Ile Thr Trp His Arg Tyr 500 505 510 Arg Pro Pro Asp Tyr Arg Asp Leu Ile Ser Phe Thr Val Tyr Tyr Lys 515 520 525 Glu Ala Pro Phe Lys Asn Val Thr Glu Tyr Asp Gly Gln Asp Ala Cys 530 535 540 Gly Ser Asn Ser Trp Asn Met Val Asp Val Asp Leu Pro Pro Asn Lys 545 550 555 560 Asp Val Glu Pro Gly Ile Leu Leu His Gly Leu Lys Pro Trp Thr Gln 565 570 575 Tyr Ala Val Tyr Val Lys Ala Val Thr Leu Thr Met Val Glu Asn Asp 580 585 590 His Ile Arg Gly Ala Lys Ser Glu Ile Leu Tyr Ile Arg Thr Asn Ala 595 600 605 Ser Val Pro Ser Ile Pro Leu Asp Val Leu Ser Ala Ser Asn Ser Ser 610 615 620 Ser Gln Leu Ile Val Lys Trp Asn Pro Pro Ser Leu Pro Asn Gly Asn 625 630 635 640 Leu Ser Tyr Tyr Ile Val Arg Trp Gln Arg Gln Pro Gln Asp Gly Tyr 645 650 655 Leu Tyr Arg His Asn Tyr Cys Ser Lys Asp Lys Ile Pro Ile Arg Lys 660 665 670 Tyr Ala Asp Gly Thr Ile Asp Ile Glu Glu Val Thr Glu Asn Pro Lys 675 680 685 Thr Glu Val Cys Gly Gly Glu Lys Gly Pro Cys Cys Ala Cys Pro Lys 690 695 700 Thr Glu Ala Glu Lys Gln Ala Glu Lys Glu Glu Ala Glu Tyr Arg Lys 705 710 715 720 Val Phe Glu Asn Phe Leu His Asn Ser Ile Phe Val Pro Arg Pro Glu 725 730 735 Arg Lys Arg Arg Asp Val Met Gln Val Ala Asn Thr Thr Met Ser Ser 740 745 750 Arg Ser Arg Asn Thr Thr Ala Ala Asp Thr Tyr Asn Ile Thr Asp Pro 755 760 765 Glu Glu Leu Glu Thr Glu Tyr Pro Phe Phe Glu Ser Arg Val Asp Asn 770 775 780 Lys Glu Arg Thr Val Ile Ser Asn Leu Arg Pro Phe Thr Leu Tyr Arg 785 790 795 800 Ile Asp Ile His Ser Cys Asn His Glu Ala Glu Lys Leu Gly Cys Ser 805 810 815 Ala Ser Asn Phe Val Phe Ala Arg Thr Met Pro Ala Glu Gly Ala Asp 820 825 830 Asp Ile Pro Gly Pro Val Thr Trp Glu Pro Arg Pro Glu Asn Ser Ile 835 840 845 Phe Leu Lys Trp Pro Glu Pro Glu Asn Pro Asn Gly Leu Ile Leu Met 850 855 860 Tyr Glu Ile Lys Tyr Gly Ser Gln Val Glu Asp Gln Arg Glu Cys Val 865 870 875 880 Ser Arg Gln Glu Tyr Arg Lys Tyr Gly Gly Ala Lys Leu Asn Arg Leu 885 890 895 Asn Pro Gly Asn Tyr Thr Ala Arg Ile Gln Ala Thr Ser Leu Ser Gly 900 905 910 Asn Gly Ser Trp Thr Asp Pro Val Phe Phe Tyr Val Gln Ala Lys Thr 915 920 925 Gly Tyr Glu Asn Phe Ile His Leu Ile Ile Ala Leu Pro Val Ala Val 930 935 940 Leu Leu Ile Val Gly Gly Leu Val Ile Met Leu Tyr Val Phe His Arg 945 950 955 960 Lys Arg Asn Asn Ser Arg Leu Gly Asn Gly Val Leu Tyr Ala Ser Val 965 970 975 Asn Pro Glu Tyr Phe Ser Ala Ala Asp Val Tyr Val Pro Asp Glu Trp 980 985 990 Glu Val Ala Arg Glu Lys Ile Thr Met Ser Arg Glu Leu Gly Gln Gly 995 1000 1005 Ser Phe Gly Met Val Tyr Glu Gly Val Ala Lys Gly Val Val Lys 1010 1015 1020 Asp Glu Pro Glu Thr Arg Val Ala Ile Lys Thr Val Asn Glu Ala 1025 1030 1035 Ala Ser Met Arg Glu Arg Ile Glu Phe Leu Asn Glu Ala Ser Val 1040 1045 1050 Met Lys Glu Phe Asn Cys His His Val Val Arg Leu Leu Gly Val 1055 1060 1065 Val Ser Gln Gly Gln Pro Thr Leu Val Ile Met Glu Leu Met Thr 1070 1075 1080 Arg Gly Asp Leu Lys Ser Tyr Leu Arg Ser Leu Arg Pro Glu Met 1085 1090 1095 Glu Asn Asn Pro Val Leu Ala Pro Pro Ser Leu Ser Lys Met Ile 1100 1105 1110 Gln Met Ala Gly Glu Ile Ala Asp Gly Met Ala Tyr Leu Asn Ala 1115 1120 1125 Asn Lys Phe Val His Arg Asp Leu Ala Ala Arg Asn Cys Met Val 1130 1135 1140 Ala Glu Asp Phe Thr Val Lys Ile Gly Asp Phe Gly Met Thr Arg 1145 1150 1155 Asp Ile Tyr Glu Thr Asp Tyr Tyr Arg Lys Gly Gly Lys Gly Leu 1160 1165 1170 Leu Pro Val Arg Trp Met Ser Pro Glu Ser Leu Lys Asp Gly Val 1175 1180 1185 Phe Thr Thr Tyr Ser Asp Val Trp Ser Phe Gly Val Val Leu Trp 1190 1195 1200 Glu Ile Ala Thr Leu Ala Glu Gln Pro Tyr Gln Gly Leu Ser Asn 1205 1210 1215 Glu Gln Val Leu Arg Phe Val Met Glu Gly Gly Leu Leu Asp Lys 1220 1225 1230 Pro Asp Asn Cys Pro Asp Met Leu Phe Glu Leu Met Arg Met Cys 1235 1240 1245 Trp Gln Tyr Asn Pro Lys Met Arg Pro Ser Phe Leu Glu Ile Ile 1250 1255 1260 Ser Ser Ile Lys Glu Glu Met Glu Pro Gly Phe Arg Glu Val Ser 1265 1270 1275 Phe Tyr Tyr Ser Glu Glu Asn Lys Leu Pro Glu Pro Glu Glu Leu 1280 1285 1290 Asp Leu Glu Pro Glu Asn Met Glu Ser Val Pro Leu Asp Pro Ser 1295 1300 1305 Ala Ser Ser Ser Ser Leu Pro Leu Pro Asp Arg His Ser Gly His 1310 1315 1320 Lys Ala Glu Asn Gly Pro Gly Pro Gly Val Leu Val Leu Arg Ala 1325 1330 1335 Ser Phe Asp Glu Arg Gln Pro Tyr Ala His Met Asn Gly Gly Arg 1340 1345 1350 Lys Asn Glu Arg Ala Leu Pro Leu Pro Gln Ser Ser Thr Cys 1355 1360 1365 <210> 51 <211> 932 <212> PRT <213> Artificial Sequence <220> <223> IGF-1R ECD (Human) <400> 51 Met Lys Ser Gly Ser Gly Gly Gly Ser Pro Thr Ser Leu Trp Gly Leu 1 5 10 15 Leu Phe Leu Ser Ala Ala Leu Ser Leu Trp Pro Thr Ser Gly Glu Ile 20 25 30 Cys Gly Pro Gly Ile Asp Ile Arg Asn Asp Tyr Gln Gln Leu Lys Arg 35 40 45 Leu Glu Asn Cys Thr Val Ile Glu Gly Tyr Leu His Ile Leu Leu Ile 50 55 60 Ser Lys Ala Glu Asp Tyr Arg Ser Tyr Arg Phe Pro Lys Leu Thr Val 65 70 75 80 Ile Thr Glu Tyr Leu Leu Leu Phe Arg Val Ala Gly Leu Glu Ser Leu 85 90 95 Gly Asp Leu Phe Pro Asn Leu Thr Val Ile Arg Gly Trp Lys Leu Phe 100 105 110 Tyr Asn Tyr Ala Leu Val Ile Phe Glu Met Thr Asn Leu Lys Asp Ile 115 120 125 Gly Leu Tyr Asn Leu Arg Asn Ile Thr Arg Gly Ala Ile Arg Ile Glu 130 135 140 Lys Asn Ala Asp Leu Cys Tyr Leu Ser Thr Val Asp Trp Ser Leu Ile 145 150 155 160 Leu Asp Ala Val Ser Asn Asn Tyr Ile Val Gly Asn Lys Pro Pro Lys 165 170 175 Glu Cys Gly Asp Leu Cys Pro Gly Thr Met Glu Glu Lys Pro Met Cys 180 185 190 Glu Lys Thr Thr Ile Asn Asn Glu Tyr Asn Tyr Arg Cys Trp Thr Thr 195 200 205 Asn Arg Cys Gln Lys Met Cys Pro Ser Thr Cys Gly Lys Arg Ala Cys 210 215 220 Thr Glu Asn Asn Glu Cys Cys His Pro Glu Cys Leu Gly Ser Cys Ser 225 230 235 240 Ala Pro Asp Asn Asp Thr Ala Cys Val Ala Cys Arg His Tyr Tyr Tyr 245 250 255 Ala Gly Val Cys Val Pro Ala Cys Pro Pro Asn Thr Tyr Arg Phe Glu 260 265 270 Gly Trp Arg Cys Val Asp Arg Asp Phe Cys Ala Asn Ile Leu Ser Ala 275 280 285 Glu Ser Ser Asp Ser Glu Gly Phe Val Ile His Asp Gly Glu Cys Met 290 295 300 Gln Glu Cys Pro Ser Gly Phe Ile Arg Asn Gly Ser Gln Ser Met Tyr 305 310 315 320 Cys Ile Pro Cys Glu Gly Pro Cys Pro Lys Val Cys Glu Glu Glu Lys 325 330 335 Lys Thr Lys Thr Ile Asp Ser Val Thr Ser Ala Gln Met Leu Gln Gly 340 345 350 Cys Thr Ile Phe Lys Gly Asn Leu Leu Ile Asn Ile Arg Arg Gly Asn 355 360 365 Asn Ile Ala Ser Glu Leu Glu Asn Phe Met Gly Leu Ile Glu Val Val 370 375 380 Thr Gly Tyr Val Lys Ile Arg His Ser His Ala Leu Val Ser Leu Ser 385 390 395 400 Phe Leu Lys Asn Leu Arg Leu Ile Leu Gly Glu Glu Gln Leu Glu Gly 405 410 415 Asn Tyr Ser Phe Tyr Val Leu Asp Asn Gln Asn Leu Gln Gln Leu Trp 420 425 430 Asp Trp Asp His Arg Asn Leu Thr Ile Lys Ala Gly Lys Met Tyr Phe 435 440 445 Ala Phe Asn Pro Lys Leu Cys Val Ser Glu Ile Tyr Arg Met Glu Glu 450 455 460 Val Thr Gly Thr Lys Gly Arg Gln Ser Lys Gly Asp Ile Asn Thr Arg 465 470 475 480 Asn Asn Gly Glu Arg Ala Ser Cys Glu Ser Asp Val Leu His Phe Thr 485 490 495 Ser Thr Thr Thr Ser Lys Asn Arg Ile Ile Ile Thr Trp His Arg Tyr 500 505 510 Arg Pro Pro Asp Tyr Arg Asp Leu Ile Ser Phe Thr Val Tyr Tyr Lys 515 520 525 Glu Ala Pro Phe Lys Asn Val Thr Glu Tyr Asp Gly Gln Asp Ala Cys 530 535 540 Gly Ser Asn Ser Trp Asn Met Val Asp Val Asp Leu Pro Pro Asn Lys 545 550 555 560 Asp Val Glu Pro Gly Ile Leu Leu His Gly Leu Lys Pro Trp Thr Gln 565 570 575 Tyr Ala Val Tyr Val Lys Ala Val Thr Leu Thr Met Val Glu Asn Asp 580 585 590 His Ile Arg Gly Ala Lys Ser Glu Ile Leu Tyr Ile Arg Thr Asn Ala 595 600 605 Ser Val Pro Ser Ile Pro Leu Asp Val Leu Ser Ala Ser Asn Ser Ser 610 615 620 Ser Gln Leu Ile Val Lys Trp Asn Pro Pro Ser Leu Pro Asn Gly Asn 625 630 635 640 Leu Ser Tyr Tyr Ile Val Arg Trp Gln Arg Gln Pro Gln Asp Gly Tyr 645 650 655 Leu Tyr Arg His Asn Tyr Cys Ser Lys Asp Lys Ile Pro Ile Arg Lys 660 665 670 Tyr Ala Asp Gly Thr Ile Asp Ile Glu Glu Val Thr Glu Asn Pro Lys 675 680 685 Thr Glu Val Cys Gly Gly Glu Lys Gly Pro Cys Cys Ala Cys Pro Lys 690 695 700 Thr Glu Ala Glu Lys Gln Ala Glu Lys Glu Glu Ala Glu Tyr Arg Lys 705 710 715 720 Val Phe Glu Asn Phe Leu His Asn Ser Ile Phe Val Pro Arg Pro Glu 725 730 735 Arg Lys Arg Arg Asp Val Met Gln Val Ala Asn Thr Thr Met Ser Ser 740 745 750 Arg Ser Arg Asn Thr Thr Ala Ala Asp Thr Tyr Asn Ile Thr Asp Pro 755 760 765 Glu Glu Leu Glu Thr Glu Tyr Pro Phe Phe Glu Ser Arg Val Asp Asn 770 775 780 Lys Glu Arg Thr Val Ile Ser Asn Leu Arg Pro Phe Thr Leu Tyr Arg 785 790 795 800 Ile Asp Ile His Ser Cys Asn His Glu Ala Glu Lys Leu Gly Cys Ser 805 810 815 Ala Ser Asn Phe Val Phe Ala Arg Thr Met Pro Ala Glu Gly Ala Asp 820 825 830 Asp Ile Pro Gly Pro Val Thr Trp Glu Pro Arg Pro Glu Asn Ser Ile 835 840 845 Phe Leu Lys Trp Pro Glu Pro Glu Asn Pro Asn Gly Leu Ile Leu Met 850 855 860 Tyr Glu Ile Lys Tyr Gly Ser Gln Val Glu Asp Gln Arg Glu Cys Val 865 870 875 880 Ser Arg Gln Glu Tyr Arg Lys Tyr Gly Gly Ala Lys Leu Asn Arg Leu 885 890 895 Asn Pro Gly Asn Tyr Thr Ala Arg Ile Gln Ala Thr Ser Leu Ser Gly 900 905 910 Asn Gly Ser Trp Thr Asp Pro Val Phe Phe Tyr Val Gln Ala Lys Thr 915 920 925 Gly Tyr Glu Asn 930 <210> 52 <211> 512 <212> PRT <213> Artificial Sequence <220> <223> IGF-1R ECD N-terminus (Human) <400> 52 Met Lys Ser Gly Ser Gly Gly Gly Ser Pro Thr Ser Leu Trp Gly Leu 1 5 10 15 Leu Phe Leu Ser Ala Ala Leu Ser Leu Trp Pro Thr Ser Gly Glu Ile 20 25 30 Cys Gly Pro Gly Ile Asp Ile Arg Asn Asp Tyr Gln Gln Leu Lys Arg 35 40 45 Leu Glu Asn Cys Thr Val Ile Glu Gly Tyr Leu His Ile Leu Leu Ile 50 55 60 Ser Lys Ala Glu Asp Tyr Arg Ser Tyr Arg Phe Pro Lys Leu Thr Val 65 70 75 80 Ile Thr Glu Tyr Leu Leu Leu Phe Arg Val Ala Gly Leu Glu Ser Leu 85 90 95 Gly Asp Leu Phe Pro Asn Leu Thr Val Ile Arg Gly Trp Lys Leu Phe 100 105 110 Tyr Asn Tyr Ala Leu Val Ile Phe Glu Met Thr Asn Leu Lys Asp Ile 115 120 125 Gly Leu Tyr Asn Leu Arg Asn Ile Thr Arg Gly Ala Ile Arg Ile Glu 130 135 140 Lys Asn Ala Asp Leu Cys Tyr Leu Ser Thr Val Asp Trp Ser Leu Ile 145 150 155 160 Leu Asp Ala Val Ser Asn Asn Tyr Ile Val Gly Asn Lys Pro Pro Lys 165 170 175 Glu Cys Gly Asp Leu Cys Pro Gly Thr Met Glu Glu Lys Pro Met Cys 180 185 190 Glu Lys Thr Thr Ile Asn Asn Glu Tyr Asn Tyr Arg Cys Trp Thr Thr 195 200 205 Asn Arg Cys Gln Lys Met Cys Pro Ser Thr Cys Gly Lys Arg Ala Cys 210 215 220 Thr Glu Asn Asn Glu Cys Cys His Pro Glu Cys Leu Gly Ser Cys Ser 225 230 235 240 Ala Pro Asp Asn Asp Thr Ala Cys Val Ala Cys Arg His Tyr Tyr Tyr 245 250 255 Ala Gly Val Cys Val Pro Ala Cys Pro Pro Asn Thr Tyr Arg Phe Glu 260 265 270 Gly Trp Arg Cys Val Asp Arg Asp Phe Cys Ala Asn Ile Leu Ser Ala 275 280 285 Glu Ser Ser Asp Ser Glu Gly Phe Val Ile His Asp Gly Glu Cys Met 290 295 300 Gln Glu Cys Pro Ser Gly Phe Ile Arg Asn Gly Ser Gln Ser Met Tyr 305 310 315 320 Cys Ile Pro Cys Glu Gly Pro Cys Pro Lys Val Cys Glu Glu Glu Lys 325 330 335 Lys Thr Lys Thr Ile Asp Ser Val Thr Ser Ala Gln Met Leu Gln Gly 340 345 350 Cys Thr Ile Phe Lys Gly Asn Leu Leu Ile Asn Ile Arg Arg Gly Asn 355 360 365 Asn Ile Ala Ser Glu Leu Glu Asn Phe Met Gly Leu Ile Glu Val Val 370 375 380 Thr Gly Tyr Val Lys Ile Arg His Ser His Ala Leu Val Ser Leu Ser 385 390 395 400 Phe Leu Lys Asn Leu Arg Leu Ile Leu Gly Glu Glu Gln Leu Glu Gly 405 410 415 Asn Tyr Ser Phe Tyr Val Leu Asp Asn Gln Asn Leu Gln Gln Leu Trp 420 425 430 Asp Trp Asp His Arg Asn Leu Thr Ile Lys Ala Gly Lys Met Tyr Phe 435 440 445 Ala Phe Asn Pro Lys Leu Cys Val Ser Glu Ile Tyr Arg Met Glu Glu 450 455 460 Val Thr Gly Thr Lys Gly Arg Gln Ser Lys Gly Asp Ile Asn Thr Arg 465 470 475 480 Asn Asn Gly Glu Arg Ala Ser Cys Glu Ser Asp Val Leu His Phe Thr 485 490 495 Ser Thr Thr Thr Ser Lys Asn Arg Ile Ile Ile Thr Trp His Arg Tyr 500 505 510 <210> 53 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Tetrapeptide (Linker) <400> 53 Gly Phe Leu Gly 1 <210> 54 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Tetrapeptide (Connector) <400> 54 Ala Leu Ala Leu 1 <210> 55 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Tetrapeptide (Connector) <400> 55 Pro Val Gly Val Val 1 5 <210> 56 <211> 120 <212> PRT <213> Artificial sequence <220> <223> hz208F2 Heavy chain H037, VH <400> 56 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Lys Ser Ser Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 57 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 light chain L018, VL <400> 57 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 58 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> Full-length hz208F2 Heavy Chain H037 <400> 58 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Lys Ser Ser Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys<​​Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 59 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Full-length hz2 Light Chain L018 <400> 59 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95<00会3924>Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 60 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 Light Chain L021, VL <400> 60 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 61 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 light chain L021 full length <400> 61 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Ser Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 62 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H047, VH <400> 62 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ser Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 63 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H047 full length <400> 63 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ser Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 64 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H049, VH <400> 64 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Lys Ser Ser Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 65 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> Full length of hz208F2 heavy chain H049 <400> 65 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met [[ID=2,1]]35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Lys Ser Ser Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 66 <211> 120 <212> PRT <213> Artificial sequence <220> <223> hz208F2 heavy chain H051, VH <400> 66 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ser Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 67[[ID=4ģ]] <211> 449 <212> PRT <213> Artificial sequence <2ż0> <223> Full-length heavy chain H051 of hz208F2 <400> 67 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ser Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 68 <211> 120 <212> PRT <213> Artificial sequence <220> <223> hz208F2 Heavy chain H052, VH <400> 68 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 69 <211> 449 <212> PRT <213> Artificial sequence <220> <223> hz208F2 Heavy chain H052 Total length <400> 69 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 70 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 Heavy Chain H057, VH<000435​​Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Lys Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 71 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H057 full length <400> 71 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Lys Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 73 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> Full-length hz208F2 Heavy Chain H068 <400> 73 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 74 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H070, VH <400> 74 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 ; Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser [[ID=二十三]]115 120 <210> 75 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 Heavy Chain H070 Full Length <400> 75 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 76 <211> 120 <212> PRT <213> Artificial sequence <220> <223> hz208F2 heavy chain H071, VH <400> 76 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 77 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 Heavy Chain H071 Full Length <400> 77 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 78 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H076, VH <400> 78 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 79 <211> 449 <212> PRT <213> Synthetic Sequence <220> <223> hz208F2 Heavy Chain H076 Full Length <400> 79 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly <210> 80 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H077, VH <400> 80 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Trp Pro Gly Asp Gly Ser Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Ser Pro Met Ile Thr Pro Asn Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 81 <211> 449 <212> PRT <213> Artificial Sequence <220> <223> hz208F2 heavy chain H077 full length <400> 81 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile T...

Claims

1. An internalizing monoclonal antibody or an internalizing IGF-1R binding fragment thereof, which binds to the IGF-1R shown in SEQ ID No.50 and is internalized after binding to the IGF-1R, and does not bind to the IGF-1R shown in SEQ ID No.82 and / or SEQ ID No.92; The antibody is selected from: a) An antibody comprising: The three heavy chain CDRs shown in SEQ ID No. 7, 2 and 3, and The three light chain CDRs shown in SEQ ID No. 10, 5 and 11; b) an antibody comprising: The three heavy chain CDRs shown in SEQ ID No. 7, 2 and 3, and The three light chain CDRs shown in SEQ ID No. 9, 5 and 12; c) an antibody comprising: The three heavy chain CDRs shown in SEQ ID No. 8, 2 and 3, and The three light chain CDRs shown in SEQ ID No. 9, 5 and 11; in, The CDRs are defined by IMGT, The IGF-1R is human insulin-like growth factor 1 receptor.

2. The internalizing monoclonal antibody or the internalizing IGF-1R binding fragment thereof according to claim 1, wherein the binding epitope of the internalizing monoclonal antibody comprises a histidine residue at position 494 of SEQ ID No. 50 and an aspartic acid residue at position 491 of SEQ ID No.

50.

3. The internalizing monoclonal antibody or internalizing IGF-1R binding fragment thereof according to claim 2, wherein the epitope comprises an amino acid sequence of at least 8 amino acids.

4. The internalizing monoclonal antibody or internalizing IGF-1R binding fragment thereof according to any one of claims 1 to 3, which has an internalization percentage of at least 40% after binding to IGF-1R.

5. The internalizing monoclonal antibody of claim 1, wherein the antibody is a chimeric antibody.

6. The internalizing monoclonal antibody according to claim 5, wherein the antibody is selected from: a) An antibody comprising: The heavy chain variable domain shown in SEQ ID No. 14, and The light chain variable domain shown in SEQ ID No.19; b) an antibody comprising: The heavy chain variable domain shown in SEQ ID No.15, and The light chain variable domain shown in SEQ ID No.20; c) an antibody comprising: The heavy chain variable domain shown in SEQ ID No. 16, and The light chain variable domain shown in SEQ ID No.21; d) an antibody comprising: The heavy chain variable domain shown in SEQ ID No. 17, and The light chain variable domain is shown in SEQ ID No.

22.

7. The internalizing monoclonal antibody according to claim 5 or 6, wherein the antibody is selected from: a) An antibody comprising or consisting of: The heavy chain shown in SEQ ID No. 24, and The light chain shown in SEQ ID No.29; b) An antibody comprising or consisting of: The heavy chain shown in SEQ ID No. 25, and The light chain shown in SEQ ID No.30; c) An antibody comprising or consisting of: The heavy chain shown in SEQ ID No.26, and The light chain shown in SEQ ID No.31; d) An antibody comprising or consisting of: The heavy chain shown in SEQ ID No. 27, and The light chain is shown in SEQ ID No.

32.

8. The internalizing monoclonal antibody of claim 1, wherein the antibody is a humanized antibody.

9. The internalizing monoclonal antibody according to claim 1, wherein the antibody is produced by a hybridoma selected from the group consisting of hybridomas CNCM I-4773, CNCM I-4774, CNCM I-4775 and CNCM I-4736 deposited at the National Collection of Microorganisms on June 26, 2013, June 26, 2013, June 26, 2013 and April 24, 2013, respectively.

10. A murine hybridoma, wherein the hybridoma is selected from the group consisting of hybridomas CNCM I-4773, CNCM I-4774, CNCM I-4775 and CNCM I-4736 deposited in the National Center for Microbiological Collection on June 26, 2013, June 26, 2013, June 26, 2013 and April 24, 2013, respectively.

11. Use of the internalizing monoclonal antibody or internalizing IGF-1R binding fragment thereof according to any one of claims 1 to 9 in the preparation of a medicament for treating cancer expressing IGF-1R, wherein the antibody delivers a cytotoxic agent to a host target site consisting of an epitope located in the extracellular domain of IGF-1R.

12. The use according to claim 11, wherein the host target site consists of an epitope located in the extracellular domain of human IGF-1R shown in SEQ ID No.

51.

13. The use according to claim 11, wherein the host target site consists of an epitope located at the N-terminus of the extracellular domain of human IGF-1R shown in SEQ ID No.

52.

14. An antibody-drug conjugate comprising the internalizing monoclonal antibody or internalizing IGF-1R binding fragment thereof according to any one of claims 1 to 9 conjugated to a cytotoxic agent.

15. Use of the antibody-drug conjugate of claim 14 in the preparation of a medicament for treating cancer expressing IGF-1R.

16. A pharmaceutical composition comprising: The antibody-drug conjugate of claim 14, and At least one excipient and / or pharmaceutically acceptable carrier.

17. Use of the pharmaceutical composition of claim 16 in the preparation of a medicament for treating cancer expressing IGF-1R.

18. Use of the antibody-drug conjugate of claim 14 or the pharmaceutical composition of claim 16 in the preparation of a medicament for delivering an agent or drug to cancer cells expressing IGF-1R in a subject.

Citation Information

Patent Citations

  • CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

    EP0451216A1

  • Improved humanized immunoglobulins

    EP0566647A1

  • Humanized immunoglobulins and their production and use

    EP0682040A1

  • Humanized immunoglobulins and their production and use

    EP0939127A2

  • Antitumor antibiotics (LL-E33288 complex)

    US4970198A